2018
EDUCATION 2018
COLLABORATION
Level 14, 477 Pitt Street ADVOCACY Sydney NSW 2000 GPO Box 4708 Sydney NSW 2001 EDUCATION RESEARCH COLLABORATIONADVOCACY Telephone: (02) 8063 4100 RESEARCH Facsimile: (02) 8063 4101 www.cosa.org.au
1 - 1 ANNUAL REPORT 2017
SECTION INDEX
COSA BOARD + COSA REPORTS 3
C COSA GROUP REPORTS 12
A AFFILIATED ORGANISATION REPORTS 24
O OTHER REPORTS 52
$ FINANCIAL STATEMENTS 54 PRESIDENTS OF COSA
1973 - 1976 Mr WB Fleming AM - Deceased MBBS FRACS FRCS(Eng) FACS 1976 - 1979 Professor L Atkinson - Deceased FRCS FRACS FACR 1979 - 1981 Dr RP Melville- Deceased MBBS FRCS FRACS FACS 1981 - 1983 Professor MHN Tattersall AO MA MD MSc FRCP FRACP 1983 - 1985 Professor GJ Clunie - Deceased CHM(Ed) FRCS(Ed) FRCS FRACS 1985 - 1987 Dr JVM Coppleson AO - Deceased MBBS(Hons) MD FRCOG FRACOG 1988 - 1989 Dr JA Levi MBBS FRACP 1990 - 1991 Professor RM Fox AM BSc(Med) PhD MBBS FRACP 1992 - 1993 Professor WH McCarthy AM MEd FRACS 1994 - 1995 Professor AS Coates AM MD FRACP 1996 - 1997 Professor RJS Thomas MBBS MS FRACS FRCS 1998 - 1999 Professor H Ekert AM MBBS MD FRACP FRCPA 2000 - 2001 Professor J Zalcberg OAM MBBS PhD FRACP GAICD MRACMA 2002 - 2003 Professor L Kenny AO MBBS FRANZCR 2004 - 2005 Dr S Ackland MBBS FRACP 2006 – Jul 2006 Professor D Currow BMed FRACP MPH 2006 - 2008 Professor D Goldstein MBBS FRACP FRCP 2009 - 2010 Professor GB Mann MBBS PhD FRACS 2011 - 2012 Professor B Koczwara AM BM BS FRACP MBioethics FAICD 2013 - 2014 Professor SV Porceddu BSc MBBS (Hons) MD FRANZCR 2015 - 2016 Professor M Krishnasamy BA RGN DipN MSc PhD 2017 – 2018 Professor P Butow AM BA(Hons) Dip Ed MClinPsych MPH PhD ANNUAL REPORT 2017
COSA VISION AND MISSION
COSA achieves QUALITY this by: • supporting the professional MULTIDISCIPLINARY and educational needs of cancer health professionals CANCER CARE FOR ALL • enhancing cancer care and control through network development The overarching mission of COSA is to improve • advocating for improvements cancer care and control through collaboration. in cancer care and control • facilitating research across the spectrum of cancer COSA MEMBERSHIP
As at 31 December 2018 there were 777 registered members of COSA. Members are drawn from the many disciplines in medicine engaged in cancer treatment and from associated research, patient care and support areas. They come from universities, private practice, government and private laboratories and other health services.
There are 2 types of postgraduate degree or fellowship for admission as an honorary member. from a recognised College or Society This membership category is offered COSA membership: that is relevant to the vision and to past Presidents of COSA and Individual membership – mission of COSA. nominees and must be approved be the COSA Board. COSA Members • Non-medical members have a specific interest in oncology and a Organisational membership – 4 STUDENT MEMBERS Affiliated and Associated professional qualification relevant to Organisations COSA’s vision and mission. A person who is undertaking full time undergraduate or post-graduate The categories of 2 RETIREE MEMBERS studies with a stream of cancer care membership of COSA are: A person who has retired from their is eligible as a student member. professional employment, who has Documented evidence of their status is required upon application annually 1 ORDINARY MEMBERS held COSA membership for 10 years prior to retirement, and who has a and membership is subject to Board A person with a specific interest continued personal interest in cancer approval. in oncology and with professional care is eligible as a retiree member, qualifications is eligible for admission subject to Board approval. 5 AFFILIATED AND as an ordinary member. ASSOCIATED ORGANISATIONS • Medical Member: Medical members 3 HONORARY MEMBERS Affiliated and Associated organisations are qualified clinical practitioners or A person who has made significant include not for profit companies, scientists with a specific interest in and sustained contributions to COSA institutions or organisations that have oncology. Medical members hold a or to cancer care in general is eligible a similar vision to COSA.
1 - 2 ANNUAL REPORT 2017
COSA BOARD + COSA REPORTS
COSA GROUP REPORTS COSA BOARD AFFILIATED ORGANISATION REPORTS
OTHER REPORTS
FINANCIAL STATEMENTS
Sandie Angus Phyllis Nick Director Butow AM Pavlakis (appointed 20 President President-Elect March 2018)
Sanchia Christine Haryana Aranda Carrington Dhillon Director Director Director
3 - ANNUAL REPORT 2017
Peter Mei Sandra Dowding Krishnasamy McKiernan Director Director Director
Felicity Shaw Wayne Director Nik Nicholls (retired 8 March Zeps Director 2018) Director
Marie Malica Chief Executive Officer
3 - 4 ANNUAL REPORT 2017
COSA BOARD + COSA REPORTS
COSA GROUP REPORTS
AFFILIATED ORGANISATION REPORTS COSA COUNCIL OTHER REPORTS
FINANCIAL STATEMENTS
Council comprises the PRESIDENT Professor P Butow AM BA (Hons) Dip Ed MClinPsych MPH PhD President, President Elect, PRESIDENT ELECT Immediate Past President, A/Professor N Pavlakis BSc MBBS MMed (Clin.Epi) PhD FRACP Chair of each COSA Group and the nominee of each Affiliated Organisation. COSA GROUP REPRESENTATIVES
ADOLESCENT AND YOUNG ADULT FAMILIAL CANCER GROUP PAEDEATRIC ONCOLOGY GROUP GROUP Chair: A/Professor N Pachter MBChB Chair: Position vacant Chair: Dr W Nicholls MBChB FRACP FRACP PALLIATIVE CARE GROUP Ms Lucinda Salmon BScm Grad Dip BREAST CANCER GROUP Chair: Professor J Phillips RN PhD Genetic Counselling FHGSA Chair: Dr S Fraser MBBS FASBP FACN GASTROINTESTINAL ONCOLOGY CANCER BIOLOGY GROUP PSYCHO-ONCOLOGY GROUP GROUP Chair: Professor N Zeps BSc (Hons) Chair: Dr L Kirsten DPsyc(Clinical) PhD Chair: Professor E Segelov MBBS PhD (Hons1) FRACP PhD RADIATION ONCOLOGY GROUP CANCER CARE COORDINATION Chair: Position Vacant GERIATRIC ONCOLOGY GROUP GROUP Chair: Professor M Agar MBBS FRACP RARE CANCERS GROUP Chair: Professor P Yates PhD RN FAAN FaChPM MPC PhD Chair: A/Professor C Scott MBBS PhD FACN FRACP GYNAECOLOGICAL ONCOLOGY CANCER PHARMACISTS GROUP GROUP REGIONAL & RURAL ONCOLOGY Chair: Mr M Powell BPharm Chair: Position vacant GROUP DipPharmPrac MSHP Chair: Professor S Sabesan INTEGRATIVE ONCOLOGY GROUP CANCER PREVENTION BMBS(Flinders) PhD FRACP Chair: Dr J Lacey MBBS FRACGP Professor B Stewart AM MSc PhD Dr R Zielinski MB.BS Hons (Sydney) BE FAChPM (FRACP) FRACI DipLaw GradDipLegalPract Hons (Sydney) LUNG CANCER GROUP CLINICAL TRIALS RESEARCH SURGICAL ONCOLOGY GROUP Chair: A/Professor N Pavlakis BSc PROFESSIONALS GROUP Chair: Position Vacant MBBS MMed (Clin.Epi) PhD FRACP Chair: Mrs D Lindsay BAppSc (Hons) SURVIVORSHIP GROUP MELANOMA AND SKIN GROUP EPIDEMIOLOGY GROUP Chair: Professor B Koczwara AM BM BS Chair: Dr D Speakman MBBS FRACS Chair: Dr H Tuffaha BPharm MBA MSci FRACP MBioethics FAICD PhD NEUROENDOCRINE TUMOURS UROLOGIC ONCOLOGY GROUP GROUP EXERCISE & CANCER GROUP Chair: Professor I Davis MBBS (Hons) Chair: Dr Y Chua FRACP Chair: A/Professor P Cormie PhD AEP PhD FRACP FAChPM Position vacant CONSUMER REPRESENTATIVE NEURO-ONCOLOGY GROUP Position vacant Chair: Dr ES Koh MBBS FRANZCR
NUTRITION GROUP Chair: Dr N Kiss PhD Adv APD
5 - ANNUAL REPORT 2017
AFFILIATED ORGANISATION REPRESENTATIVES
AUSTRALASIAN GASTRO-INTESTINAL AUSTRALIAN AND NEW ZEALAND MEDICAL ONCOLOGY GROUP OF TRIALS GROUP UROGENITAL & PROSTATE CANCER AUSTRALIA Professor T Price MBBS FRACP TRIALS GROUP Professor C Karapetis MBBS FRACP DHlthSc (Medicine) Professor I Davis MBBS (Hons) PhD MMedSc FRACP FAChPM AUSTRALASIAN LEUKAEMIA & MELANOMA AND SKIN CANCER LYMPHOMA GROUP AUSTRALIA NEW ZEALAND TRIALS LIMITED GYNAECOLOGICAL ONCOLOGY Professor M Shackleton MBBS PhD (Jan-May) Professor M Hertzberg MBBS GROUP FRACP PhD FRACP FRCPA (Jan-Apr) A/Professor A Brand MD (May-Dec) A/Professor P Mollee ONCOLOGY SOCIAL WORK MMEd FRCS(C) FRANZCOG CGO MBBS(Hons) MMedSc FRACP FRCPA AUSTRALIA (Apr-Dec) A/Professor P Beale BSc Ms K Hobbs MSW MAASW AUSTRALASIAN LUNG CANCER MBBS FRACP PhD TRIALS GROUP PRIMARY CARE COLLABORATIVE BREAST CANCER TRIALS A/Professor N Pavlakis BSc MBBS CANCER CLINICAL TRIALS GROUP Professor G B Mann MBBS PhD FRACS MMed (Clin.Epi) PhD FRACP (Jan-Oct) Professor L Trevena CANCER NURSES SOCIETY OF MBBS(Hons) MPhilPH PhD AUSTRALASIAN METASTASIS AUSTRALIA (Oct-Dec) A/professor J Rhee BSc(Med) RESEARCH SOCIETY (Jan-Jun): Ms J Campbell CCN MBBS(Hons) GCULT PhD FRACGP Professor E Thompson PhD (Jun-Dec): Ms C O’Kane Cancer Nurse PSYCHO-ONCOLOGY COOPERATIVE AUSTRALIA AND NEW ZEALAND Practitioner RESEARCH GROUP SARCOMA ASSOCIATION CANCER SYMPTON TRIALS and (Jan-May) Dr J Couper MBBS MD Dr J Desai MBBS FRACP PALLIATIVE CARE CLINICAL STUDIES MMed(psych) FRANZCP AUSTRALIAN & NEW ZEALAND COLLABORATIVE (May-Dec) Dr J Shaw BApplSc CHILDRENS HAEMATOLOGY Dr P Allcroft BMBS FRACP M Pall Care BPsych(Hons) PhD ONCOLOGY GROUP COOPERATIVE TRIALS GROUP FOR ROYAL COLLEGE OF PATHOLOGISTS Dr C Fraser FRACP MBBS MPH NEURO-ONCOLOGY OF AUSTRALASIA AUSTRALIAN AND NEW ZEALAND Professor A Nowak MBBS FRACP PhD Dr K Lee MB ChB FRCPA HEAD & NECK CANCER SOCIETY FACULTY OF RADIATION ONCOLOGY TROG CANCER RESEARCH A/Professor M Batstone MBBS Dr D Forstner MBBS (Hons) FRANZCR Dr P Sundaresan BSc(Hons) MBBS BDSc(Hons) MPhil(Surg) FRACDS(OMS) FRANZCR PhD FRCA(OMFS) HUMAN GENETICS SOCIETY OFAUSTRALASIA AUDITORS (Jan-Mar) Ms M Young GradDip SocSci BDO (Fam Therapy) MHSc (Gen Couns) Level 11 FHGSA 1 Margaret St (Mar-Dec) A/Professor N Pachter Sydney NSW 2000 MBChB FRACP
5 - 6 ANNUAL REPORT 2017
COSA BOARD + COSA REPORTS
COSA GROUP REPORTS
AFFILIATED ORGANISATION REPORTS REPORT OF THE PRESIDENTOTHER REPORTS
FINANCIAL STATEMENTS
I am pleased to Achievements in 2018 was returning home to Perth after attending the COSA ASM in Sydney. present my second Some of our noteworthy achievements Paul was a beloved member of the and final annual report in 2018 include: cancer community, especially of COSA. Many members of Paul’s family and contribution as COSA Financial surplus against a Board colleagues from Cancer Council WA approved small budget deficit President. I am proud to attended the opening so they could say COSA continues to The official launch of the COSA witness us honouring Paul in this hold high standing in the Exercise in Cancer Care position small way. The Governor of Western oncology community, statement in May 2018 Australia, the Honourable Kim Beazley AC, officially opened the ASM and The successful completion of the building on partnerships also recognised Paul and his family first year of the two-year pilot in his speech. Mr Beazley brought his and collaborations. implementation project for the personal style and rhetoric from his We have an important Australasian Tele-Trial Model days as Federal Minister for Defence seat at the table of the Record attendance and sponsorship (1984 to 1990) and the government’s National Cancer Expert for the Cancer Pharmacists Group response to the discovery of asbestos Reference Group and courses in the naval fleet, which was a perfect introduction to the inclusion of Oversubscribed inaugural Breast the Cancer Australia mesothelioma in the COSA program. Intercollegiate Advisory Cancer Masterclass Recognising the importance of the Excellent attendance at events Group. In 2018 we were Tom Reeve Award for Outstanding for advanced trainees in medical Contributions to Cancer Care, we invited by the Australian oncology Council on Healthcare moved the recipient oration from Introduction of online educational the conference dinner into the main Standards (ACHS) to modules program. Professor Grant McArthur lead the working group was the very deserving recipient in Four government submissions, most 2018 and delivered an inspiring oration in the development of in partnership with Cancer Council on the critical role of collaboration Australia a new oncology clinical across his career. Professor McArthur indicators, and I am Annual Scientific believes that advancement in cancer knowledge and treatment grateful to Professor Eva Meeting Segelov for agreeing to development comes from working As always, the culmination of together to achieve progress faster. chair this important work. another busy year for COSA was the He also emphasised the critical role of ASM in Perth. The 2018 ASM was a clinician-scientists like him who work successful event with 745 delegates in in the clinic and the lab ensuring that attendance. We always plan for lower the real experiences of patients drive numbers on the west coast as some of the focus of research. our members find the travel time and As is COSA practice we closed out expense challenging, and of course the ASM with the COSA Presidential we have fewer local members in Perth. Lecture, given by Mr Tim Hammond However, attendance exceeded our on “The Politics of Cancer”. When he expectations and the vibe was high accepted the invitation, he was the and the feedback on the program Federal Labor Member for Perth. excellent. When he resigned from Parliament In the opening ceremony we were in May 2018 (to spend more time pleased to recognise the legacy of Paul with his young family) Mr Hammond Katris who sadly died unexpectedly confirmed his commitment to on Saturday 18 November 2017 as he present at COSA. Before entering 7 - ANNUAL REPORT 2017
As always, the Parliament, Mr Hammond practised Governance as a barrister, predominantly advising culmination of another and appearing on behalf of victims of In March 2018 we farewelled one of busy year for COSA asbestos diseases. This combination of our inaugural co-opted directors, was the ASM in Perth. his political career and working with Ms Felicity Shaw. Ms Shaw joined The 2018 ASM was mesothelioma patients, made him the COSA Board in May 2014 when an ideal candidate for the Lecture. we were implementing our new a successful event Mr Hammond spoke passionately governance strategy. Her background with 745 delegates in about his experience representing as a lawyer brought us much needed attendance. mesothelioma patients when and valuable skills. Ms Shaw made practising law, providing the perfect significant contributions to COSA, end to the conference. notably as a member of the Audit, Risk and Finance Committee and providing For those members that could not guidance on the 2017 Constitution attend, you missed another excellent review and contractual arrangements and highly educational conference, with ASN Events, COSA’s conference but you will be pleased to know organiser. In June 2018 we welcomed that the videos of all presentations new co-opted director Ms Sandie delivered in the plenary hall and one Angus who also brings valuable legal of the concurrent rooms are now qualifications. 2019 will see the end available for member only access on of the third term for a number of our the COSA website. inaugural directors, thus opening the Government way for new candidates. Submissions Thanks and COSA members contributed to Acknowledgments four government submissions In closing I would like to thank the throughout 2018, three of which were COSA Board and Council members for in partnership with Cancer Council their support throughout 2018. Thanks Australia (CCA). to Professor Sanchia Aranda and Response to the Draft Cancer Council Australia for continuing Phyllis Butow AM our mutually beneficial relationship. Implementation Plan for the COSAProfessor President National Health Genomics Policy My sincere thanks to the COSA 2017-2018 Framework, January 2018, CCA and members who continue to support the COSA organisation and our important work. And finally, thanks to Marie Malica and Response to the TGA public the COSA staff who work tirelessly to consultation on the Management ensure COSA continues to meet the and Communication of Medicines needs of our members. Shortages in Australia, April 2018, CCA and COSA
MBS Review taskforce – Oncology Clinical Committee report, July 2018, COSA
Feedback on the TGA Discussion Paper on Communication plan for patients and health professionals on priority and provisionally registered medicines, July 2018, CCA and COSA
7 - 8 ANNUAL REPORT 2017
COSA BOARD + COSA REPORTS
COSA GROUP REPORTS
AFFILIATED ORGANISATION REPORTS REPORT OF THE CHIEF EXECUTIVEOTHER REPORTSOFFICER
FINANCIAL STATEMENTS
Once again 2018 was a very busy year for the COSA team. I will leave it to the COSA Group Chairs to report on the activities of their Groups and will concentrate on the ASM on other activities not featured elsewhere for my report.
Annual Scientific function in providing professional Karapetis and Nick Pavlakis – the development for our members. content was capably presented. Meeting Health Technology Assessment We included mesothelioma in the The culmination of COSA’s efforts in Oncology: Challenges and program as we have many talented each year is the ASM. It is not only Opportunities Difficult decisions and local WA clinicians contributing to our premier educational event, it the challenging patient in cancer the understanding and treatment of also provides the best professional care – strategies for the cancer this deadly disease, including Anna networking opportunity in oncology. clinician. Hosted by the COSA Nowak who brought that expertise In fact, 64% of respondents to the Epidemiology Group and held in to the committee. Anna guided the event evaluation reported their partnership with the International mesothelioma content which looked motivation for attending as “the Society for Pharmacoeconomics and at the latest evidence on some of opportunity to network with other Outcomes Research the critical issues like whether all health professionals”. The next highest patients should be biopsied, the role The Changing Landscape of Clinical response at 63% being “to hear expert of immunotherapy, and the role of Trials. Hosted by the COSA Clinical speakers from a variety of cancer genetics. fields” and 58% for both “to attend key Trials Research Professionals Group, sessions in the conference program and sponsored by St John of God Tim Clay did an amazing job as relevant to my practice” and “to Hospital Subiaco the 2018 ASM convenor. Not only learn about new research, trials and did he lead the ASM program, The Cancer Pharmacists Clinical innovative programs in cancer care he also planned and chaired the Development Workshop. Hosted and control”. Trainees Weekend. We are extremely by the COSA Cancer Pharmacists grateful to Tim (and his patient and Group and sponsored by Slade Prior to start of the 2018 ASM, we understanding wife) for his enormous Health hosted the Advanced Trainees role in the success of the ASM. Weekend on the Saturday and Sunday. Difficult decisions and the This intensive 2-day course attracts We were delighted that 97% of survey challenging patient in cancer care advanced trainees in surgery, medical respondents indicated they would – strategies for the cancer clinician. and radiation oncology; as well as attend or recommend others to Led by senior members of the COSA junior medical staff and allied health attend future COSA ASMs – almost as Psycho-oncology Group professionals. This year’s program was high as the result last year of 98%. We jam packed, focusing on “Everything Our ASM themes of gastro-intestinal are confident COSA members and you need to know about upper cancers, mesothelioma, technology, delegates continue to be invested in GI cancers”. It was encouraging to genomics and prevention were all keeping up with trends in oncology know that delegates reported in the featured throughout the program. research and treatment, as well as evaluation they were satisfied that the The Committee ensured COSA’s engaging with areas not traditionally event delivered high-quality content, multidisciplinary focus was included considered as part of the COSA and a resounding 100% stated they in every session, and the speakers were program. Therefore, we are eager would attend again or suggest others of the highest calibre. Unfortunately, to ensure this continues and grows do so. our international expert in GI cancer, further. Dirk Arnold withdrew late due to On Monday we hosted four diverse unforeseen personal circumstances. Trainee Events and well attended pre-conference But thanks to our national experts workshops. These have become an In addition to the COSA Trainees in GI cancer who stepped in –Eva important component of COSA’s Weekend, once again COSA hosted a Segelov, David Goldstein, Chris number of other events specifically for Advanced Trainees in 2018.
9 - ANNUAL REPORT 2017
ATOM – the Advanced Trainees professional interests might be in We were delighted Oncology Meeting held in Sydney in health psychology, but she can now that 97% of survey March 2018. This Roche sponsored add proficiency in governance to respondents indicated meeting, with a program developed her bailiwick. Phyllis was the fourth by trainees for trainees, provides a President I have worked with during they would attend or comprehensive review of current my time at COSA, the second non- recommend others to oncology practices and includes clinical doctor and the third woman! attend future COSA presentations on topics not covered I think COSA is leading the way in in traditional meetings. Comments diversity – even our Board has more ASMs – almost as high from the evaluation included “Most than 50% women. as the result last year useful/practical education event so I have been working in oncology for of 98%. far!” and “Very helpful and useful for nearing 20 years now and (almost) training, information pitched at AT every day at COSA is a highlight. level is always great!” Suffice to say This is in no small part due to the we are already planning the 2019 enthusiastic and dedicated people I event. am surrounded by. My sincere thanks Breast Cancer Preceptorship. to the COSA Board, Council and Audit, Identifying a gap in educational Risk and Finance Committee for their needs for breast cancer continued support and guidance, and management, this inaugural event to the COSA members that contribute was held in September 2018 with to our activities. But most importantly, sponsorship from Amgen. Guided it is the staff that continue to inspire by Nick Zdenkowksi and Janine me. The team remained stable Lombard, the program was tailored throughout 2018, with no changes to meet the needs of medical from last year. COSA Project Managers oncology advanced trainees and Rhonda DeSouza, Chantal Gebbie, junior consultants. Registration Hayley Griffin, Jessica Harris and Gillian reached capacity prior to close, Mackay continue to excel. My endless indicating the necessity in this thanks to Fran Doughton who not area. We were encouraged by only supports myself, but everyone the excellent feedback and have else around her, and always with great Marie Malica secured sponsorship for the 2019 humour. Chief Executive event. Based on delegate feedback I look forward to working more closely Officer and the structure of the program we with our new President Nick Pavlakis have decided to change the name and am excited about the possibilities to “Breast Cancer Masterclass” in that 2019 will bring for us all. 2019. Thank you and acknowledgements Once again, I am lamenting the departure of another President. It has been an absolute pleasure working with Phyllis Butow during her tenure as COSA President. Phyllis’s
9 - 10 ANNUAL REPORT 2017
COSA BOARD + COSA REPORTS
COSA GROUP REPORTS COSA AFFILIATED ORGANISATION REPORTS SNAP SHOT OTHER REPORTS
WHERE NT ARE YOU? FINANCIAL STATEMENTS 5 QLD WA 161 59 SA 49 NSW 256 ACT OVERSEAS WHO 13 VIC 17 194 ARE YOU? TAS Administration / Management 115 23 Advanced Trainee 47 Clinical Research Professional 94 Educator / Academic 61 Exercise Physiologist 26 Medical Oncologist 139 Nurse Nutritionist/ Dietitian 27 145 Pharmacist 165 Psycho-Oncologist 38 Radiation Oncologist * Members can Surgeon 18 52 indicate more than Other 106 one profession
58 WHAT DID 63 YOU ATTEND? 87 2018 COSA education 784 opportunities ACTNOW (58) 92 ASM (784) ATOM (63) Breast Cancer Preceptorship (87) CPG Foundation Course (92) 121 CPG Advanced Course (121) Online Education Modules (34) Pharmacology of Cancer Chemotherapy Course (23) 34 Trainees Weekend (57) 23 Total (1319) 57
11 - ANNUAL REPORT 2017
COSA GROUP REPORTS
BREAST CANCER Breast density has been a huge or major focus of discussion in this GROUP group (something COSA is also working on in conjunction with 2018 has been an extremely busy year. other bodies). COSA has been invited to be involved in several new breast cancer projects Optimising early detection of breast with Cancer Australia and I, as Chair cancer in Australia of the Breast Cancer Group have been A project which looks at the feasibility privileged to represent COSA at the of a tailored screening service or ‘risk following: stratified breast screening’. The chairs for this project are Surgeon Bruce Shared follow up and survivorship Mann and Program Manager (Victoria model of care for early breast cancer BreastScreen), Vicki Pridimore. Topics Susan Fraser patients Chair, Breast Cancer Group discussed include: Cancer Australia ran a series of workshops in Sydney in early 2018 Risk assessment (looking at various with the aim to develop a shared care models). CANCER CARE plan and consider the input from all Over-diagnosis. stakeholders and consumer groups. COORDINATION GROUP The project involves handing over Alternative screening modalities. The Cancer Care Coordination follow-up care to a patients GP upon Costs benefits and harm of risk- Group have been working behind completion of their treatment for based breast cancer screening. the scenes to set up a membership early breast cancer. My role included survey that will inform our future reviewing all the available on-line Reviewing current clinical practice directions. We are fortunate to have education on breast cancer and breast related to tailored screening and received in-kind research support imaging currently available to General early detection services in Australia. from the Queensland University Practitioners. This project continues of Technology, which helped us to into 2019 and will be rolled out upon Influencing best practice in draft a research protocol and ethics completion. metastatic breast cancer project The project chaired by Fran Boyle is application for the Group survey. The Breast Screening Technical Reference part of the overall strategy of Cancer survey will build upon a previous Group (BSTRG) Australia. It aims to develop a list survey that was distributed to our Meeting 2 – 4 times a year the BSTRG is of appropriate and inappropriate Group ten years ago. We expect the responsible for providing expert advice oncology practices to influence best results will provide insights into the and guidance to the Department of practice in the setting of metastatic changing nature of the cancer care Health on a range of research outputs breast cancer in Australia. It also aims coordination environment and the commissioned or being considered by to influence and support clinicians professional development needs of the Department. These include: and patients in making wise decisions health professionals in dedicated about the most appropriate care. coordination roles. The data Providing guidance on the direction, gathered will support our advocacy scope and methodology to be used 2019 is shaping up to be another efforts to improve coordination in research outputs relating to very busy year in the breast cancer of care at system, service and breast cancer. realm and I am looking forward to individual patient level. It will also representing COSA. Following approval Reviewing and commenting on the provide important data to update from COSA Council Professor Rik outputs of research on breast cancer COSA’s Position Statement on Care Thompson and myself are hoping to screening for methodological rigour Coordination in 2019 and develop further advance our breast density and application to the Australian professional development activities position statement along with and in screening context. for our members. conjunction with other groups. We continue to recognise I would like to thank COSA Council the importance of facilitating for its support and giving me the communication amongst cancer care opportunity to be involved in so many wonderful projects.
11 - 12 COSA BOARD + COSA REPORTS
ANNUAL REPORT 2017
COSA GROUP REPORTS
AFFILIATED ORGANISATION REPORTS
coordinators and we are pleased to Educational activities in 2018 in drug dosing, how liver impairment advise that in late 2018 we appointed During 2018,OTHER the CPG REPORTS provided influences dosing considerations and an editor for The Coordinator - Claire significant education and training the impact of electronic medicines Kelly. We are looking forward to opportunities to a wide variety of management in cancer therapy. working with Claire to produce cancer health professionals from across Many pharmacists submitted oral this newsletter and encourage our Australia: abstracts or gave poster presentations members to get in touch if you have FINANCIAL STATEMENTS outlining their research and were of CPG Foundation Clinical Practice for information about your activities to a very high quality, with a number Cancer Pharmacists Course – 25-27 share with your care coordination being nominated for Best of the Best May colleagues. poster discussion sessions. The CPG Cancer Nursing Society of Australia representative on the ASM organising A number of Group members Annual Congress – 20-23 June committee was Michael Cain from WA attended the 2018 COSA ASM where who did a fantastic job in ensuring we were pleased to see a number of Advanced Trainee Pharmacology of pharmacist involvement in the presentations and posters on topics Chemotherapy Education Modules – program. related to care coordination. The 11 August Group is now planning another of its CPG Executive Committee and CPG Advanced Clinical Practice for very successful webinars on the topic Membership Update Cancer Pharmacists Course – 1-2 of digital innovations in cancer care At the beginning of 2018, the CPG September that is based on one of the concurrent committee grew to eight members sessions held at the ASM. CPG Pre-ASM Clinical Development with the election of Kimberley-Ann Workshop – 12 November Kerr, Courtney Oar and Jim Siderov AM. Kimberley-Ann, Courtney and Jim These events were very well attended have been fantastic in providing their with record numbers attending both expertise and fresh ideas during 2018 the Foundation and Advanced Cancer and we look forward to their continued Pharmacist courses. This demonstrates involvement over the next 12 months. an ongoing requirement to meet the As at November 2018, our membership educational needs of those working stood at 222 (either group members or in cancer care as well as a significant COSA members with cancer pharmacy commitment by cancer health care as an area of interest) which makes us professionals to further their knowledge one of the larger groups within COSA. and skills. I would like to once again Additionally, we have updated our thank the numerous CPG members group terms of reference to ensure for their enthusiasm and passion in they are fit for purpose – these were Patsy Yates getting involved with education at endorsed by COSA Council at their Chair, Cancer Care these events including all members of November meeting and will soon be Coordination Group the CPG committee. We look forward available on the COSA website. to continuing our commitment to education in 2019.
CANCER PHARMACISTS Other activities during 2018 GROUP Other activities have included key contributions from CPG members to the PBAC consultation on pan-tumour indications for immunotherapies, the eviQ Renal and Hepatic Dose Modification Reference Group and the ACSQHC/NCERG National Chemotherapy Governance Framework Committee: Jenny Casanova, Working Group. Kimberley-Ann Kerr, Dan COSA ASM: 13-15 November 2018, McKavanagh (Deputy Chair), Courtney Michael Powell Perth Chair, Cancer Oar, Michael Powell (Chair), Gail Many CPG members attended and Pharmacists Group Rowan, Geeta Sandhu, Jim Siderov were heavily involved in the COSA An extremely busy year of activities for ASM in November. The Medicine the Cancer Pharmacists Group began Matters concurrent session with a with the election of new members theme of “getting the dose right” in to the CPG executive committee cancer therapeutics was very well and ended with a highly successful attended – topics covered included COSA ASM in Perth with significant anti-cancer therapy in the older pharmacist involvement. patient, the significance of sarcopenia
13 - ANNUAL REPORT 2017
CLINICAL TRIALS relevance of clinical trials in everyday more efficiently manage research practice, challenges in identifying programmes. RESEARCH targets, and future directions. Dr Dr Niloufer Johansen (SJOG Subiaco) PROFESSIONALS GROUP Adeline Tan gave a fascinating insight and Ms Lesley Miller (University of WA) into the preparation, analysis and outlined the Continuous Improvement During 2018 the Clinical Trials classification of tissue samples, the in Care-Cancer Project, which Research Professionals Group provision of intraoperative diagnoses concentrates on the implementation Executive Committee aimed to and tissue banking. The importance of values-based health care, the key increase the profile of the group and of frozen section diagnoses during central goal of every health care to provide members with high quality surgery was also highlighted by Dr Raj organization and how to increase opportunities to enhance professional Mohan, who outlined pre-operative patient support through a more development. We decided to reach evaluation and staging procedures for coordinated team approach. out to our members via an online ovarian cancer; including the aim to survey to obtain feedback on how achieve optimal cytoreduction and In the final session Dr Eva Zopf, from to further improve the effectiveness the role of neoadjuvant chemotherapy the Australian Catholic University, gave of the CTRPG. The results of the in the treatment of advanced ovarian an update on exciting research on the survey indicated that members cancer. application of exercise as medicine for welcome further education in areas cancer patients. Increasing evidence Ms Annika Andrews, Senior Legal impacting on trial conduct including from observational studies suggest Counsel from St John of God ICH-GCP, research ethics and that regular exercise can reduce Subiaco Hospital demystified the governance, protocol development, the risk of cancer-specific mortality contractual framework of clinical trial translational research and patient and improve quality of life. A range agreements, explaining sponsorship, reported outcome measures, as well of mechanisms may be driving compensation, indemnity and the as the promotion of networking this protective effect, a number of differences between general and no- opportunities. We realised that the physiological adaptations occur when fault insurance. This was followed by COSA website is a key resource, people exercise that may modulate an informative talk on phase I trials by as 70% of our members learned tumour progression and some Ms Zelda Herbst from Linear Clinical about the CTRPG online. Members evidence exists that exercise may Research who reported that positive provided links to helpful websites and enhance a patient’s ability to tolerate health outcomes for patients with resources which will be added to our higher doses of treatment. Exercise advanced disease had been achieved area of the website. improves quality of life; the ideal by accelerating the research process scenario is that cancer patients not I am delighted to report that another and providing life-changing therapies only receive an anti-cancer plan but highly successful Clinical Professional faster. Initiatives to match patients also a prescription to exercise. Day Workshop was held 12 November to clinical trials such as the THRIVOR in Perth. A local subcommittee was application and ClinTrial Refer have Throughout the year the membership formed to prepare for the workshop, been successful, and capacity is being of the Executive Committee changed, led by Sanela Bilic and including developed to perform complex studies we welcomed two new general Tammy Corica, Claire Howarth and where patients are matched to clinical members, David Mizrahi from Sydney Joanne Youd. They did a wonderful trials based on molecular profiling of Children’s Hospital and Adam Stoneley job to pull together an exciting their disease. from ICON Cancer Foundation. agenda under the theme “The Joanne Hakanson stepped down after A presentation about the Australasian Changing Landscape of Clinical Trials” accepting a new position. Annette Health and Research Data with support from the Executive Cubitt, from the Royal Brisbane and Manager’s Association was given Committee. The workshop was Women’s Hospital continued as by Adam Stoneley and Tammy sponsored by St John of God Subiaco Deputy Chair, Alison Richards from Corica. The purpose of AHRDMA Hospital and COSA and a number Flinders Medical Centre as Secretary, is to foster and promote health of stimulating and educational Sanela Bilic from St John of God research and data management by presentations were given by invited Subiaco Hospital and Natasha Roberts providing professional development guest speakers who very generously from Royal Brisbane and Women’s opportunities, educational activities contributed their time and expertise. Hospital as general members. I and resource materials. The first session “Patient’s Journey am pleased to acknowledge the from Diagnosis to Cancer Treatment” Dr Helen Atkinson, Executive commitment and high-level support was presented by clinicians from Officer from Curtin University provided by all members of the St John of God Subiaco Hospital gave an update on the WA Health committee. Translations Network Clinical Trial and Western Diagnostic Pathology/ We continued to provide support and Data Management Centre, a Western Women’s Pathology. Dr Tarek for the COSA Australasian Tele Trials year after it was established. The Meniawy shared two patient case Model by reviewing a supervision plan centre acts as a central node for the studies in ovarian and cervical cancer and subcontract, and Adam Stoneley conduct of national and international to demonstrate the link between contributed as a member of the clinical trials, engages with public emerging data and the real world, Steering Committee. highlighting the importance and health system researchers and identifies barriers and enablers to 13 - 14 COSA BOARD + COSA REPORTS
ANNUAL REPORT 2017
COSA GROUP REPORTS
AFFILIATED ORGANISATION REPORTS
During an Annual General Meeting, EPIDEMIOLOGY GROUP New Executive Committee Members members were updated about the OTHER REPORTS Two active members have been activities of the CTRPG Executive The Epidemiology Group held a appointed to the Executive Committee during 2018 and Pre-ASM workshop titled "Health Committee, which reflects increasing an invitation was extended for Technology Assessment in Oncology, interest in the Group: nominations to fill a vacant committee Challenges and Opportunities" on Dr Susan Jordan position. A number of excellent FINANCIAL STATEMENTS Monday 12 November 2018 in Perth. Susan is a Senior Research Fellow and suggestions were received to guide The workshop was organised in head the Cancer Causes and Care new initiatives to be undertaken collaboration with the International group at QIMR Berghofer Medical during 2019. One of these is to hold Society for Pharmacoeconomics Research Institute, Brisbane. another Clinical Professional Day and Outcomes Research-Australian prior to the COSA ASM this year in Chapter (ISPOR-AC) and was Dr Ashley Hopkins Adelaide and we will aim to include endorsed by Cancer Voices Australia Ashley is a pharmacist and a National the topics proposed by members who with a ‘Consumer Included’ logo. Breast Cancer Foundation of Australia responded to our online survey. Early Career Research Fellow working The workshop gave an overview of the in the Precision Medicines Group at I would like to sincerely thank all of role of health technology assessment the Flinders Centre for Innovation in our members and COSA staff for their and economic evaluation for cancer Cancer, Flinders University. support during 2018. The CTRPG will treatments in a contemporary continue to promote positive changes Australian context. Challenges faced Active Participation in COSA’s through education, networking, the by stakeholders such as consumers, Initiatives and Activities provision of resources and leadership clinicians, decision makers, academics The Group, represented by its Chair to further improve the excellent and industry were discussed as well and Executive Committee, has been standard and conduct of oncology as opportunities to improve current actively involved in COSA events and clinical trials research throughout processes and the evidence base using initiatives. Epidemiology Group was Australia and New Zealand, and real-world evidence. well represented in Council Meetings beyond. and ASM sessions and presentations The workshop was very interactive in 2018. We participated in a number and well attended by clinicians, policy of important initiatives including makers, epidemiologists, health RANZCR position statement on economists, analysts and researchers. informed decision making in the It was chaired by Paul Scuffham, management of localised prostate Director of Menzies Health Institute cancer, the COSA response to the MBS Queensland, and had an excellent Review Taskforce Oncology report, line-up of speakers representing and the COSA Mammographic density various institutions and sectors. working group. Speakers included Anne Cust, the University of Sydney; Richard Norman, Curtin University; Sally Wortley, the University of Sydney; Richard De Abreu Lorenco, University of Technology Dianne Lindsay Sydney; Claire Vajdic, UNSW Sydney; Chair, Clinical Trials Research Greg Cook, BMS Australia; Brian Wall, Professionals Group consumer representative; Sarah Norris, The University of Sydney; Danny Liew, Monash University.
Issuing Epidemiology Group’s First Newsletter (Epi-news) The first edition of Epi-news was circulated in September 2018. The Haitham Tuffaha purpose of this newsletter is to share Chair, Epidemiology Group with Group members some of the research and progress being made in cancer epidemiology. Our members have a diverse range of skills and experiences, and we are reaching out to seek their involvement in the Group activities, and to learn about their initiatives and achievements. The newsletter will be issued every six months.
15 - ANNUAL REPORT 2017
EXERCISE AND CANCER oncology, surgery, nursing, nutrition, being supported by over 20 influential public health and other disciplines. cancer and health organisations. GROUP On behalf of the group I would The COSA Position Statement on like to sincerely thank all Executive The Exercise and Cancer Group is Exercise in Cancer Care was officially Committee members for their time committed to progressing a national launched on 7 May 2018 at the Peter and commitment: Di Adams, Morgan approach to the implementation of MacCallum Cancer Centre. At the same Atkinson, Lucy Bucci, Anne Cust, Liz exercise in cancer care. time it was highlighted in an article Eakin, Sandi Hayes, Sandie McCarthy, published in the Medical Journal of Group Aims and Objectives Andrew Murnane and Sharni Patchell. Australia and an MJA podcast. We were The overarching aim of this Group I’d also like to acknowledge the overall delighted to receive extensive national is to have exercise incorporated as contribution of the three retiring and international media coverage a standard component of care for committee members during their which helped to disseminate the people with cancer. The primary tenure; thank you Anne Cust, Liz Eakin position statement. COSA would like objectives of the Group are to: and Sandi Hayes. The group will be to sincerely thank the working group seeking expressions of interest for new Promote and progress a national who developed the position statement committee members in 2019. approach to the implementation of and everyone who provided feedback evidence-based exercise in cancer COSA Position Statement on Exercise during the consultation. care in Cancer Care The Exercise and Cancer Group is Our Group has developed a position Foster and facilitate effective now focussing on implementation statement on exercise in cancer care research, education and advocacy of of the position statement. COSA which can be downloaded from: the role of exercise in cancer care called for expressions of interest https://bit.ly/2whIvom. for an implementation working Engage stakeholders and The position statement endorses group in November and we were collaborate with partners to improve evidence-based guidelines and applies delighted with the level of interest and the quality of, and access to, exercise them to the Australian setting. The multidisciplinary mix. Representatives in cancer care statement is intended to provide have been appointed in the following Provide a multidisciplinary forum guidance to all members of the multi- categories: implementation science, for discussion and exchange of disciplinary cancer team and calls for medical oncology, radiation oncology, knowledge and experiences related exercise to be viewed as an adjunct surgical oncology, nursing, exercise to exercise in cancer care therapy and incorporated into routine physiology, physiotherapy, general cancer care. The position statement practice, dietetics, health economics Group Membership has been endorsed by the Medical and a consumer representative. In 2019 The group’s membership has Oncology Group of Australia, Cancer work will begin on developing and remained stable in 2018, with Council Australia, Exercise and Sports executing an implementation strategy approximately 200 professionals Science Australia and the Australian to integrate exercise within routine representing exercise physiology, Physiotherapy Association as well as cancer care. physiotherapy, radiation and medical
15 - 16 COSA BOARD + COSA REPORTS
ANNUAL REPORT 2017
COSA GROUP REPORTS
AFFILIATED ORGANISATION REPORTS
COSA 2018 Annual Scientific Meeting the value of nurses in promoting Exercise featured strongly at the exercise OTHERamong REPORTS people with 2018 ASM in Perth thanks to the haematological cancer (work led by contribution of Carolyn McIntyre on Matthew Perich) the ASM organising committee. The using exercise to improve ‘Exercise and Cancer’ plenary session fatigue and quality of life during was recorded and the presentations FINANCIAL STATEMENTS chemotherapy in colorectal cancer are available for COSA members to patients (work led by Eva Zopf) view on the COSA website (https:// www.cosa.org.au/events/past-annual- integrating exercise medicine into scientific-meetings/): cancer care in the hospital setting (work led by James Fletcher and Scott Fisher - Mice, Meso and Curtis Forbes) and community- Exercise Prue Cormie based setting (work led by Prue Chair, Exercise & Carolyn McIntyre - Exercise for Cormie) Cancer Group patients with mesothelioma Calls were made for more research Janette Vardy - Challenges in investigating the potential influence physical activity for colorectal cancer of exercise on treatment tolerance; survivors how exercise may aid in preventing sarcopenia; whether technology Prue Cormie - Implementing supported interventions influence exercise in cancer care abs common side-effects/symptoms; and A range of abstracts presented exciting how to most effectively implement new work in the field of exercise exercise into routine clinical practice. oncology. Some of the highlights The group’s AGM was held at the 2018 included: ASM where discussions centred on the the use of technology to track importance of a strategic approach to physical activity and symptom our implementation work. The focus response (work led by Michael of the group’s work in the coming Marthick) years will be on implementing the calls made within the COSA Position haematologist perspectives of the Statement on Exercise in Cancer Care. important role of exercise for people with myeloma (work led by Jennifer Nicol)
17 - ANNUAL REPORT 2017
FAMILIAL CANCER Mark Jenkins – Epidemiologist Australia (HGSA) Familial Cancer – Epidemiology of Inherited GI Clinics Clinical Professional Day, GROUP Cancer disorders which will be held on Tuesday 27th August 2018, at the Mantra resort, Kim Hobbs – Psychosocial impact Kingscliff, NSW. of having an inherited cancer disorder Contribute Familial Cancer topics and speakers to the COSA ASM to be Dean Fennell – BAP1 and held in Adelaide on November 2019. mesothelioma Contribute to the Cancer Genetics This report is also on behalf The development of a national session at the HGSA conference in of the Human Genetics Society consensus plan for routine Wellington, New Zealand in August of Australasia (HGSA) immunohistochemistry (IHC) testing 2019. of the mismatch repair (MMR) The activities of the COSA Familial proteins in colorectal cancer to Update the prescribing guidelines Cancer Group (FCG) in 2018 have detect Lynch syndrome. A position for medications to lower the risk of focussed on supporting continuing statement calling for reflex MMR breast cancer. training, education and development IHC testing for all newly diagnosed of resources and guidelines to achieve Review the terms of references and colorectal and endometrial cancer consistency of practice. Specific strategic plan for the group. was endorsed at COSA Council and activities undertaken in 2018 included; the HGSA Council meeting in 2018. I wish to thank all those on the The successful running of the COSA/ It will appear soon on the COSA Executive in 2018 for their work during Human Genetics Society of Australia website. the year. I also wish to thank Nicholas (HGSA) Familial Cancer Clinics Pachter, who has chaired this group The COSA FCG continues to work Clinical Professional Day, which was for several years, he has made a lasting with the COSA Mainstreaming held on Tuesday 4 September 2018 contribution and provided excellent Group regarding the development, at the Mantra resort, Kingscliff, NSW. leadership to the Executive and the distribution and evaluation of The day featured presentations on Familial Cancer community. Nicholas resources to support Oncologists in the following themes: has decided to step down from the discussing and facilitating ovarian position of Chair but will continue to CDH1 gene/ Hereditary Diffuse cancer treatment-focused genetic serve on the Executive. Gastric Cancer Syndrome testing (TFGT). These resources have been well received by many The 2019 COSA FCG/HGSA Cancer Colorectal polyposis sites across several states and data Genetics SIG executive members are; Models of Care - revisiting the from the evaluation project is being Lucinda Salmon (VIC) Chair three P’s Patients, Practitioners and analysed. Development of an online Panels educational module is also underway Rachel Williams (NSW) Deputy chair to support the ongoing training Breast Cancer Predisposition – Nicholas Pachter (WA) Immediate past of health professionals wishing to beyond high risk genes chair upskill in this area. The day was well attended and Fiona Webb (ACT) Secretary The COSA FCG Executive and the received. The Executive thanks all HGSA Cancer Genetics Special Susan Dooley (NSW) Treasurer the speakers who made it such an Interest Group (SIG) Executive voted excellent day with all of their hard work Members; Nicola Poplawski (SA), Kathy in favour of amalgamating their preparing and presenting their talks. I Tucker (NSW), Mary-Anne Young (NSW), executive committees. These groups also acknowledge the support provided Linda Warwick (ACT), Helen Mar Fan have overlapping interests and thus by Astra Zeneca, COSA and kConFab in (QLD), Simon Troth (QLD), Alexandra combining executives allows for a making this day happen. Lewis (VIC). broader inclusion of professional The selection of Familial Cancer groups on the executive. We believe topics and speakers for the 2018 this will also create opportunities to Lucinda Salmon COSA ASM held in Perth in broaden the reach of work undertaken Chair, Familial Cancer Group November. The FCG arranged a by the executive which is of benefit session entitled “GI Cancers and for members of both associations. Mesothelioma” and the following The amalgamated group will seek Nicholas Pachter Speakers presented: endorsement of the executive model Council Representative, HGSA at upcoming COSA and HGSA council Hooi Ee – Gastroenterologist – meetings. Surveillance of Lynch syndrome In 2019, the COSA FCG/HGSA Cancer Marina Wallace – Colorectal SIG executive plans to: Surgeon – Management of Familial Adenomatous Polyposis Develop the program for the 2019 COSA/Human Genetics Society of
17 - 18 COSA BOARD + COSA REPORTS
ANNUAL REPORT 2017
COSA GROUP REPORTS
AFFILIATED ORGANISATION REPORTS
GERIATRIC ONCOLOGY Guidelines Development Working We are also keen to feature more Group – TheOTHER Group REPORTS is aiming local activities, and to include stories GROUP to develop guidelines/practice that demonstrate the range of points to help improve the clinical multidisciplinary initiatives that our The COSA Geriatric Oncology Group management of older adults with members are involved with – so please continues to focus on priority cancer. These will provide Australian get in touch if you have information activities to improve outcomes for health professionalsFINANCIAL STATEMENTSwith access to an that we can share with our readers. older Australians with cancer. overview of recommended practices Research Working Group – required to ensure that older adults The Geriatric Oncology Group with cancer have access to optimal established this working group cancer care. The Group experienced to develop research capacity and some resourcing issues in the support collaborative networks to help increase for guideline development during the the quality and quantity of geriatric year, so this has been slower than had oncology research in Australia. Several hoped, but we are continuing activity research concept development in 2019. “workshops-by-teleconference” have Information Sharing – GO eNews, the now been convened by the Group Group’s online newsletter, continues and these proved to be a valuable to be issued bi-annually, and during forum to enable the exchange of ideas 2018 two editions were circulated in Meera Agar while providing a multidisciplinary January and July. We are grateful to Chair, Geriatric Oncology Group perspective to help develop research Wee-Kheng Soo for his leadership in concepts. No submissions were editing this publication and ensuring received in 2018 but we plan to offer our members are kept up-to-date a further opportunity to support about Group activities as well as research and project evaluation for our national and international initiatives members, but the format will evolve in geriatric oncology. We would after consultation with members. We love to see broader engagement are pleased that many of the studies across our audience and are always discussed within this forum continue open to suggestions for content. to progress.
19 - ANNUAL REPORT 2017
NUTRITION GROUP achieved. In the opening plenary benefit. This partnership will support Marian highlighted the challenges an increase in collaborative activities The Nutrition Group aim to provide of recognising cancer-related between the two organisations to a national platform to advocate for malnutrition in the age of obesity, address nutrition and cancer issues. and support optimising nutrition for noting that body composition is more As a first collaborative activity, DAA people with cancer. important than BMI or weight. She funded an external research prize shared practical tips in Wednesday’s for the highest quality abstract The e-news initiative, introduced in breakfast session for optimising presented by a dietitian at the 2018 2016, continues to be well received. nutritional care, drawing on the recent ASM. Erin Laing was the inaugural The e-news is circulated to Nutrition European Society of Parenteral and recipient of this award for her excellent Group members quarterly with the Enteral Nutrition (ESPEN) guidelines presentation and quality research aim of keeping members up to date for nutrition for people with cancer. into nutrition and neuroendocrine with the activities of the Group, Joining Marian was Professor Stephen tumours undertaken within her PhD informed about upcoming events of Clarke offering and insightful look candidature. interest, relevant new resources and at cancer malnutrition from the At the August COSA Council meeting research in the area of nutrition and oncologist’s perspective and Jane the group received approval to cancer, and profiling clinicians and Stewart who provided an overview commence development of a researchers in the area. of the impressive program of work position statement on cancer-related undertaken within the Victorian One of the highlights of the year was malnutrition and sarcopenia. Work Cancer Malnutrition Collaborative. invited speaker, Professor Marian de will commence on the position This session was well attended and van der Scheuren from VU University statement early in 2019 including a achieved the highest number of Medical Centre Amsterdam, at call for expressions of interest from registrations out of the breakfast the 2018 COSA ASM. Marian put the broader COSA membership to sessions offered at the ASM. nutrition front and centre at the be involved in its development. To ASM however, conveyed the strong The Dietitians Association of support the development of the message that it is with a multimodal Australia (DAA) joined COSA as an position statement the Nutrition and multidisciplinary approach that associated organisation in 2018 Group Executive undertook a survey optimal nutrition (and supportive following discussions between the of multidisciplinary cancer clinicians’ care) for people with cancer can be two organisations about the mutual awareness, perceptions and practices
Professor Marian de van der Scheuren
19 - 20 COSA BOARD + COSA REPORTS
ANNUAL REPORT 2017
COSA GROUP REPORTS
AFFILIATED ORGANISATION REPORTS
regarding cancer-related malnutrition PSYCHO-ONCOLOGY interactions with family members, and sarcopenia in December. OTHER REPORTS some of which were demonstrated via Results from the survey will support GROUP short films, with all attendees receiving identification of priority areas for the a copy of the new guideline’s booklet. The Psycho-oncology Group actively position statement. participated in the 2018 COSA ASM in The Psycho-oncology Annual General Group members continue to be Perth. TheFINANCIAL conference STATEMENTS opening session Meeting was held during the COSA involved with the malnutrition paid tribute to Paul Katris, who we ASM. At this meeting we discussed in Victorian Cancer Malnutrition lost in 2017, and the announcement our identity as a Group and its future Collaborative, led by the Peter of the Cancer Council Western direction. It was unanimously decided MacCallum Cancer Centre Nutrition Australia Paul Katris Honours/Masters that the group would no longer be department and funded by the Scholarships in his memory. This known as the Australian Psycho- Victorian Department of Health and scholarship funds cancer researchers oncology Society (OZPOS) / COSA Human Services (DHHS). Further in Western Australia. One of the four Psycho-oncology Group and would funding was received in 2018 to scholarships available will be given now be called COSA Psycho-oncology commence two new projects to to someone pursuing their studies in group. The meeting also gave an develop an optimal care pathway for psycho-oncology. opportunity to announce that there nutritional management of people is now a vacancy in the Executive Sadly, at the end of 2018, we had with cancer and to translate and Committee for which there will be an another loss in psycho-oncology when culturally adapt the malnutrition advertisement in early 2019. Dr Melanie Price died unexpectedly. screening tool into the top 5 Mel was the former Executive Director Planning for the 2019 COSA ASM in languages other than English in of the Psycho-oncology Co-operative Adelaide is already underway with Victoria. Nutrition group members Group (PoCoG). She was a well-loved Professor Matt Loscalzo, Executive have been involved in project and respected person in the Australian Director, Department of Supportive committees, project lead roles and oncology community as well as an Care Medicine at City of Hope steering groups within the program. important contributor, mentor, and confirmed to attend. The conference Throughout 2018 the group continued driving force in the international and program strongly features areas of efforts to find funding to revamp of national psycho-oncology research interest for psycho-oncology with the highly successful evidence-based community. The Australian Psycho- the theme being: Putting Precision guidelines for nutritional management oncology Community, and broader and Personalisation into Practice – of adult patients with head and neck oncology community have been Urological cancer, Age and gender in cancer. These guidelines are used saddened by her loss. Her contribution cancer practice, and Digital health in by dietitians and multidisciplinary over the past 22 years to psycho- cancer. teams nationally and internationally oncology and to improving the lives of I am looking forward to working to support nutrition practice in head people with cancer and their families with all of you in the year ahead and and neck cancer and locating funds to will be her legacy that will continue to welcome contact from you all. support their maintenance will remain live on. a priority activity for the group. The 2018 COSA ASM provided an The group held an AGM at the 2018 opportunity for our group members to ASM to determine priorities and connect with each other but also, we activities for 2019. had a strong representation of psycho- oncology content from our group Thank you to all our members for members throughout the conference helping to maintain a small but program. There was an excellent pre- active and motivated group who are conference workshop entitled: Difficult passionate about optimising nutrition decisions and the challenging patient for people with cancer. in cancer care – strategies for the cancer clinician. The distinguished list of speakers at this workshop included Lisa Miller, Jane Turner, Justin Dwyer, Laura Kirsten Fran Orr, Cathy Mason and Paula Watt. Chair, Psycho-Oncology Group This workshop was followed the next morning by the Breakfast Session: How to manage challenging family interactions and promote effective family involvement in cancer care: Launching the TRIO Guidelines. Led by Ilona Juraskova, Phyllis Butow and Rebekah Laidsaar-Powell, attendees were provided with a summary of Nicole Kiss the new guidelines, evidence-based Chair, Nutrition Group strategies for managing challenging
21 - ANNUAL REPORT 2017
RARE CANCERS GROUP MacCallum Cancer Centre and Royal REGIONAL AND RURAL Melbourne Hospital, and will soon GROUP The executive of the Rare Cancers open in Western Australia (St John of God Hospital); South Australia (Royal Group (RCG) for 2018 comprised In 2018 the Regional & Rural Group Adelaide Hospital); and Queensland of Clare Scott (Chair), Damien Kee continued to focus on the unique (Royal Brisbane and Women’s (Deputy Chair), and members Phyllis issues facing cancer service delivery Hospital). Underpinning the program Butow, Hugh Dawkins, Michelle outside metropolitan areas. is a nationally accessible clinical and Harrison, David Goldstein, Sandra Fundamentally our goals each year tumour specimen database developed O’Toole, Tim Price, David Thomas, Toby don’t change. We remain focused on with BioGrid Australia. The program Trahair, Alison Trainer and Kate and further identifying the gaps in cancer aims to improve the identification and Richard Vines. Joining the Executive care and working to find solutions. consolidation of isolated rare cancer is Michael Brown, who replaces Gillian We principally serve as an advisory cases across Australia allowing more Mitchell, who served two years on the group and aim to work with other meaningful research to be undertaken. Executive but has relocated to Canada. peak Cancer bodies to operationalise The Executive of the Rare Cancers Key actions from our consumer these solutions. Group was the first COSA group to partners, Rare Cancers Australia (RCA), The key strategic event in 2018 was have both consumers and clinician included hosting the 4th annual to gather the key leaders from the members. CanForum at Parliament House in regional cancer centres. This is a September 2018. This annual meeting Group activities biennial event that aims to build upon continues to be highly influential, 2018 was a significant year for rare previous work and ideas. A face-to- bringing together key leaders in cancers in Australia. The importance face meeting was held in May 2018 of cancer research, treatment, and of research in underpinning access the Network of Directors and Clinical policy, and has a record of achieving to treatments was recognized by the Leads of Regional Cancer Centres tangible outcomes for patients with Australian Government with substantial in Sydney. The agenda included rare cancers. RCA also launched their commitments to rare cancers and discussion of workforce capability Rare Cancer Knowledge Base. This is a diseases announced through the requirements at regional sites, defining web-based resource for patients with Medical Research Future Fund (MRFF) best practice regional and rural cancer rare cancers in Australia hosting disease and the Australian Cancer Genomics care, an update on implementation information, links to support services, Medicine Centre (ACGMC, PI David of the Australasian Tele-Trial Model, and an evolving database of clinicians Thomas). identifying areas of advocacy for with interests in particular rare cancers regional and rural oncology, training Genomic testing is especially important (www.knowledge.rarecancers.org). for rare cancers as they often lack and education initiatives, plus evidence-based therapies based on The Rare Cancer Knowledge Base aims improving communication within the histology. The RCG’s continuing trials to address a major unmet need for Network and with a wider audience. of genomics (NOMINATOR in QLD, patients with rare cancers by facilitating Key action items from the meeting SA, VIC, WA and MoST in NSW) will be access to verified information and were to develop a “Regional Clinical supercharged in 2019 when they are expertise in their specific rare cancer. Services Report” which can be used rolled into the ACGMC. This program Complementing this resource, the for advocacy, a renewed focus on will provide genomic sequencing for RCG is developing the National Rare education and regular newsletters to more than 5,000 patients nationally Cancer Portal, under the umbrella engage COSA members. The day was a (one site in each state and territory), of the AGCMC. This Portal will utilize great success and provided an excellent with dynamic matched treatment telehealth to provide all Australians forum to facilitate communication and arms developed in partnership with with centralised access to nationwide collaboration between regional cancer the pharmaceutical industry. The expertise specific to their rare cancer, centres. addressing any potential geographic importance of this program was A workforce survey was conducted inequity, and facilitating their highlighted in the preliminary data from of all the Australian regional cancer optimal diagnosis, molecular testing, NOMINATOR presented at the 2018 centres and in 2018 there were management, treatment and support. COSA Annual Scientific Meeting. A key approximately 37 FTE medical finding from this presentation was that oncologists. This is a massive increase one-fifth of the rare cancers tested had from the early days in 2007 when genomic aberrations identified that there were closer to 5 FTEs. This reflects could be matched to an existing drug several points worth mentioning: 1) already proven in another cancer type. a career as a rural oncologist is an A further third of tumours had findings increasingly sought-after role, 2) there that may be targetable in the future. has been a noteworthy improvement The Group is also promoting access to in the level and sophistication of cancer more basic and translational research care in the regions, and 3) there is likely into rare cancers through the Stafford still a large unmet need for regional Fox Rare Cancer Program. This program and rural patients and more resourcing is active in Victoria through the Peter is required.
Clare Scott Chair, Rare Cancers Group 21 - 22 COSA BOARD + COSA REPORTS
ANNUAL REPORT 2017
COSA GROUP REPORTS
AFFILIATED ORGANISATION REPORTS
The Regional & Rural Group also had a SURVIVORSHIP GROUP became the inaugural Editor of the small but productive AGM at the COSA OTHER REPORTS Survivorship Newsletter which delivers conference with attendance from It has been another busy year for the up to date news and resources straight members of the Executive Committee COSA Survivorship Group with many into your inbox. With expert help from and Regional & Rural Network, as well activities relating to research and fantastic Gillian Mackay, the Group as a number of conference attendees delivery of care for cancer survivors Project Manager, we have updated FINANCIAL STATEMENTS based in regional areas. There was an in Australia. the terms of reference for the group update on the progress of the tele- and conducted a survey on members trials model and more importantly The highlight of the year was preferences for future work which will interest from attendees about rolling indisputably the national patient inform the Group’s work strategy for the model out across Australia. There reported outcome (PRO) Think Tank the next few years. is clearly a strong need and desire to in Sydney, August 2018. The Think Thanks to Gillian for her skillful move from the pilot phases in QLD Tank, expertly facilitated by Dr Alison support and to the energetic and and NSW to a wider roll out. For further Evans, brought together stakeholders visionary Executive comprising Ray details on the COSA Tele-Trial Project from diverse disciplines across Chan, Richard Cohn, Haryana Dhillon, supported by MTPConnect, please see Australia to focus our discussion Michael Jefford, David Joske, Karolina the information under “Other Reports”. on how we can best implement PROs into routine clinical practice in Lisy and Janette Vardy for their The Regional & Rural Executive Australia irrespective of the setting wonderful input throughout the year Committee got a fresh look in and technology availability. The that made all this work possible. November 2018 with Sabe Sabesan recommendations of the report ending his 5-year term as Chair of (available at https://www.cosa.org.au/ the Group. Rob Zielinski stepped up groups/survivorship/resources/) from his role as Deputy Chair and Sid Baxi who is a current member of the provided a roadmap for the work Regional & Rural Executive Committee in this area that the Survivorship was nominated and approved as the Group will be leading in 2019 and new Deputy Chair. Sabe will remain beyond that will provide a detailed on the Regional & Rural Executive blueprint on implementation of PROs Committee along with Peggy Briggs, into routine cancer care in Australia. Michail Charakidis, Wei‐Sen Lam and At their November 2018 meeting, Craig Underhill. Thank you to the COSA Council gave in-principle Executive Committee for their time and endorsement for our Group to oversee commitment which allows us to work the implementation of PRO activity, Bogda Koczwara AM on behalf of our membership. and to create a working group to lead this initiative. The PRO Think Chair, Survivorship Group If you would like to participate in the Tank discussion has also focused our Regional & Rural Group or be kept thinking on what aspects of PRO informed of our activities, please login work need further research and I am to your member profile on the COSA sure many grant applications will be website and select ‘Regional and Rural strengthened by the deliberations at Oncology’ as either a ‘COSA Group’ or the meeting. ‘Area of Interest’. We strongly encourage members from all disciplines to get Many members of the Survivorship involved with our group. Group have also contributed to work in other priority areas including the development of the Digital Health Strategy which is to be released in 2019, and collaborations with PC4 and PoCoG on multimorbidity and cardiac late effects. Last year also focused our thinking on how to disseminate information about the COSA Survivorship Model of Care and a small working group is pulling together two publications on this topic that are about to be submitted.
The year also marked our increased focus on capacity building and Rob Zielinski strengthening of the Group Chair, Regional and operations to better support Rural Group our members. Dr Karolina Lisy
23 - ANNUAL REPORT 2017
AFFILIATED ORGANISATION REPORTS
AUSTRALASIAN a multidisciplinary focus and the patients with metastatic CRC receiving changing needs of the organisation. oxaliplatin. GASTRO-INTESTINAL TRIALS GROUP New Clinical Trials New trial for rectal cancer, RENO, will Three new studies in colorectal cancer study the ‘Watch and Wait’ strategy in commenced recruitment in 2018. patients who have developed a Clinical Complete Response with concurrent MODULATE, this study aims to test chemo-radiotherapy. whether it is possible to reverse the resistance of MSS colorectal cancer to The MASTERPLAN clinical trial PD1 inhibition by combining the PD1 for high-risk and locally advanced inhibitor nivolumab with other drugs pancreatic cancer patients will Australasian Gastro-Intestinal designed to stimulate lymphocyte determine whether SBRT in Cancer Trials Group (AGITG) is a infiltration of tumours. To date, 50/90 addition to modern chemotherapy multidisciplinary collaborative group participants have been enrolled into is superior to the current standard of medical and research professionals the study. of chemotherapy alone in both who conduct clinical trials to improve the neoadjuvant and definitive The SPAR study will evaluate the treatment for gastro-intestinal (GI) setting. An important component effect of simvastatin (SIM) on efficacy cancers. Through the tireless efforts of of MASTERPLAN is to incorporate and toxicity of pCRT in rectal cancer the AGITG membership, we have been high-quality tissue collection to patients, and on systemic and local instrumental in achieving significant facilitate future molecular and inflammatory responses. changes in clinical practice locally genetic research. MASTERPLAN is a and globally. LIBERATE is a study to investigate major multidisciplinary collaboration The 57 clinical trials conducted by “liquid biopsies” as a method of of Australia’s leading pancreatic the AGITG, since the group was first evaluating RAS mutation status in clinicians and scientists in the formed as a network of investigators patients with advanced colorectal context of a multicentre phase II trial in 1991, have involved over 4,000 cancer. This involves determining the sponsored by AGITG, conducted by patients treated at 90 sites in Australia, accuracy of results of “liquid biopsies”, NHMRC Clinical Trials Centre, and 8 sites in New Zealand and over 90 compared to genetic testing of cancer done in collaboration with the Trans sites located across Asia, Europe and tissue. Different methods of testing Tasman Radiation Oncology Group North America. We have published “liquid biopsies” will be studied and (TROG) and was awarded funding by 127 journal articles as a result of compared. The study will also assess the Medical Research Future Fund clinical trials and the group has whether the ability of “liquid biopsies” Grant. to detect cancer gene mutations is made 222 presentations of study In addition, DYNAMIC – Pancreas will different at different time points. findings at national and international join the pancreatic cancer space in conferences. In collaboration with WEHI, two circulating tumour DNA Analysis to Our 2018 activity highlights include: new studies focusing on circulating informing adjuvant chemotherapy. tumour DNA including Dynamic-III Strategic Implementation Activities Changes within AGITG and Dynamic-Rectal commenced Three new initiatives were Professor John Simes retired from our recruitment. These studies will approved by the Board and SAC for Board of Directors. We sincerely thank determine whether a chemotherapy commencement in 2019 including John for his years of dedication and decision based on the presence or the Translational Research Model, contribution to the group’s research absence of circulating tumour DNA and additional concept development program including his role of AGITG- after surgery will be more effective programs such as the Idea Generation CTC Group Coordinator. The Board than standard of care treatment. also thanks Dr David Watson for his Workshop and Endorsed Study Model. We look forward to the development contribution to AGITG. We welcomed Research Priorities of the following trials over the coming Professor Steve Ackland, Professor At the meeting held in December, year: Andrew Barbour and Elizabeth Thorp the SAC set the research priorities for to the Board and Dr Katrin Sjoquist as OXTOX, recipient of the 2018 AGITG 2019, including “thinking outside the AGITG-CTC Group Coordinator. Innovation Fund Award, aims to box” such as pharmacogenomics, pre- Membership of the Upper and Lower determine whether ibudilast has the habilitation and nutrition; rare cancer GI Working and the Scientific Advisory potential to decrease the severity possibilities, developing concepts in Committee were refreshed ensuring of acute neurotoxicity and CIPN in 23 - 24 COSA BOARD + COSA REPORTS
COSA GROUP REPORTS
ANNUAL REPORT 2017
AFFILIATED ORGANISATION REPORTS
OTHER REPORTS
the rectal cancer space; and clinical trials in HCC and liver SBRT to name a few. FINANCIAL STATEMENTS
AGITG Awards The 2018 John Zalcberg OAM Award for Excellence in AGITG Clinical Trials Research was awarded to Professor John Simes of The University of Sydney. The John Zalcberg OAM Award recognises a member of the AGITG who has made a significant and outstanding leadership contribution John Simes receiving to AGITG clinical trials research over the 2018 John Zalcberg a sustained period. Professor Simes OAM Award was a founding member of the AGITG in 1991 and was a key member of the team of investigators that developed AGITG members Professor Andrew with in-depth discussion with the the first clinical trial conducted in Barbour, Associate Professor Mustafa input of expert preceptors. Australia for gastro-intestinal cancer Khasraw and Professor Nik Zeps. The Commonwealth Neuroendocrine patients. In 2018, the AGITG membership Tumour Collaboration (CommNETs) Professor Janette Vardy of The grew to over 1,100 members from held its first Clinical Trials University of Sydney was awarded the multidisciplinary backgrounds Development Workshop in Hong $200,000 Innovation Fund grant in including medical, research, science, Kong in December. The Workshop 2018 for the OXTOX pilot study. The allied health, nursing and consumer. brought together leaders in the field Innovation Fund is made possible – NETs clinicians, researchers and Meetings through generous contributions from consumers from across Australia, New We celebrated our 20th AGITG donors and supporters of the AGITG. Zealand and Canada. Eight clinical Annual Scientific Meeting in Brisbane trial concepts were selected for The 2018 AGITG-Merck Kristian with over 360 delegates. The ASM presentation at the workshop. After Anderson Award was awarded to is a fantastic opportunity for our robust discussion, a vote determined Dr Rosemary Habib, who will receive members and GI cancer researchers four concepts to be further developed a grant of $36,700 to complete the to discuss current and new clinical at the workshop and in the coming first year of her PhD at The University trials and developments in GI months. For more information on of Sydney. Her research will focus on research in Australia, New Zealand CommNETs go to: gicancer.org.au/ whether CAR T-cells can be used to and internationally. Our stellar group commnets. trigger an immune response in colon of international faculty included cancer patients. The Kristian Anderson Professor Brendan Moran, Professor As we look towards 2019, a major focus Award is awarded in honour of Kristian Sabine Tejpar, Professor Diana Sarfati, will be our Annual Scientific Meeting Anderson, who was diagnosed with Professor Aldo Scarpa, Professor Jae- in South Australia in August featuring colon cancer in 2009 and successfully Ho Cheong, Professor Graeme Young, both local and international key lobbied the federal government for Dr Daniel Renouf, and Professor Daniel opinion leaders. affordable access to cetuximab. He Chang. Awards were presented to For more information about AGITG, passed away in 2012, leaving behind Dr Lorraine Chantrill for Best of New visit gicancer.org.au. a legacy as someone who made life- Concepts; Dr Belinda Lee for Best of extending treatment accessible to Posters; Dr Hui-Li Wong for Best of many people with colon cancer. Fast Forward. The Olivia Newton-John Cancer Wellness and Research Centre Community Engagement won the Outstanding Site Award. The GI Cancer Institute is the community division of the AGITG. In A 2-day Preceptorship in rectal cancer 2018 it continued to raise awareness was held at Monash University in and funds for clinical trials research. May by Professor Eva Segelov. The The Gutsy Challenge community areas covered included screening, fundraising program was a huge multimodality management of early, success, with two teams of trekkers locally advanced and metastatic taking on Tasmania’s 60km Overland disease, and supportive care. Current track. AGITG board member Professor clinical practice was debated, gaps Tim Price Steve Ackland led the trek, which in knowledge were identified and Chair, AGITG raised over $120,000. A team of ten potential research ideas were floated. cyclists also rode over 100km through Targeted at junior clinicians in the Snowy Mountains in the L’Etape oncology, the workshop consisted of Russell Conley Challenge in November, including small groups and interactive sessions Chief Executive Officer
25 - ANNUAL REPORT 2017
AUSTRALASIAN Members and 7 Life Members. We had different ways to action these priority 22 clinical trials open and were able to areas as we continue to work in this LEUKAEMIA & develop and approve three new clinical area. LYMPHOMA GROUP trials during the year. A major focus was Through the establishment of on the National Blood Cancer Registry a stable structure and financial and ways to secure funding for the data base, we were able to increase our registry and sample biobank. organisational expertise by employing a Through our involvement in the Select Communications & Marketing Manager Committee Inquiry into funding as well as a Philanthropic & Fundraising for research into cancers with low Manger to increase brand awareness During 2018, the Australasian survival rates, we were quite pleased and long-term sustainability. with the final report and the 25 Leukaemia & Lymphoma Group As a result, the ALLG was able recommendations put forward by the (ALLG) celebrated 45 years of clinical to develop a sound Corporate committee. The next steps for ALLG will trial research and we are deligted to Communication Strategy and a be to remain actively involved in the report that it has been another highly Philanthropic Strategy. During the implementation phase. successful year for the ALLG. We have development phase of Corporate continued to improve our external Further to this, the ALLG applauded the Communication Strategy, we identified image, strengthened engagement launch of the landmark report called the need to define our organisational with members, staff, partners, ‘Economic evaluation of investigator- values. Organisational values are other foundations and government. initiated clinical trials conducted by necessary to support the vision, shape Significant improvements have taken networks.’ Released in August 2017, the culture, and reflect the type of place, focussing on servicing the by the Australian Commission on organisation the ALLG is by defining needs of our members and continuing Safety and Quality in Health Care and the way we work as an organisation sound corporate governance. the Australian Clinical Trials Alliance with members, staff, stakeholders, The ALLG, with an established and (ACTA), the welcomed report analysed and industry partners. Through stable structure including a steady 25 Australian clinical trials initiated by consultations with the Board, staff, financial base has been able to clinicians. One of the most significant and membership, we identified and increase the number of clinical trials findings was the 5.8:1 benefit-to-cost adopted four organisational values: and accelerate trial recruitment rates ratio of clinical trials – meaning that integrity, quality, collaboration and so that trial results can be quickly for each $1 invested in clinician-driven innovation. clinical trials in Australia, benefits of achieved and translated into improved Thank you to all the members and $5.80 can be realised. outcomes for patients with blood staff of the ALLG that continue to cancer. ALLG continued efforts with those that make ALLG the success it is known As a member organisation, we have share our vision by joining with HSANZ for, and we look forward to taking the continued to make gains in our four key to facilitate the second annual Blood ALLG’s scientific endeavours to a new strategic directives: to deliver significant Cancer Forum. Chaired by Prof Andrew level of achievement and prominence scientific outcomes, enhance brand Roberts, the forum is an opportunity in the world of Haematology and and reputation, foster a passionate for the blood cancer foundations and blood cancers. We would also like to membership base and ensure long- organisations to share common areas acknowledge all the participants who term sustainability. We have continued for advancing blood cancer initiatives. join an ALLG clinical trial, without their to work in alignment to progress our The forum included representatives extraordinary contribution to science strategic goals by focusing on trial from Leukaemia Foundation Australia, the ALLG would not be able to provide diversity and quality, considering Lymphoma Australia, Myeloma better outcomes for cancer patients better ways to engage members, and Australia, and Snowdome. Three hence our tag – “Better Treatments… improving our operational efficiency. priority areas were identified in 2017, Better Lives.” these include improving care for rural, Membership reached 799 Members; regional and remote communities; consisting of 414 Full Members, 335 access to new medicines; and support Associate Members, 43 Community for research. The forum explored
The ALLG 2018 Clinical Trial Peter Mollee Staff Chairman Scientific Advisory Committee, ALLG
25 - 26 COSA BOARD + COSA REPORTS
COSA GROUP REPORTS
ANNUAL REPORT 2017
AFFILIATED ORGANISATION REPORTS
OTHER REPORTS
AUSTRALASIAN LUNG Education / Events Robert Li, a Medical Oncologist from One of the most important aspects of the Memorial Sloan Kettering Cancer CANCER TRIALS GROUP ALTG is connectingFINANCIAL researchSTATEMENTS outcomes, Centre in New York City specialising information and evidence to the in the molecular profile of patients’ scientific, healthcare professional tumours and leads the clinical and patient communities. We do this research program targeting the HER2 through a number of events, including gene in lung cancers, continued on our annual preceptorship and with their highly informative talks 2018 has been another outstanding symposium. about immunotherapy and Targeted year for the Australasian Lung Cancer Therapy in NSCLC respectively. Trials Group (ALTG) As the peak body Developing our next generation of Complementing our international representing clinical trials in lung researchers saw ALTG hosted its fourth guest speakers were local leaders cancer, the successes of 2018 would annual preceptorship workshop in the field including A/Prof Wendy not have been possible without in lung cancer. 40 participants Cooper, (Pathology discussion on the dedication and support of the attended including for the first- PDL1 & TMB) A/Prof Tom John (EGFR broader leadership team of ALTG and time members of the nursing and Mutated NSCLC latest data), Dr the diverse member base which is consumer communities. For two days, Malinda Itchins, (ALK NSCLC update) growing year on year. the intensive active learning program Prof Anna Nowak and A/Prof Nick covered a broad range of lung cancer Under the direction of ALTG President Pavlakis (Mesothelioma and Dream topics including EGFR, ALK, ROS1 and Nick Pavlakis, the Scientific Advisory Trial update). immunotherapy, with early career Committee (SAC) Chair Ben Solomon, researchers, and junior consultants New for 2018 was the addition of and dedicated committee members across a range of clinical specialities our speaking tours with the aim to and collaborative partners, ALTG mentored by eminent figures in the increase ALTG presence in the local continues to provide strategic vision field. Learning via small groups with health care and patient communities, and operational leadership across the a preceptor has shown to enhance as well as increase knowledge and lung cancer clinical trials space. participant’s ability to critically evidence for treatment options in Funding of the program appraise and evaluate evidence the lung cancer space. Positioned One of the significant highlights for supporting the evolution of clinical nicely after the World Lung Cancer 2018 has been the renewed funding practice in lung cancer. Conference, the speaking tours were arrangement from Cancer Australia also an informal approach to shining This event has become a must do for for the next 3 years. Not only does a light on the progress to date of any new or emerging lung cancer this provide financial sustainability research and the impact clinical trial consultant or researcher and in 2019, for the program over this time, it also outcomes has on the lung cancer the Preceptorship workshop will recognises the enormous contribution space globally. ALTG hosted two take place again in October 2019 in the ALTG program offers lung cancer speaking tours – one in Melbourne Melbourne. patients Australia wide. Alongside this and one in Brisbane in the lead up to grant funding, we continue to work In October, 110 delegates attended the annual symposium in October. with a number of industry partners the third annual ALTG Symposium in Collectively, both events attracted who remain incredibly supportive Sydney. This one-day event, generously more than 80 participants across the and connected to the vision of the supported by our industry partners, health care and patient communities. program attracted esteemed international The theme for these dinner and local speakers to cover a very events was the Evolving Role of Clinical trials comprehensive lung cancer program. Immunotherapy in the Management On the back of 2017, where there Mr Chris Draft Founder, President of Lung Cancer. Thanks to our were a large number of new clinical and CEO of the Chris Draft Family international and local speakers Mr trials initiated, the year began with Foundation in Atlanta, Georgia, set Chris Draft, Dr Sanjay Popat, Dr Robert recruiting participants across a diverse the inspirational tone for the day from Li, A/Prof Tom John, Prof Ken O’Byrne portfolio of clinical trials. This has a consumer perspective, with his for their time in discussing patient continued throughout 2018, with moving talk about his wife, who sadly and clinical perspectives in this space. recruitment numbers tracking on or lost her battle to lung cancer in 2011. above schedule. This is great news Membership Our other international speakers for the lung cancer community, in ALTG continues to attract a diverse Dr Sanjay Popat, a Consultant that the ALTG collaborative group are and active membership base. With Thoracic Medical Oncologist from working hard to offer new treatments over 740 members across Australia The Royal Marsden in London, to as many eligible lung cancer and New Zealand, ALTG is highly Honorary Clinical Senior Lecturer in patients as possible. So far this year, valued as an inclusive and educated the Molecular Genetics and Genomics the ALTG collaborative group have membership group for lung cancer Group at the National Heart and Lung recruited over 170 patients to our clinical trials across Australia and Institute, Imperial College London clinical trial portfolio and initiated at NZ. Internationally recognised by and current Chair of the British least 1 new trial. other collaborative groups as the Thoracic Oncology Group (BTOG); Dr
27 - ANNUAL REPORT 2017
go to for clinical trials in Australia for lung cancer, ALTG continues to participate and collaborate with international counterparts such as CCTG (Canadian Cancer Trials Group), ETOP, European Thoracic Oncology Platform among others to bring lung cancer clinical trials to patients in Australia and NZ. Alongside TACT – Thoracic Alliance for Cancer Trials of which ALTG is a member, the aim is to ensure that treatment options and future possibilities for care are widely available to lung cancer patients in our community.
Conclusion We look forward to 2019 and building on the successes of this year to take ALTG’s scientific and educational endeavours to new heights and prominence on a global stage across lung cancer clinical trials.
Nick Pavlakis President, ALTG
27 - 28 COSA BOARD + COSA REPORTS
COSA GROUP REPORTS
ANNUAL REPORT 2017
AFFILIATED ORGANISATION REPORTS
OTHER REPORTS
AUSTRALIA AND NEW of all disciplines, as well as scientific of recurrent and primary refractory and allied health sarcoma experts. Ewing sarcoma. This study is funded ZEALAND SARCOMA FINANCIAL STATEMENTS by a grant from CanTeen and is open The theme for the ASM was ASSOCIATION at both adult and paediatric sarcoma “Collaboration and Innovation: The centres. 2018 has been a milestone year for multidisciplinary approach to sarcoma the sarcoma community, with the care”. We were grateful to have two Please visit our website to find out more former Australasian Sarcoma Study esteemed international guest speakers about our clinical trial and study projects Group (ASSG) celebrating its 10th – Robin Jones, a medical oncologist and how you can be involved. with a specialist interest in bone and anniversary; and the successful 2018 Sarcoma Research Grants soft tissue sarcomas from The Royal merger of the Australian Sarcoma Program Marsden (UK), and Rob Pollock, a Group (ASG) and ASSG forming the Each year, we are able to award the consultant sarcoma surgeon who Australia and New Zealand Sarcoma Sarcoma Research Grants thanks to the specialises in hip and knee surgery, and Association (ANZSA) at its annual generous donations of our supporters. bone and soft tissue tumours from the general meeting in Perth on 12 In 2018, we awarded four recipients with Royal National Orthopedic Hospital October 2018. grants worth $120,000 for their research (UK). We were glad that the discussions projects. ANZSA will work closely with ANZSA will remain a not-for-profit were robust and to know that them to ensure they have adequate charitable organisation with the main many delegates went home feeling resources to produce high-quality goal of improving the outcomes of inspired to do more for the sarcoma research. We look forward to receiving patients affected by sarcoma and community. related tumours through research, updates from them. In the meantime, clinical trials, education and advocacy. The 2018 ASM also saw the inaugural please visit our website to read more meeting of the National Sarcoma about their research projects. ANZSA has also introduced new Nurses Group – formed to improve Looking ahead in 2019, we are excited membership processes and has now and coordinate services provided to to work with our partners to continue formalised membership categories – sarcoma clinicians and patients. Ordinary Member, Associate Member, achieving the objectives we have set Life Member and Corresponding Clinical Trials out to do. Our project pipeline is robust, Member. Our membership is open to ANZSA is committed to facilitating and we can’t wait to share more positive healthcare and research professionals, access for sarcoma patients to a updates with you in due time. diverse range of well-designed clinical consumer or patient advocates, and In the meantime, the 2019 ANZSA ASM research studies, where results that those from non-clinical backgrounds will be held on 11-12 October 2019 in The are generated will have a substantial who have a vested interest in sarcoma Canberra Rex Hotel. Be sure to save the international impact on improving the research. We encourage you to join us dates now. More information will be diagnosis and treatment for sarcoma as we provide members with a wide made available soon. range of benefits especially for those patients. Some of our ongoing clinical who are looking to embark on sarcoma trials include: We thank all our partners, sponsors and members for their continued support related research. SARC032 – A phase II randomised and trust in us and the work we do. It controlled trial of neoadjuvant The team is currently embarking on a will be another strong year ahead with pembrolizumab with radiotherapy new brand exercise that includes the renewed hopes of closing the gaps and adjuvant pembrolizumab in development of a new ANZSA website in sarcoma diagnosis and treatment patients with high-risk, localised and company logo among others, through research breakthroughs. which will be launched in early 2019. soft tissue sarcoma of the extremity. This is a collaboration between the At this time, we want to thank the sarcoma cooperative clinical trial founding Chair of ASSG, Professor groups in the USA and SARC that David Thomas, who resigned from will be opened at three adult sites the ANZSA Board in October 2018 in Australia as well as multiple sites to consolidate his focus on sarcoma globally. research. Professor Thomas has been a steadfast supporter of the ASSG/ANZSA NORTH – A phase II study of and a passionate advocate for sarcoma panobinostat in paediatric, patients and the sarcoma research adolescent and young adult patients community. We look forward to our with solid tumours including ongoing collaborations. osteosarcoma, malignant rhabdoid tumour/atypical teratoid rhabdoid 2018 Annual Scientific Meeting tumours and neuroblastoma. This Jayesh Desai Our 2018 ASM, held in October in Perth, study is funded by the NH&MRC and Chair, Scientific Advisory was again a great success as we had jointly run with ANZCHOG. Committee the privilege of hosting more than 120 delegates, most of whom were local rEECur – An international randomised controlled trial of and international clinicians, researchers Denise Caruso chemotherapy for the treatment Chief Executive Officer
29 - ANNUAL REPORT 2017
AUSTRALIAN & NEW international and national trials across over 165 children are diagnosed with multiple tumour streams. brain cancer each year. Recent studies ZEALAND CHILDREN’S have shown that brain cancers can be ANZCHOG would like to thank our HAEMATOLOGY classified into distinct tumour groups supporters for their generous support, through molecular profiling, and each of ONCOLOGY GROUP and we look forward to continuing these tumour groups respond differently these valued relationships throughout to various treatments. 2019. The AIM BRAIN project provides access Collaborative relationships with to the latest molecular profiling for national and international trial Australian and New Zealand children ANZCHOG has had a highly successful consortia diagnosed with brain tumours, year, securing several grants throughout Our expanding trial portfolio is largely implement a platform for clinical 2018 to support the ANZCHOG attributable to our burgeoning diagnostic testing for paediatric brain Office and the conduct of a range of relationships with a range of cancer, using state-of the art molecular childhood cancer trials to be opened international trial consortia and the genetic and epigenetic techniques. throughout Australia and New Zealand. capacity to maximise trial opportunities This project is an international research as they arise. We are working with Our infrastructure grant, funded collaboration, with the German-led a range of international trial groups through Cancer Australia’s Support Molecular NeuroPathology 2.0 study across the spectrum of childhood For Cancer Clinical Trials Program, (MNP2.0) providing immediate access to cancers, including networks from has been awarded for a further 3 years, this cutting-edge platform. Researchers Europe, United Kingdom, USA and which will enable trial development, at the Hudson Institute of Medical Canada. Opening an international trial particularly through supporting Research and Monash Health, led by in Australia and New Zealand presents our tumour-specific and discipline- Associate Professor Elizabeth Algar, are individual challenges each time, across specific groups. ANZCHOG’s Groups concurrently establishing the Australian areas such as contract development, have accelerated their trial activities, platform, with the pilot phase nearing agent importation and distribution, creating cohesive networks between completion, with the national rollout data storage and highly variable all of the Australian and New Zealand slated for 2019. regulatory requirements. ANZCHOG children’s cancer centres, and building acts as a central point for the resolution “Both stages of this project are vital. opportunities with their relevant of these issues, and as we work to Professor Stefan Pfister’s team at the international trial colleagues. In operationalize trial conduct with each German Cancer Research Centre (DKFZ) addition, ANZCHOG was awarded international group, we are establishing are leaders in this area, and we are funding through the Australian Brain effective functional trial models, paving very fortunate to have their support to Cancer Mission (5 years) to enhance the way for standardized processes for develop this technology in Australia”, access to the latest international future studies. said Dr. Chris Fraser, Chair of ANZCHOG. brain cancer trials for Australian “If we can accurately determine the children. This funding will enable Over the last year, we have worked exact type of brain cancer that a child more paediatric brain cancer trials closely with the Australian and New has at diagnosis, we have the best to be available throughout Australia Zealand Sarcoma Association (ANZSA) information to decide what treatment and support targeted projects to to open two trials at paediatric and is the most appropriate for each child. enhance trial access. Augmented by adult cancer centres, maximising trial Already, we are seeing the benefits of the generous support from The Kids access for eligible patients. Through the making treatment decisions armed with Cancer Project, we have enhanced Australian Brain Cancer Mission, we will the additional information provided by our capacity to provide centralised, be developing our collaborative work molecular profiling, whereby we can high-quality trial support services to with COGNO, looking to achieve similar minimise the burden of treatment side- our childhood cancer centres, fulfil our outcomes for Australian patients with effects and give our children the greatest national sponsor responsibilities and brain cancer. chance of surviving brain cancer.” as well facilitating our collaborative Focus on… AIM BRAIN relationships with key international trial ANZCHOG would like to acknowledge ANZCHOG’s Access to Innovative consortia. the vital support of our AIM BRAIN Molecular profiling for BRAIN cancers funders, the Australian Government ANZCHOG has also secured grants (AIM BRAIN) project is a four-year study, (through Cancer Australia), the Robert for specific trials from funding directly applying the latest laboratory- Connor Dawes Foundation and Carrie’s opportunities in 2018 (including The based technology to clinical practice, Bickmore’s Beanies 4 Brain Cancer Kids Cancer Project, Carrie’s Beanies to accurately diagnose brain cancers in Foundation. for Brain Cancer and Australian children. Government Medical Research Future For more information on ANZCHOG’s Despite the outstanding success in Fund), and utilising grants awarded activities, please visit the ANZCHOG the treatment of many paediatric in previous years, we have opened website (http://www.anzchog.org). cancers in past two decades, curative eight new investigator-initiated treatment for the majority of brain ANZCHOG’S Annual Scientific Meetings trials throughout Australia and New cancers remains an ongoing challenge. Our 2018 Annual Scientific Meeting was Zealand in the last 12 months, greatly In Australia, brain cancer kills more held in Sydney in June 2018, hosted by expanding ANZCHOG’s portfolio of children than any other disease and Children’s Hospital at Westmead. With
29 - 30 COSA BOARD + COSA REPORTS
COSA GROUP REPORTS
ANNUAL REPORT 2017
AFFILIATED ORGANISATION REPORTS
OTHER REPORTS
nine international speakers, a range of intensive effort put forward to attract Chris O’Brien Travelling Fellowship and national presenters, as well as a great the 2026 International Federation of joined us from the US, specifically the scientific and social program, it was a Head andFINANCIAL Neck Oncologic STATEMENTS Societies Massachusetts Eye and Ear Hospital to huge success! (IFHNOS) meeting to Brisbane. share their experience and learn from Chaired by Prof Sandro Porceddu (a local clinicians. In 2019 we will be heading to the Past-President of COSA) the team put beautiful city of Christchurch (13- The ANZHNCS has been fortunate forward their proposal to the IFHNOS 15th June, 2019) with the meeting to have recruited Rod Wellington as Board and to everyone’s great delight theme of “Families and Cancer”. With a non-clinical board member. Rod were successful. This meeting will leading international keynote speakers has extensive experience in clinical hopefully attract over 2000 delegates (including Dr. Uri Tabori and Dr. governance and government advocacy, to Brisbane in 2026. Our binational Marilyn Hockenberry) combined with and we hope will be able to assist us in meeting in 2019 will be held in a dynamic program, it is going to be our aims to improve the management Adelaide chaired by Dr Brian Stein and another great meeting and we invite of head and neck cancer at a state and we invite those members of COSA who you to join us! For more information, national level. We also maintain a strong have an interest in Head and Neck visit our 2019 ASM website. partnership with organisations such as Oncology to join us from the 19-21 Beyond Five and the Cancer Council September. based head and neck cancer support Research is supported by the groups who provide patient centered ANZHNCS by the provision of a venue education and resources. for the presentation of research results From a clinical perspective Head and from early and late career researchers Neck Cancer has not been exempt from at the annual scientific meeting, and the general push towards survivorship the functions of the ANZHNCS research and quality of life. Like a number of other foundation chaired by A/Prof David cancer streams survival is improving Wiesenfeld. With regards to research steadily and thus quality of life and output ANZHNCS members punch quality of survivorship becomes ever well above their weight in terms of high more important. Immunotherapy has impact publications and members are shown some spectacular results and frequently seen as invited speakers on Chris Fraser head and neck cancer is no exception Chair, ANZCHOG the world stage. A number of members to this. Clinicians are currently caught are also on the editorial boards of between an educated public who are prominent journals in the field. The rightly enthused by media reports and a foundation has had a particularly lack of clear evidence-based treatment AUSTRALIAN AND NEW successful year with over $54,000 in protocols with which to apply the ZEALAND HEAD & NECK donations, and $50,000 in grants. The therapy. Never the less, there is a clear Foundation Board and its Chair should CANCER SOCIETY change in management underway and be congratulated on their tireless it will be exciting to see its effect in a efforts in the very competitive arena of number of years. cancer fund raising. In summary, 2018 has proved to be a On the education front ANZHNCS has busy year for the ANZHNCS. Like many moved firmly into the digital space cancer societies the executive board are and with the assistance of Alison Black The Australian and New Zealand volunteers and finding time to dedicate developed the “Love your Mouth” Head and Neck Cancer Society’s to running organisations on top of clinical Video https://www.youtube.com/ overall mission is to achieve greater work and research is a never-ending watch?v=IwbB0lBlJD8&feature=youtu. prevention and early detection of challenge but ultimately a rewarding be. Oral health is a particularly head and neck cancers, and improved one. important, and frequently neglected treatment and ongoing care of component of head and neck cancer patients. This is undertaken through care so the generation of this video as four key activities: Scientific meetings; a resource for patients and carers is research; education and advocacy. very timely. The ANZHNCS also offers The highlight of our annual calendar is a developing nations grant as part the Annual Scientific meeting which of its educational activities for those was held in Melbourne in conjunction countries of more limited resources with the International Society for and this year we were delighted to Maxillofacial Rehabilitation. This saw host Dr Bibek Acharya from Nepal delegates from Australia, New Zealand, who spent time at our conference, and and the rest of the world join to discuss meeting with prominent Australian contemporary management of head units. In addition, we were pleased to Martin Batstone and neck cancer with a particular focus be joined by Dr Kevin Emerick who Past President, ANZHNCS on rehabilitation. This year also saw an was the successful recipient of the
31 - ANNUAL REPORT 2017
AUSTRALIAN AND NEW TheraP continues to go from strength its ability to identify gaps in areas of to strength, reaching 50% of its clinical need and pull together the ZEALAND UROGENITAL recruitment target in the final quarter right mix of professional disciplines, & PROSTATE CANCER of 2018 and looking likely to reach groups and resources to meet those TRIALS GROUP 75% within the first quarter of 2019. needs, all in the name of improving This is a testament to the great work genitourinary (GU) patient outcomes. being done with nuclear medicine in Throughout the past year the ANZUP treating prostate cancer. programs have encouraged and The final quarter of 2018 also saw the supported concept development prostate cancer trial ProPSMA reach within its membership. The Concept its recruitment target and move into Development Workshops, GU ANZUP has already hit the ground follow-up. We also had the launch Preceptorship and of course the running in 2019 having barely of TIGER, a randomised phase III ANZUP Annual Scientific Meeting recovered from the pace of 2018, our testicular cancer trial now open in (ASM), which continues to grow 10th anniversary year. And what a 3 sites nationally, as well as more in scope and influence, have all year it was! The difficult part of this internationally. endeavoured to bring together review is deciding what to leave out, multidisciplinary healthcare Finishing the year in the strongest which is a nice problem to have. professionals to help develop, foster fashion possible was grant funding and promote GU cancer research. In 2018 we saw both the ENZAMET for three important trials; BCG MM, an and ENZARAD trials reach their open label, multi-centre, two-stage, Our 2018 ASM was our biggest yet respective recruitment targets in phase III trial adding mitomycin to and a great way to celebrate our 10th the first half of the year. Both are BCG as adjuvant intravesical therapy anniversary. We had close to 400 now in follow up and the eyes of the for high-risk, non–muscle-invasive delegates in attendance, and we were international community are upon bladder cancer; ongoing testicular joined by seven international speakers them waiting for the research results cancer trial P3BEP; and NINJA, a phase and 65 local speakers and chairs they will generate. II randomised, novel integration of new focussed on communicating and prostate radiation therapy schedules sharing the theme of “Putting People All of our ongoing trials in 2018 have with adjuvant androgen deprivation, First”. reached milestones. Kidney cancer co-badged with and led by TROG. trials UNISoN and KEYPAD, and The ASM continues to provide a vital BCG+MM is already close to 40% of its prostate cancer trial Pain-Free TRUS connection between our membership overall recruitment target and NINJA B are recruiting well. Bladder cancer and the international GU community. opened at three sites in early 2019. trial PCR-MIB reached 25% of its The interaction between speakers and recruitment target before the year was With several new trials on the horizon delegates provides a platform where out which is a great achievement to including RAMPART and UNICAB, experiences, learnings and enthusiasm build on in 2019. ANZUP continues to demonstrate
31 - 32 COSA BOARD + COSA REPORTS
COSA GROUP REPORTS
ANNUAL REPORT 2017
AFFILIATED ORGANISATION REPORTS
OTHER REPORTS
can be shared, which, in turn will ideas to the point of becoming full- Sandown Racecourse in Melbourne on hopefully lead to the generation of scale studies. the 17th March and Sydney Motorsport new research and trial ideas for GU FINANCIAL STATEMENTS Park on the 10th September. Following In 2018, ANZUP funded eight projects cancers. these important fundraising events proposed by ANZUP members so we look forward to announcing more The Community Engagement Forum they could further develop ideas Below the Belt Research Fund Award was again held in 2018. This free public that will address the need for new recipients. forum was open to the general public treatments as well as supportive and and attracts patients, family, carers psychological care for the patient. Our 10th anniversary year in 2018 was and support groups. The audience certainly a banner year for ANZUP, The Below the Belt Research Fund was again given the opportunity to and this growth continues in 2019. We is of course supported by our annual engage with an experienced team of look forward to sharing this growth fundraising event, the Below the Belt healthcare professionals and patient and all the positive developments and Pedalthon. It has been held annually advocates to learn about ANZUP and outcomes for cancer treatment, and in Sydney since 2013 and was held for its research as a cooperative clinical ultimately the patient, in 2019 and the first time in Melbourne in March trials group. They were able to hear beyond. 2018. personal experiences from patients explaining what it is like to participate To date, the Below the Belt Pedalthon in a clinical trial and how to manage has raised close to $1.5 million their clinical trial experience, the dollars to support the Below the Belt cost of cancer care, and also the Research Fund and our membership impact of treatment on relationships as they continue to identify research and intimacy. Again, there was an gaps and develop new concepts. encouraging number of attendees We are constantly humbled by the with a lot of open discussion. level of support we receive from our membership and from the community The Community Engagement Forum at large for this event. Not only does is a mainstay of the ANZUP ASM the Pedalthon offer a great day out program and will again be held in for all involved, but participants and conjunction with the ANZUP 2019 their supporters alike are directly ASM in Brisbane on 21 – 23 July. Ian Davis contributing to vital research. Every Chair, ANZUP The Below the Belt Research Fund cent raised through the Pedalthon Awards is another important part of goes straight into the Below the Belt the ASM that focusses on developing Research Fund to support research clinical research concepts from within identification and development. our membership. This fund provides In 2019 the Pedalthon will return to seed funding to progress new trial
33 - ANNUAL REPORT 2017
AUSTRALIA year. Since inception ANZGOG has active volunteer group within our funded six studies with a further three membership with more than 100 NEW ZEALAND identified for funding in 2018. members taking part in committees, GYNAECOLOGICAL workings groups, education sessions Clinical Trials – along with the and other activities to mentor ONCOLOGY GROUP six OASIS studies, ANZGOG has a members and support our research. further nine studies either recruiting or in development through its Strategic Goals – ANZGOG reviewed its collaborations with the University of 2013-2018 Strategic Plan and defined Sydney, NHMRC Clinical Trials Centre. its goals for the next five years through The Annual Report gives me a chance These studies include ‘homegrown’ to 2023. These goals are: to celebrate the many successes studies by ANZGOG investigators ANZGOG has had over the past year GOAL 1 : Innovative and equitable and international collaborations and thank the many people who have clinical trials in gynaecological cancers. through the Gynecologic Cancer given generously of their time, energy InterGroup with such countries as GOAL 2 : World-class translational and intellect to our organisation. Canada, the United Kingdom and research in gynaecological cancers. I would like to recognise the Italy. These studies also represent GOAL 3 : Capacity building for contribution by Assoc Professor Alison the multi-disciplinary nature of gynaecological cancer research in Brand as Chair of ANZGOG over ANZGOG with surgical and exercise Australia and New Zealand. the past six years. During this time physiology clinical trials as well ANZGOG achieved financial stability as immunotherapy and medical GOAL 4 : Strategic partnerships, and we strengthened both our oncology treatments. collaboration and engagement. culture of professional mentoring and Funding for research – ANZGOG GOAL 5 : Organisational capacity leadership, increasing membership achieved funding in 2017-2018 year aligned with our research agenda. to almost 900 members. The annual for the Stics and Stones study from trial portfolio increased significantly to We will continue to develop further NHMRC and funding and drug support more than 15 trials in development or maturity in our organisational for Solace 2 from Astra Zeneca. In the recruiting patients. capability and financial sustainability last 5 years from 2013-2018 ANZGOG to support our gynaecological cancer ANZGOG is committed to building has had 1597 patients recruited across research goals in an efficient and a research portfolio and, where 16 studies. We are continuing to build streamlined manner. This is supported required, self-fund research. Our our research portfolio to ensure more through a range of activities not least goals include a spectrum of trials – trials are available for patients, which of which is ANZGOG’s commitment to Phase II trials, signal-seeking trials hopefully means better care and public fundraising and philanthropy. and early-phase trials where we are better opportunities for treatment, looking for new avenues of care, and but also further knowledge within the Thank you to our Supporters - We have also supportive care. It is important treatment of gynaecological cancers. an outstanding array of supporters that we draw on all of the domains of helping us fundraise for research Translational ANZGOG – a significant gynaecological cancer care: surgery, and the conduct of clinical trials at initiative is TR-ANZGOG which radiation, nursing, allied health and hospitals. These include individual addresses the critical need to collect medical oncology. fundraisers, women sharing their biospecimens associated with clinical stories in the media, on Facebook This is being achieved through a trials for research into biomarkers, and our websites, companies and variety of initiatives: molecular signatures, identification organisations that run events and of therapeutic targets and other OASIS (Ovarian cancer Alliance for fundraisers - thank you all. translational studies. After wide Signal-seeking Studies) – this initiative consultation we were able to secure I would like specifically to to test new targeted therapies against funding and a Project manager to start acknowledge the ongoing passion molecular sub-types of ovarian cancer this initiative in 2018. provided by Duncan McPherson AM, is a series of innovative signal-seeking and his tireless work with the Team Phase II studies. ANZGOG has been ANZGOG membership has more Teal harness racing industry initiative successful growing funding for this than doubled to 869 members in the #getrealsupportteal. Together with initiative from an initial philanthropic last five years with members from Michael Taranto over $300,000 has seed funding grant of $1.1million to all Australian States and Territories been raised for ANZGOG over the last now almost $11million. Six studies are and all parts of New Zealand. These 2 years. either recruiting or in development. members include doctors, scientists, consumers, trial coordinators, nurses, Charlie Brown is another significant Fund for New Research Grants – with data managers, exercise physiologists, supporter of ANZGOG and has taken the vision of fostering new research health economists and biostatisticians. on the role of ‘Ambassador at Large’ ideas which will eventuate in a clinical We engage with them through of the ‘Save the Box’ fundraising trials, this grants scheme is funded by our Annual Scientific Meeting in initiative promoting awareness of public donations and awards up to April, tumour working groups and gynaecological cancers and the need $150,000 to a maximum of three pilot our annual Research Development for further funding for research. or pre-clinical research projects each Day in November. We have a very
33 - 34 COSA BOARD + COSA REPORTS
COSA GROUP REPORTS
ANNUAL REPORT 2017
AFFILIATED ORGANISATION REPORTS
OTHER REPORTS
Survivors Teaching Students® is Since then, BCT has grown to be the 40th Annual Scientific Meeting another outstanding initiative. This largest, independent, clinical trials BCT’s 40th Annual Scientific Meeting volunteer program brings the faces research groupFINANCIAL in Australia STATEMENTS and New (ASM) was held from 25-27 July at and voices of ovarian cancer survivors Zealand, with almost 800 members The Westin Sydney and included and caregivers into the classrooms of and 101 participating institutions. Our the Trials Coordination Forum, two health professional students to teach research program has improved the days of Scientific Sessions and a 40th them about women’s experience treatment of breast cancer, led to Anniversary Conference Dinner at Luna with ovarian cancer diagnosis and changes in the way breast cancer is Park. The following international guest treatment. Over 800 students were managed and has saved millions of speakers presented at the ASM: reached in year one of the program lives through research collaboration. Associate Professor Peter Dubsky - with 18 presentations to medical Our clinical trials have also contributed heads up the Breast Cancer Centre schools completed. The program is to a significant improvement in at the Hirslanden Clinic St. Anna in now rolling out across Australia. We breast cancer survival rates and falling Lucerne, Switzerland; thank the outstanding contribution mortality rates. More than 15,000 by so many women and their families women have been participants in BCT Professor Timothy Whelan - a supporting this program. research. Radiation Oncologist and Associate Chair of Research in Our people are our strength and I World First Clinical Trials the Department of Oncology at want to thank all ANZGOG members, BCT started two new clinical trials McMaster University in Canada; staff and our supporters who have in 2018 which are both looking at contributed to another successful year how patients may benefit from Professor Carlos Arteaga - Director for clinical research in Australia and immunotherapy, which uses the of the Harold C Simmons Cancer New Zealand. patient’s own immune system Center and Associate Dean to aid in their cancer treatment. for Oncology Programs at UT Immunotherapy is not in routine use Southwestern Medical Center; as a treatment option for breast cancer Professor Hope S Rugo - Professor in Australia and New Zealand, but of Medicine in the Division of breast cancer researchers are learning Haematology and Oncology at from the results of research in other the University of California San cancer types, such as melanoma, Francisco (UCSF), Helen Diller lung cancer and bladder cancer. The Family Comprehensive Cancer DIAmOND and CHARIOT clinical Center, and Director, Breast trials will use different combinations Oncology and Clinical Trials of immunotherapy in patients with Education; different breast cancer subtypes, that are more likely to respond to immune Professor Cristin Print - the manipulation. Professor Sherene Loi University of Auckland’s Department Philip Beale is the Study Chair of both of these of Molecular Medicine and Chair, ANZGOG trials and a member of our Scientific Pathology, he leads the Genomics Advisory Committee. Into Medicine Strategic Research BREAST CANCER Initiative in Auckland and Chairs TRIALS the Auckland Regional Tissue Bank Scientific Advisory Board.
As part of BCT’s 40th celebrations, a Q&A Event was held at The Art Gallery of NSW on the eve of the ASM, to discuss the past, present and future of breast cancer research. The event was broadcast live on Facebook and was 40th Anniversary moderated by Channel 10 presenter Breast Cancer Trials (BCT) celebrated Sandra Sally. The panel consisted of its’ 40th anniversary in 2018. Professor Alan Coates AM, Associate Originally called the Australian New Professor Prue Francis, Associate Zealand Breast Cancer Trials Group Professor Nicholas Wilcken, Professor (ANZBCTG), BCT first began in 1978 Fran Boyle AM, Professor Cristin Print in the Department of Surgery, at and Ms Leslie Gilham. the Royal Melbourne Hospital. BCT started with one Data Manager, Trial Results Announced at ASCO one computer, one National Health The results of two clinical trials were and Medical Research Council Professor announced at the American Society of (NHMRC) grant and 14 collaborating Sherene Loi Clinical Oncology Annual Meeting in institutions. June 2018:
35 - ANNUAL REPORT 2017
TAILORx - Some women with The Alan Coates Award for CANCER NURSES the most common type of breast Excellence in Clinical Trials cancer may no longer need to have Research was awarded to Professor SOCIETY OF AUSTRALIA chemotherapy to increase their Fran Boyle AM; chance of survival when guided The Robert Sutherland Award for by a diagnostic test. The study Excellence in Translational Research found that for some women with was awarded to Professor Carlos hormone receptor (HR) positive, Arteaga; HER2 negative, axillary lymph node-negative breast cancer, The John Collins Medal and Travel Reflecting on 2018, I can honestly say treatment with chemotherapy and Grant was awarded to Dr Synn Lynn it was a very exciting and productive, hormone therapy after surgery is Chin; if somewhat challenging year for the no more beneficial than treatment The Study Coordinator Prize was Cancer Nurses Society of Australia with hormone therapy alone. A awarded to Ms Victoria Sproule. (CNSA). genetic test called Oncotype DX or 21-gene assay may identify up Consumer Advisory Panel Celebrating 21 years of cancer nursing: to 70% of women with early stage Leonie Young, Sheryl Fewster and CNSA’s inaugural congress was held HR positive HER2 negative breast Cheryl Grant completed their terms in Sydney in 1998, which means we cancer, which has not spread to the on the BCT’s Consumer Advisory celebrated our 21st birthday this year! lymph nodes, who can be spared Panel (CAP) in 2018 and BCT sincerely Founder members Prof Patsy Yates chemotherapy and the side effects thanks them for their years of and Dr Laurie Grealish provided an of this treatment, especially those commitment and volunteer service interesting reflection on the past who are older than 50 years of age. to BCT’s research program. Leonie 21 years, as well as a glimpse into Professor Joanna Dewar is the BCT Young was an original member of the future of cancer nursing. We Study Chair of TAILORx. CAP, which formed 20 years ago, and look forward to the next 21 years of was the Chair of the committee from supporting Australians affected by SOFT & TEXT – These trial results 2010-2018. Cheryl Grant joined CAP cancer. will change the management of in 2004 and Sheryl Fewster joined in breast cancer in young women It was also a timely occasion for 2003 and is now the Chair of BCT’s with oestrogen receptor positive granting Life Fellowship of CNSA to Communications and Fundraising early breast cancer, leading to Prof Mei Krishnasamy, in recognition of Committee. Leslie Gilham is the new fewer recurrences and improved her strong commitment to our society CAP Chair. overall survival. The trials found and her dedication to the profession of that premenopausal women with cancer nursing. hormone receptor–positive, HER2- Changes in leadership of the negative breast cancer and a high organisation: risk of recurrence, who are treated Following our inaugural Chief Executive with an aromatase inhibitor plus Officer Sam Gibson’s return to clinical ovarian function suppression, may practice, we were pleased to welcome gain a 10% to 15% improvement in Sonja Cronjé as CNSA’s new CEO in freedom from distant recurrence February. Sonja brought to the position at 8 years. Associate Professor Prue extensive senior executive experience Francis is the BCT Study Chair of gained in not-for-profit organisations, SOFT and TEXT. including almost five years as Senior 2018 Breast Cancer Trials Awards Executive Officer of the Faculty of BCT Travel Grants and Awards Bruce Mann Radiation Oncology at the Royal recognise the valuable contribution Chair, BCT Australian and New Zealand College of BCT members to the Group’s of Radiologists, and she has certainly clinical trials research program; proven how much she is capable of. provide professional development In April, then CNSA President Jane opportunities for members; recognise Campbell had to resign from the outstanding achievement by position and the Board due to family researchers, clinicians and scientists circumstances. Jane had been an in their particular field; and help active CNSA member, and we are promote the research activities of BCT grateful for her contribution to cancer and encourage participation in them. nursing over many years. My term as All BCT awards are at the discretion of President commenced as we were the Board of Directors. conducting the first Director elections, In 2018, the following awards were drafting the first annual report and presented: preparing for the first annual general
35 - 36 COSA BOARD + COSA REPORTS
COSA GROUP REPORTS
ANNUAL REPORT 2017
AFFILIATED ORGANISATION REPORTS
OTHER REPORTS
meeting of CNSA as a company limited The Board and CEO have also been CNSA member benefits: by guarantee. It was a busy time and a working on developing the most The CNSA Board and staff are always steep learning curve for all involved, but appropriateFINANCIAL organisational STATEMENTS structure trying to improve the value that CNSA also very exciting to be part of history in and business support systems to members get from the society. One of the making for our wonderful society of manage the day-to-day operations and our most valued member benefits is cancer nurses. support our passionate volunteers in the Sosido online knowledge sharing implementing the strategic priorities. and networking community, through Professorial Advisory Council: which members can stay abreast of All CNSA members who are Full Conferences and events: the latest research impacting their Members or Honorary Life Fellows The 2018 Annual Congress was held in practice, crowdsource information, and have been conferred with a Brisbane from 21-23 June, attracting discuss trending topics and network Professorship by a University are invited 686 delegates. The theme was “Science, with peers. We were delighted when to join the Professorial Advisory Council Symptoms and Service Delivery” and CNSA-Sosido was shortlisted for an – which aims to provide the Board of the scientific program – which included industry award to recognise and Directors and the CEO with high level, seven pre-congress symposia – was very reward excellence within healthcare expert and independent advice on well received. communications in Australia. CNSA’s strategy and efforts in the areas CNSA and the New Zealand Nurses of research, education, advocacy and CNSA also supported several research Organisation Cancer Nurses College policy matters concerning cancer care and special projects grants in 2018: co-hosted a joint plenary session on and the nursing profession. “Global Diversity: Equity and Access” •Nursing workforce preparedness to The PAC met in Brisbane on 21 June, at the International Conference on deliver cancer survivorship care; and brainstormed significant political, Cancer Nursing held in New Zealand in Consumer and nurse-led economic, social, technological and September. development of co-designed video legal factors that could impact on Through our Adolescent and Young resources for patients receiving CNSA. Through their expertise and Adult Specialist Practice Network, immunotherapy and their caregivers; collective experience, CNSA is better CNSA proudly supported an AYA nurses able to navigate some of the complex Achieving Recovery from Cancer: Health and Wellbeing for Adolescents and Young Adults; and PAC meeting held in Brisbane on 21 June The development of Vascular Access Device Guidelines.
A summary of all CNSA member benefits is listed on our website. We are currently working on exciting new member benefits for next year – so watch this space!
Fostering relationships with key stakeholders in the cancer space, and raising our profile as the national peak body for cancer nursing, is a priority for policy and advocacy issues that could workshop in Sydney in December, CNSA, and we truly value being part impact the society. held in conjunction with the 3rd of COSA. We look forward to further Strategic planning and organisational Global AYA Cancer Congress in Sydney. collaborations with you all in 2019, to structure: Titled “Nursing AYAs with Cancer: improve the outcomes and experiences The Board of Directors met in June An interactive workshop exploring for Australian cancer patients and their to discuss the strategic direction and lessons from international nursing loved ones. priorities of CNSA. We are very proud practice, leadership, innovations and to have developed a consumer-focused opportunities in AYA cancer nursing”, vision for the organisation – Best this event included content relevant possible outcomes and experiences to anyone working in the AYA nursing for all people affected by cancer. We field, or those with an interest in the also reviewed and reaffirmed CNSA’s ongoing development of this specialist mission – Promoting excellence in role in the AYA multidisciplinary team. cancer care and control through the Throughout the year, CNSA’s professional contribution of cancer Regional Groups and Specialist nurses. Practice Networks also hosted many We plan to finalise and launch CNSA’s professional development and new strategic plan in 2019, with input networking events, attracting more from our Committees, Regional Groups than 1,000 cancer nurse attendees. Lucy Patton and Specialist Practice Networks. President and Board Chair, CNSA
37 - ANNUAL REPORT 2017
CANCER SYMPTON Reference and Membership have also page on the CST website and an been confirmed. online application form. Membership TRIALS and PALLIATIVE is available for both individuals and The CST national team is in place, led CARE CLINICAL STUDIES organisations. by the Chair, Professor Meera Agar COLLABORATIVE and the National Manager, Ms Linda Researcher resources Brown. In December a Research CST aim to support our members Assistant-Writer was recruited to through access to a range of resources support our clinical trial researchers via our website, including the to develop new study concepts into development of Standard Operating clinical trial protocols. Procedures (SOPs) with a new SOP specifically to support new study A strategic plan has been developed, ideas and proposals in the cancer including projected targets and goals population. Under development is a and our vision statement: process manual to guide coordinating ‘The role of CST is to engage in high and principal investigators through the quality clinical research that provides clinical trial process. the evidence base to underpin and optimise quality symptom Palliative Care Clinical management in supportive care for Studies Collaborative people affected by cancer.’ (PaCCSC)
Concept development workshops Inaugural Post-Doctoral Research In 2018, a concept development Fellow Appointments workshop schedule was established In early 2018 PaCCSC announced the within our annual events calendar. appointment of its first ever Post- Establishment of CST Three workshops were offered to Doctoral Research Fellow. Dr Slavica Cancer Symptom Trials (CST) was members and interested health Kochovska’s academic background established in 2017 to address the professionals. Topics included in theoretical linguistics and over unmet symptom management needs ‘breathlessness’, ‘haematological ten years’ research and teaching of Australians living with cancer cancer and supportive care’ and experience in linguistics and language through investigator-initiated or ‘cognitive and neurological disorders’. education at both the undergraduate academic (industry-independent) Participants were invited to submit and postgraduate level has proven to clinical trials. CST core infrastructure new concept ideas for presentation be invaluable to improving the science funding is from the Australian Federal at the workshops and, if appropriate, of consenting palliative and supportive Government via Cancer Australia supported to progress their ideas. care populations to clinical research; and the collaborative is proactive in Events pages have been created engaging consumers and working applying for competitive grants to on the CST website to promote the with colleagues in the USA to submit support the conduct of our program workshops and we proactively invite the Collaborative’s first ever NIH grant. of clinical research. members to participate via our joint CST/PaCCSC newsletter. A second Post-Doctoral Research The CST governance structure was Fellow, Dr Annmarie Hosie, Phd was established and ratified at the first Research Program also appointed in 2018. Dr Hosie is meeting of the CST Management The current research program a registered nurse with expertise Advisory Committee in December concentrates on seven research foci in palliative and aged care. Her 2018.The structure also includes areas. Investigator teams are in place previous role research is focused on a Scientific Advisory Committee, to develop concepts ratified by the delirium recognition, prevention and Consumer Advisory Group and Scientific Advisory Committee, which management in advanced illness, and study-specific Trial Management met for the first time in December strategies to promote ethical research Committees. Committee Terms of 2018. At this meeting, the Committee participation by older people with reviewed the current research cognitive impairment. She is currently program and considered opportunities a lead investigator of a cluster to expand the program into the future. randomised trials of multi-component, non-pharmacological interventions Membership The CST membership terms and to prevent delirium for hospitalised database has been established people with advanced cancer, the and recruitment is underway. PRESERVE pilot study. Initial membership has been Annual Research Forum established with the appointment The PaCCSC Annual Research Forum of the governance committees. A was held in Sydney in February 2018. membership recruitment plan is in Amongst a number of member and place and includes a dedicated web new study presentations, the Program
37 - 38 COSA BOARD + COSA REPORTS
COSA GROUP REPORTS
ANNUAL REPORT 2017
AFFILIATED ORGANISATION REPORTS
OTHER REPORTS
included guest presentations from Professor Matthew Kiernan, Co- Director of the Brain and Mind Centre FINANCIAL STATEMENTS and Bushell Chair of Neurology at the University Sydney and Ms Tanya Symons known internationally in the trials world for her work in developing trial strategy and resources and working with government bodies to drive trial efficiency.
Other Conferences The ASM of the Australian and New Zealand Society of Palliative Medicine (ANZSPM) provided PaCCSC members with an opportunity to touch-base, network, share ideas and update on what was happening locally, nationally SAC meeting with Dr Liz Hovey and internationally in clinical research in palliative care. PaCCSC are fortunate to have members who are actively COOPERATIVE TRIALS successful grant application to CANTEEN was specific to funding engaged in their own programs of GROUP FOR NEURO- research as well as contributing to the adolescent and young adult efforts of the Collaborative. A number ONCOLOGY participation in this study of members presented their work at SEQUITUR (SEQUential ANZSPM. ImmunoTherapy in patients with Underserved Rare cancers), funding for the neuro-oncology aspects of this study
2018 was a busy year for COGNO, with As at early 2019, we are still awaiting many highlights and achievements, the outcome of several grant several of which are summarised applications for MRFF funding which below - were submitted in 2018. We also saw COGNO continued to work on a changing of the guard for our SAC, expanding its clinical trials portfolio with long-time SAC chair, Dr Liz Hovey, with regular meetings of its stepping down from this position after Scientific Advisory and Management many years of service. Our sincere Committees, and quite a few grant thanks and appreciation to Liz and our Peter Allcroft submissions, some of which were warm welcome to new SAC chair, A/ Council representative, CST specific opportunities brought about Prof Hui Gan. and PaCCSC by the welcome focus on brain A successful Ideas Generation cancer through the Australian Brain Workshop held in May, under the Cancer Mission. Grants achieved in co-convenorship of Drs Kathryn 2018: Field and Ben Chua. The Workshop $2.5million grant from the included sessions on Enhancing Australian Brain Cancer Mission Research Quality in Neuro- to improve treatments and oncology, Summary of Australian outcomes for adults with brain CNS Oncology and Workshopping cancer through increasing access for Trial Unmet Needs, group to high quality international discussions on glioma, rare tumours cancer clinical trials. and brain metastases, as well as presentation and discussion of new Confirmation of renewed support concepts. Our 2019 Ideas Generation through to 2021 from Cancer Workshop will be held in Sydney on Australia, assuring our core Friday 24 May. activities in trial development Another successful Annual Scientific Two grants for PersoMed-I Meeting, held in Brisbane in (Personalised targeted therapy October, thanks to convenor, Dr for adolescent and young adult Mark Pinkham, and his hardworking medulloblastoma patients), our organising committee (Drs Lucy first trial in medulloblastoma. A Gately, Lindy Jeffree, Bryan Day,
39 - ANNUAL REPORT 2017
Matthew Foote, Hamish Alexander, uptake in primary brain tumours FACULTY OF RADIATION Ms Tamara Ownsworth, Jenny using focussed ultrasound" Chow and Yi Feng). A fantastic ONCOLOGY COGNO Most Outstanding Poster scientific program with the theme Presentation – awarded to A/ of Targeting survival: living well Prof Zarnie Lwin for her abstract with brain cancer in the era of "I’m the handbrake": a qualitative precision treatments and including interview study of the experiences international speakers Professors of informal carers for patients Faculty of Radiation Oncology Mark Gilbert, Eric Sulman, Susan living with glioma" The Faculty of Radiation Oncology Chang and Dr Terri Armstrong, as had another busy year during 2018. well as Australian experts, was very Continuation of COGNO’s outreach Business as usual activities coupled well received by delegates. Our 2019 and education activities through with some larger pieces of work, with ASM will be held in Sydney from its Outreach and Education a focus on advocacy efforts, continued 27 – 29 October, convened by Dr Committee, chaired by A/Prof Zarnie to keep our membership engaged. Jonathon Parkinson. Lwin. This included the 2018 COGNO Outreach Education Preceptorship Advocacy Inaugural BTAA Lynette Williams which was awarded to Dr Abdi Reza, RANZCR continues to engage with Award for best poster related to a neurosurgeon from Indonesia, the Commonwealth Department of supportive care research. This and enabled his attendance at the Health, particularly through attendance award honours the memory of the ASM as well as an observership at at the Radiation Oncology Roundtable late Lynette Williams who lost her the Royal Brisbane and Womens meetings (April and October). These battle with GBM and was presented Hospital. meetings provide members an at the COGNO ASM Dinner. The opportunity to raise issues with relevant award was made possible by funds Continuation of COGNO’s Departmental officials in an open and raised by Lynette’s husband William partnership with MSD for the collaborative forum. (Billy) Williams in partnership with MSD Hubert Stuerzl Memorial the Ghana Australia Association Educational Award, won this year by In late November, the Faculty hosted and BTAA. First prize recipient Dr Arian Lasocki, a radiologist. The the annual Faculty of Radiation was Ms Megan Jeon for her poster Award will enable Arian to attend Oncology Industry Roundtable. The "Prevalence and severity of difficulty an international neuro-oncology Industry Roundtable is a forum for the sleeping in patients with CNS cancer scientific conference and undertake Faculty and industry to share updates receiving palliative care in Australia"; a neuro-oncology preceptorship in on various activities. We were provided second prize recipient was Miss 2018/19. with updates around MRI linacs from Lobna Alukaidey for her poster industry and shared updates on the COGNO membership numbers "Longitudinal health related quality Targeting Cancer campaign and the ended the year at 718, a huge of life in patients with benign and Asia Pacific Radiation Oncology Special increase on the 22 members back in low-grade brain tumours" Interest Group’s work in developing 2007 when COGNO was established. countries. Inaugural #COGNO18 Top Tweeter We look forward to a continued Award – hotly contested during the increase in 2019, and improved Medicare Benefits Schedule Review ASM, but unquestionably won by engagement. The Medicare Benefits Schedule Dr Sarah Shigdar @SassStem (who (MBS) Review Taskforce released was locked out of her own account two pertinent (among many) clinical because the large number of tweets committee reports that the Faculty suggested she may be a tweet-bot!) provided submissions to. These included the long-awaited Report Continuation of COGNO awards to from the Oncology Clinical Committee, encourage researchers and young which sees a new radiation oncology investigators- schedule being developed, and the COGNO Young Investigator Report from the Urology Clinical Award – presented to Mr Ali Committee. Dulfikar for his abstract "Baseline The Faculty is pleased to see that functional status in post- the Oncology Clinical Committee is operative glioma patients prior recommending a new schedule. This to adjuvant radiation: relevance Anna Nowak is a once in a lifetime opportunity to to participation in a supervised Chair, COGNO modernise the near 30-year-old current exercise programme” schedule. There is still much work to be done. The focus moving forward COGNO Most Outstanding Oral Jenny Chow is to ensure that the Government Presentation – awarded to Dr Executive Officer, COGNO Simon Puttick for his abstract implements the schedule, but only "Increasing antibody theranostic after an opportunity to model and pilot it.
39 - 40 COSA BOARD + COSA REPORTS
COSA GROUP REPORTS
ANNUAL REPORT 2017
AFFILIATED ORGANISATION REPORTS
OTHER REPORTS
FINANCIAL STATEMENTS
The Urology Clinical Committee report Clinical Excellence position statement is available for provided an opportunity to ensure that In early 2018, the Faculty, alongside download from www.ranzcr.com/ men approaching active treatment our Tripartite partners (the Australian college/document-library/informed- for prostate cancer are given an Society of Medical Imaging and decision-making-in-the-management- opportunity to see both a urologist Radiation Therapy (ASMIRT) and of-localised-prostate-cancer-position- and a radiation oncologist through the Australasian College of Physical paper. the inclusion of an explanatory note Scientists and Engineers in Medicine Organisational Governance and for radical prostatectomy items. In (ACPSEM)) published version 2 of Sustainability addition, we argued that the man’s the Radiation Oncology Practice The Faculty of Radiation Oncology decision not to seek advice from a Standards (ROPS). The ROPS were Council will welcome a number radiation oncologist is documented in first launched in 2011 and have been of new faces in 2019, including the his medical record. lauded internationally. Version 2 incoming President of the Trans- brings together both the Australian Targeting Cancer Tasman Radiation Oncology Group and New Zealand variants into one The Radiation Oncology Targeting (TROG), who sits as a member of comprehensive document. Cancer campaign celebrated five years Council. and continues to go from strength The Faculty has modified and With my term as Dean concluding to strength. The Targeting Cancer promoted a patient charter for at the end of 2018, the Faculty of website (www.targetingcancer.com. departments and centres to put up in Radiation Oncology Council elected au) has been gaining record numbers waiting areas. Originally developed by Dr Madhavi Chilkuri as the next Dean of hits almost monthly; almost the Canadian Association for Radiation (2019-20). Madhavi, a Townsville-based doubling traffic between 2017 and Oncology (CARO), the charter outlines radiation oncologist, brings a wealth 2018. The dedication of the clinical the rights that patients undergoing of experience to the role. Until the end leadership and advisory team has radiation therapy have. This is freely of 2018, Madhavi was the Chair of the seen international attention on the available from the RANZCR website Quality Improvement Committee. I campaign from many countries. (www.ranzcr.com/college/document- am confident that Madhavi Chilkuri library/radiation-oncology-patient- I encourage you all to reach out and will continue to actively engage with charter). engage with #targetingcancer on COSA as one of the Faculty’s key social media (Twitter, Facebook). One of our biggest pieces of work stakeholders. in 2018 was the publication of the Education Informed Decision Making in the RANZCR is undergoing a Training Management of Localised Prostate and Assessment Reform across Cancer position statement. Prostate both clinical radiology and radiation cancer had been identified as one oncology training programs to ensure area where radiation therapy was that our programs are based upon underutilised in Australia and became best practice. The reform includes the focus of Targeting Cancer. It was reviewing the current curriculum, a timely publication, particularly determining learning outcomes for given the MBS Review. Supported the program, evaluating existing by international evidence, it is the assessments, and determining and Faculty’s position that all men developing the most appropriate approaching active treatment for assessment tools to measure learning prostate cancer are fully informed of outcomes. This will culminate in new Dion Forstner all the available treatment options Dean, Faculty of Radiation training programs being launched in – including radiation therapy. The Oncology, RANZCR 2021.
41 - ANNUAL REPORT 2017
MEDICAL ONCOLOGY Directions in Personalised Cancer immunotherapeutic strategies that Therapy, reflected the position that medical oncologists can deploy. GROUP OF AUSTRALIA while personalised cancer therapy has International speaker, Dr Michael become core business for medical Postow, USA was joined by Australian oncology practice, as an ever-evolving leaders in immuno-oncology. field it continues to pose many The 2018 ACORD Workshop was challenges for us as a profession. successfully delivered in early We thank the Planning Committee As the national body for Australian September with a record number and, Convenor, Prof Tim Price for medical oncology, the Association of 75 participants from India, organising key world leaders in clinical has a strong and diverse membership Bhutan, Pakistan, Singapore and research and practice to participate; base with an ever-growing number the Philippines among others and Prof Nicoletta Colombo, Italy; Prof of trainee members, as interest in 30 Faculty (including 10 Future Bernard Escudier, France; Dr Jack our speciality grows. MOGA would Faculty) attending. Convenor, Prof West, USA; A/Prof Jarushka Naidoo, like to acknowledge the invaluable Martin Stockler once again gathered USA and Prof David R. Gandara, USA. contribution that our members have a stellar international Faculty. The We acknowledge and thank our many made over the last year to the work of ACORD participants departed the Australian colleagues who joined the Association. Workshop tired but full of energy the faculty as presenters or to chair and determination to bring to Educational Activities and Events sessions. fruition the clinical trials protocols In 2018 MOGA managed a broad Highlights of the program included that they developed over the week selection of educational programs. sessions on gynaecology, lung, long program. MOGA acknowledges Our Communications Skills genitourinary and rare gynaecologic, the generous support of the Clinical Training Program delivered by the thoracic and germ cell cancers. Oncology Society of Australia, Cancer Pam McClean Centre focussed The meeting explored new Australia, Cancer Council Australia on Transition to Palliation. This directions in targeted therapies, and the William Rudder Foundation mandatory training requirement pharmacogenomics and molecular as long-term collaborators for this for medical oncology trainees is an biomarkers. Prof Paul Worley, the important international initiative. important area of patient-clinician National Rural Health Commissioner, communication. MOGA funded Oncology Drugs and Treatments gave a spirited and inspiring welcome Travel Awards for trainees to attend The Oncology Drugs Working Group, presentation. MOGA has a strong the Annual Scientific Meeting (ASM) led by Dr Deme Karikios, met commitment to the development of and over 40 trainees participated in regularly in 2018 with the PBAC and medical oncology research and clinical the Sciences of Oncology Program, other regulatory bodies to address practice in rural and remote Australia. convened by Professor Mark oncology issues under consideration Shackleton. The Young Oncology Prof Georgina Long and her by Australian bodies. They also Group of Australia now in its fourth planning team, presented MOGA’s ensured that current, accurate year of operations continued to third biannual Immuno-Oncology advice on clinical practice and trial provide support and guidance Forum: Insights and Advances. The developments was directed to key for junior consultants, organising Forum has become an important decision–makers throughout the educational and professional initiatives component of the Association’s year. This included participating in throughout the year. educational programming, in the special PBAC meeting held in providing a comprehensive and August on PD-1 and PD-L1 checkpoint The ASM and Immuno-Oncology practical update on the current clinical inhibitor immunotherapies and Forum in Adelaide provided great IO data for many cancer streams. The subsidy options for multiple cancer opportunities for our members Forum explored the practicalities types. to come together for networking, of working with this treatment research, education and professional MOGA continued to provide modality in clinical practice, including development. The ASM New representation for our profession
41 - 42 COSA BOARD + COSA REPORTS
COSA GROUP REPORTS
ANNUAL REPORT 2017
AFFILIATED ORGANISATION REPORTS
OTHER REPORTS
FINANCIAL STATEMENTS ACORD 2018 Workshop
through lobbying and advocacy Workforce pioneering activities in anticancer work. This resulted in some major Medical oncology workforce planning pharmacology and advocacy for milestones. In August new legislation is core to sustaining and safeguarding oncology treatments have contributed and a strategy for national medicine the Australian profession and the greatly to improvements in patient shortages was announced by the provision of quality cancer care and outcomes nationally. He is one of Therapeutic Goods Administration health care planning in Australia. 2018 Australia’s most respected and (TGA). MOGA was pleased to join forces saw the culmination of three years dynamic medical oncologists and with the TGA in November as part of research activity by our Workforce has demonstrated an unfailing of this new strategy and A/Prof Gary Taskforce; A/Prof Zarnie Lwin (Chair), commitment to the Australian Richardson will represent MOGA and A/Prof Rosemary Harrup, Prof Chris medical oncology profession. our speciality in assisting the TGA in Karapetis and Dr Deme Karikios. managing shortages. External members of the Taskforce were Prof Alex Broom, Professor Partnerships of Sociology, University of NSW, In 2018 MOGA strengthened its and Prof David Sibbritt, Professor strategic alliances both in Australia of Epidemiology, University of and globally. The Association actively Technology Sydney. networked across the Asia Pacific region, attending the Annual Scientific The Taskforce developed and Meetings of the Japanese and published three studies that provide Singaporean Societies as well as the up to date, actionable evidence-based fourth ESMO Asia. data, about the Australian medical oncology workforce to assist in: MOGA collaborated with numerous organisations notably the Private Identifying areas of need in the Chris Karapetis Cancer Physicians of Australia and existing workforce and training; Chair, MOGA the Australian Medical Association on Developing advocacy and lobbying projects and submissions in response activities around major national to major national medical issues such areas of concern to the Australian as the ongoing Medicare Benefits medical oncology workforce. Schedule Review. The Association worked closely with the Royal Our Members Australasian College of Physicians Prof Stephen Ackland received this through the Adult Medicine Council year’s MOGA-Novartis Oncology and the Training Committee on Cancer Achievement Award for his a diversity of professional training outstanding contribution to medical initiatives. oncology in Australia. Prof Ackland’s 43 - ANNUAL REPORT 2017
MELANOMA AND SKIN Specifically, closely aligned line with Dr Donna Milne; Melbourne, Victoria, the original aims of ANZMTG and Australia CANCER TRIALS LIMITED according to a new constitution, MASC A/Professor Victoria Mar; Melbourne, Trials has been established to: Victoria, Australia Facilitate, design, conduct, analyse, A/Professor Anne Cust; Sydney, New publish and promote research, South Wales, Australia particularly clinical trials in melanoma and non-melanoma skin Professor Peter Soyer; Brisbane, 2018 was by many measures an cancer; Queensland, Australia historic year for our national co- Develop and advance the scientific Dr Richard Martin; Auckland, New operative clinical trials group basis of research, particularly clinical Zealand in melanoma and skin cancer. trials; Most notably, following extensive Professor Michael Millward; Perth, consultation and planning, I am Collaborate with people, groups, Western Australia, Australia delighted to announce the formation companies and bodies as In concluding this announcement of of ‘Melanoma and Skin Cancer appropriate to pursue these MASC Trials and as we look towards Trials Limited’ (MASC Trials), a objectives; and to a promising future, it is important to not-for-profit company limited by Foster optimal patient care through reflect on and recognise the efforts guarantee. This new entity currently development and maintenance of Professor John Thompson AO and comprises the previous Executive of standards and through clinical colleagues at MIA, and before that Committee of the (former) Australia research including clinical trials. the Sydney Melanoma Unit, who were and New Zealand Melanoma Trials visionary in their creation of the group Group (ANZMTG), which was an Consistent with these aims, MASC in 1999. Indeed, MIA’s contributions unincorporated research group Trials has a governance framework then and since cannot be overstated; within the University of Sydney that will support the expectations of they have provided remarkable and hosted and supported by the the funders of its research and the support to our national group since its Melanoma Institute Australia (MIA). needs of its trialists, collaborators and conception almost two decades ago. The incorporation of MASC Tials, other members. This framework will which has a governance structure facilitate independence for the group Additionally, the Board of MASC Trials akin to other successful collaborative and its staff in assisting our researchers particularly recognises the other groups (e.g. AGITG, ANZUP), to develop and manage research founding members of the group, represents an exciting development projects, as well as in the many Professor Michael Henderson (Peter in the melanoma and skin cancer field interactions and collaborations that MacCallum Cancer Centre (PMCC)), that has been necessitated by the support these aims. Professor John Kelly (The Alfred increasing complexity and breadth of Hospital), Dr Ben Brady (Cabrini To facilitate transition to new collaborations and trials engaged by Health, Victoria), A/Professor Rachael governance and operational models, our group. Morton (University of Sydney, Sydney), the new Board of MASC Trials Professor Bryan Burmeister (University Since 2015, the group’s Executive comprises the most recent ANZMTG of Queensland, Queensland) and Dr Committee (now the Board of MASC Executive Committee. In line with Campbell Rose AM, and others who Trials) has been keenly aware of the MASC Trials’ constitutional mandate have built and ushered the group to increased need for the group to be for national representation on the this exciting juncture. nimble, responsive and independent Board, I am particularly pleased in its decision-making in order to welcome two new members to 2018 Research Highlights best to address the needs of our the Board, Profs Peter Soyer and Despite the time and effort that has patients, trialists and collaborators. Michael Millward, who will not only been put into developing MASC Trials, As a recipient of federal government improve representation but also add I am even more pleased to report that funding from Cancer Australia, the tremendous experience in governance 2018 was an exceptional year for the group also appreciated the imperative and oversight of collaborative research. group, with record breaking research for a truly national entity with The Board of MASC Trials thus and other activity: governance that was appropriately currently comprises: representative. The governance 12 studies were active and open structure provided by MASC Trials Professor Mark Shackleton (Chair); to recruitment across multiple will address these needs, and thereby Melbourne, Victoria, Australia hospitals in 11 countries [01.07 SS01.13 Hair Spare, 01.09 RTN2, 01.10 offer improved performance and Professor Andrew Spillane (Deputy CARPETS, 01.12 EAGLE FM, 02.12 recruitment within investigator- Chair); Sydney, New South Wales, RADICAL, 02.14 CombiRT, 01.15 initiated melanoma and skin cancer Australia trials across the wide breadth of our CHARLI, 02.17 MEL-SELF, 03.17 Skin region. Paul White (Company Secretary); Cancer Prevention, 06.17 iMOVE, Melbourne, Victoria, Australia 09.17 PRIME002 and 04.18 Surgical Management Survey]; Professor Gerald Fogarty; Sydney, New South Wales, Australia
43 - 44 COSA BOARD + COSA REPORTS
COSA GROUP REPORTS
ANNUAL REPORT 2017
AFFILIATED ORGANISATION REPORTS
OTHER REPORTS
A Scientific Advisory Committee, Our fantastic staff had the supported by 7 Discipline Specific opportunity to attend the Australasian Committees was established MelanomaFINANCIAL Conference STATEMENTS in Melbourne (including 60+ active members / 15 during October 2018. Along with meetings conducted); 3 presentations by the team for 01.07 WBRTMel, 03.12 MelMarT and 31 new research proposals were 06.17 iMOVE, the Annual General submitted for development; Meeting was well attended by 40+ 589 patients were recruited across members and at the conclusion of the projects in the entire portfolio; conference, I was honoured to present inaugural research excellence prizes 280 new members joined in 2018 – for early career researchers for the the most in a single year – bringing best Oral and Poster presentations. the total membership to 1,512 Oral award winner, Dr Julia Lai-Kwan members / 33 countries; (PMCC) and Poster award winners, At least 5 new studies are expected Dr Ashleigh McEvoy (Edith Cowan to open to recruitment in 2019 [04.17 University) and Ms Lei Yang (PMCC), SMARTI, 07.17 Uveal Melanoma were most deserving of this accolade Registry, 10.17 GoTHAM, 02.18 and we look forward to following their MelMarT-II and 05.18 ACBC], with research progress. more studies pending funding On behalf of the Board of MASC Trials, announcements; I look forward to continuing to work Final analysis of the 01.07 WBRTMel with the COSA community to create, trial; collaborate and partner in the delivery, via trials and other research, of 31 grant applications were improved outcomes for patients and submitted by the group, with 11 families affected by melanoma and successful so far– the most in a skin cancer. single year; importantly these grants have brought in $AUD10million+ in research funding to melanoma and skin cancer that would not otherwise have been available to facilitate research and trials in our field. We applaud all of the research teams for their efforts and note our gratitude to the funders supporting these important new projects: including but not limited to the following:
Dr Shahneen Sandhu, PMCC; 10.17 GoTHAM, MRFF APP1167738 Mark Shackleton Chair, MASC Trials Prof Michael Henderson, PMCC; 02.18 MelMarT II; NHMRC APP1161574
AProf Victoria Mar, Cancer Australia Support for People With Cancer Grant - Improving Melanoma and Skin Cancer Awareness in regional and rural Australia.
Dr Donna Milne; 06.17 iMOVE; PMCC Research Foundation
Prof Gerald Fogarty; Genesis CancerCare, AMIGOs projects; Industry
AProf Katy Bell, University of Sydney, MIA; 02.17 MEL-SELF NHMRC APP1163054
45 - ANNUAL REPORT 2017
ONCOLOGY SOCIAL high and evaluations overwhelmingly Our clinical work reflects the emerging positive. The theme was ‘The Things trends in cancer care and our value WORK AUSTRALIA We Don’t talk About: Psychosocial base is consistent with the mutual Challenges in Oncology Social Work’. efforts of both organisations to make a The international keynote speaker was positive impact to continually enhance Professor Matthew Loscalzo from City of the quality of cancer care. Kim Hobbs Hope, Duarte California making a long- has been the OSWANZ representative awaited return to Australia. on COSA Council in 2018 and will continue in this role in 2019. As a The 14th conference (and first under group, we look forward to ongoing the OSWANZ banner) will be held OSWA continues to grow and collaborative endeavours with all of the in Hobart from 21st-23rd November thrive. As a non-profit, incorporated disciplines represented within COSA. with a theme of ‘Unique footprints: national organisation our mission is Recognising the biopsychosocial the enhancement of psychosocial implications of the cancer site’. Progress services to people with cancer is underway to finalise the line-up of and their families throughout the invited speakers. For more information, treatment trajectory. In particular check in on the OSWANZ website we focus on the most marginalised, www.oswa.net.au. under-served and vulnerable groups in the population whose access to An ongoing research initiative to better cancer care and overall outcomes understand the scope of oncology may be diminished due to their social work practice is continuing. Data sociodemographic disadvantage. We collection for the first stage is complete strive for excellence in psychosocial and analysis is underway, led by Dr care through clinical service delivery, Rosalie Pockett from the University of along with networking, research, Sydney. Future stages of the project will Kim Hobbs advocacy, resource development and focus on needs analysis and evaluation Council representative, OSWA engaging in collaborative initiatives of interventions. Progress is updated with other organisations. in presentations at each national conference. Our participation with Cancer Council PRIMARY CARE Australia in progressing the agenda None of the work achieved throughout COLLABORATIVE around the financial burden of 2018 would have been possible cancer care, and contributing to a without the extraordinary voluntary CANCER CLINICAL combined response to the Australian commitment of the OSWA Executive TRIALS GROUP Public Service Review, are two recent and Management committees. I would examples in which the real world like to acknowledge and welcome our clinical experience of oncology social new President Nick Hobbs from the workers adds value and depth to the Royal Hobart Hospital. Nick takes the development of position statements, title of inaugural OSWANZ President policy and resources that assist in along with the onerous task of improving access and equity for all convening the conference committee people with cancer. for Hobart. Our immediate past president Ray Araullo will stay on the We have continued to provide support This year we are pleased to report that committee to smooth the transition of and infrastructure to assist in the we have extended our reach to include leadership and we thank him for his development and successful funding in our membership oncology social sage guidance throughout his term as of cancer in primary care clinical workers in New Zealand. The name of President. Particular thanks go to Olga trials. In 2018, we warmly welcomed our organisation will be changing to Gountras, our long-serving and highly our new Advisory Committee, Joint OSWANZ to reflect the incorporation of efficient Secretary. Each state, territory Community Advisory Group (JCAG) our trans-Tasman colleagues. We have and New Zealand have nominated and Scientific Committee members. signed off on a revised Constitution representatives who, along with clinical and we are actively promoting the Podcasts experts in various oncology sub-groups, changes to increase membership We have launched ourselves into the take responsibility for convening local numbers. We gratefully acknowledge world of podcasts with two new series professional development events the generosity and expertise of our available on iTunes, Soundcloud, and ensuring that the organisation legal collaborators at Slater and Gordon Stitcher and Spotify. Both of the continues to flourish. for their assistance in devising the new podcasts have been nominated in the Constitution. As an Affiliated Organisation of COSA, Australian Podcast Awards for 2018. OSWA is closely aligned with the In 2018 OSWA hosted our 13th national Cheers with Peers is a podcast hosted strategic directions in cancer care that conference in November in Canberra. by Sibel Saya, who guides Early Career are priority areas for COSA and other Once again registration numbers were Researchers through the maze that key stakeholder cancer organisations.
45 - 46 COSA BOARD + COSA REPORTS
COSA GROUP REPORTS
ANNUAL REPORT 2017
AFFILIATED ORGANISATION REPORTS
OTHER REPORTS
is primary care research. What’s the difference between a mentor and a sponsor in academia? How does an FINANCIAL STATEMENTS Early Career Researcher make those connections to collaborate with L-R New Advisory Committee members, Barbara Irwin, Amanda Piper, Jennifer international researchers? Sibel talks Walker. New JCAG members Louise Bailey, Jason White, and new Scientific with mid to senior researchers about Committee members Rebecca Bergin, Anne Cust, Neli Slavova-Azmanova issues that are important to Early Career Researchers. She finds out about overdiagnosis in primary care. The Presented a cancer in primary care things you wished you knew and things panel included Sanchia Aranda, Anne symposium at the Primary Health you didn’t know about being an Early Cust, Kirsten McCaffery, Jon Emery and Care Research Information Service Career Researcher. consumer Geoff Pritchard. (PHCRIS) Research Conference in Melbourne Research Round-Up is a monthly Cancer Council Victoria’s Rebecca podcast where Dr Kristi Milley and Bergin won the best presentation Hosted a workshop at the Cancer Sophie Chima deep dive into current on her project ‘Concordance Nurses Society of Australia Annual research and how this impacts primary between Optimal Care Pathway Congress in Brisbane, about getting care. It is a fascinating insight into recommendations in primary started and succeeding in Nurse-Led current and historical contexts of and secondary care for colorectal Translational Research cancer in primary care literature. cancer patients in Victoria.' The best Our palliative care-working group poster was awarded to Sibel Saya You can check out the episodes of both led by Prof Geoff Mitchell published for ‘Discrimination of the Australian series at pc4tg.com.au/podcasts. two substantial systematic reviews Population into Colorectal Cancer investigating end-of-life symptom PC4 Scientific Symposium Screening Categories Using RISK control and patient and carer Our fifth Scientific Symposium Prediction Models’. was held in Sydney at the Novotel, expectations and advance care Darling Harbour on 25th May 2018. Researchopoly plans in primary care We decided to initiate and design a The Symposium highlighted PC4’s We hosted Dr Fiona Walter, from unique idea to showcase the support objectives of nurturing research the University of Cambridge, who PC4 can offer to researchers. We collaboration and developing new updated us on new approaches to debuted Researchopoly at the Primary primary care research. It was a fruitful cancer diagnostics in primary care Health Care Research & Information day, driving discussions around in the UK current research, pathways and new Service (PHCRIS) conference in August 2018. Using our favourite pastime New concepts presented methodologies. The Symposium 10 provided the prospect of engaging with of board games, it is played like at workshops Monopoly but instead of becoming professionals, and consumers to share Active studies 29 ideas on increasing studies that focus a property mogul, players become on the role of primary care in cancer. research moguls. Players began with Studies opened to recruitment 11 a research idea and developed that Publications 12 The day opened with plenary speaker idea through consumer involvement, Dr David Weller, who leads the concept development, systematic Conference presentations 20 Cancer and Primary Care Research reviews, peer review, funding Training Awards 5 International Network (Ca-PRI), and applications and promotion of their is a member of the National Cancer research findings. Researchopoly was Research Institute Primary Care Clinical a fun and interactive way for people Studies Development Group. Dr Weller to understand how PC4 can help and spoke about The International Cancer improve the quality of their research. Benchmarking Partnership, which is a crucial collaborative team that pursues New COSA Council representative reasons for international cancer survival We would like to thank Lyndal Trevena differences. for her role as our COSA Council Representative. Joel Rhee has been Prevention and diagnosis, survivorship nominated as our new Council and alternative trial design were Representative. the themes of the day. Consumer involvement is crucial to our activities PC4 in a snapshot and members of our Joint Consumer 12% growth in membership, nearly Advisory Group shared their personal 700 members strong Jon Emery stories and perspectives on research Chair, PC4 collaboration. Members represent over 30 different health and research disciplines Another highlight of the Symposium Joel Rhee was the panel discussion on We reached 500 Twitter followers Council representative, PC4 @PC4TG
47 - ANNUAL REPORT 2017
PSYCHO-ONCOLOGY members, have been tasked with Recurrence (FCR), Cognition and designing national implementation Prevention. CO-OPERATIVE trials to showcase how the recognition We rounded out 2018 with a second RESEARCH GROUP and management of these common concept development workshop at psychiatric disorders could be the end of November. Six research substantially improved. The working proposals were reviewed, and we groups are to be commended on look forward to our PoCoG members their continued diligence and hard further developing their research in work in developing resources to the coming year. support the work more broadly. In line with PoCoG’s governance Our portfolio of research was also structure, in May, Professor David 2018 was a year of consolidation expanded to include multimorbidity Kissane stepped down after a two- and growth for the Psycho- and brain cancer. Stakeholder year term as SAC Chair and handed oncology Co-operative Research consultation workshops were held in the baton to Associate Professor Group (PoCoG), as we continued 2018 and working groups established Haryana Dhillon. Dr Lisa Beatty was on our mission of improving the to develop programs of work to also appointed Deputy SAC Chair to psychological wellbeing of cancer address key challenges associated support Haryana. At the end of 2018, patients through a diverse program with these important supportive Prof Jeremy Couper also stepped of research. care initiatives. We’re also proud to down as PoCoG Chair and Professor report that in 2018 we contributed to In mid-May we hosted a concept Brian Kelly, former PoCoG Deputy the development and conduct of 17 development workshop themed Chair will lead PoCoG into 2019 and supported studies, while a further 13 around the issue of fear of cancer beyond. recurrence (FCR). PoCoG has led the were administered directly through international research agenda in FCR the PoCoG Executive Office. PoCoG has a busy year planned in 2019 and always welcomes new in part as a result of our development PoCoG’s flagship ADAPT Program members. If you would like to find out of our Conquer Fear intervention hit a major milestone in 2018. This more about our group and activities, for treatment of FCR. PoCoG’s work ambitious program of work to please visit our website http://www. in this area has generated active implement a clinical pathway for pocog.org.au/ or email the executive research amongst our members anxiety and depression in routine office at [email protected] and their work was showcased at practice, is on track with site our workshop. We look forward engagement, start up, and data to tracking the progress of these collection well underway in our projects as PoCoG supported studies cluster RCT, with many lessons learnt. over the years to come. In response Interest in the ADAPT pathway is to the increased interest in FCR, in growing around the country and conjunction with the CDW PoCoG we continue to explore options for undertook a horizon scanning project application in other environments. to establish a national agenda for FCR research priorities. The last year has also seen PoCoG revitalise our special interest groups Talking about research, in 2018 (SIG), with a review of existing groups PoCoG continued to develop our and their performance indicators. Of research program targeting models note, we have launched several new of care to support wider access to special interest groups with more to Jeremy Couper treatments for depression, anxiety follow. It is a testament to the varied Chair, PoCoG and adjustment disorders. Working interests of our members that we now groups, comprised of PoCoG have SIGs devoted to Fear of Cancer
47 - 48 COSA BOARD + COSA REPORTS
COSA GROUP REPORTS
ANNUAL REPORT 2017
AFFILIATED ORGANISATION REPORTS
OTHER REPORTS
ROYAL COLLEGE OF pathway or through Recognition of protocols are in progress for cancers Prior Learning (RPL). of the head and neck as well as an PATHOLOGISTS OF FINANCIAL STATEMENTS Endometrium protocol update which Medicare Benefit Schedule (MBS) AUSTRALASIA is in development. Each protocol to be review developed or updated incorporates the The RCPA has worked towards the 8th edition of TNM staging as well as creation of a Medicare schedule that the internationally agreed standards keeps up with the best evidence-based from the International Collaboration medical practice and the changing on Cancer Reporting (ICCR). costs associated with these tests. In www.ICCR-cancer.org The Royal College of Pathologists addition, the RCPA has put forward of Australasia (RCPA) principle a recommendation to the Medical In 2007 at the National Roundtable objectives are to train and support Service Advisory Council (MSAC) on SPRC, the consensus statement pathologists and senior scientists to to include a structured reporting was that “cancer care in Australia improve the use of pathology testing component and increased fee in MBS will benefit from the development, utilising the highest quality evidence items of level 6 & 7 complexity, as publication and adoption of a series of and expert collaboration. part of the MBS review. The matter is voluntary, national structured reporting currently under consideration. standards for each cancer type.” One of the key mechanisms for raising the standard of pathology and cancer World Health Organisation (WHO) Our recent SPRC survey indicated information is through the work of the Classification of Tumours that many laboratories are now Cancer Services Advisory Committee Nominations from pathology colleges increasingly using some form of (CanSAC). CanSAC is a multidisciplinary and organisations from around the structured reporting despite limitations committee which has oversight for world, including the RCPA, were sought in Laboratory Information Systems (LIS). all cancer related activities within the for participation in an international While this is encouraging, laboratories RCPA. We are pleased to highlight editorial Board for development of the should be considering the structure the following notable achievements 5th series of the WHO Classification of and format of pathology reports, accomplished in 2018. Tumours. The RCPA was very fortunate particularly considering that the to have Dr Sunil Lakhani, Dr Anthony J anticipated revised NPAAC Information Australian guidelines for HER2 testing Gill, and Dr Puay Hoon Tan included in and Communication Requirements of breast cancer the standing committee. is expected to include minimum The first set of Australian HER2 requirements for pathology reports as The development schedule testing guidelines were published in part of the strategic direction of the proposed by Professor Ian Cree of the late 2018. They were developed by pathology sector to move towards International Agency for Research a multidisciplinary working party of standardised terminology and on Cancer (IARC), was comparatively Australian experts in breast pathology, reporting. This yearly survey provides expedited. At this stage IARC plan established by CanSAC, for the purpose key information on the implementation to publish the 5th series volumes of creating a locally relevant response of SPRC in relation to LIS capability in both a web-based form as well to complement the American Society as well as the extent to which cancer as the traditional paper version. It is of Clinical Oncology (ASCO)/College reporting checklists are currently anticipated that the web version will of American Pathologists (CAP) 2018 used in Australasia. It is essential for allow faster updates and more rapid focused update. understanding the current situation uptake of scientific advances in the way and functional capability of our Molecular pathology practice tumours are classified. The National Pathology Accreditation laboratories. With an increased focus on Advisory Council (NPAAC) will soon Structured Pathology Reporting of digital health data and data extraction, be implementing the revised NPAAC Cancer Project the uptake of structured pathology Requirements for Supervision in http://www.rcpa.edu.au/Library/ reporting and use of standardised the Clinical Governance of Medical Practising-Pathology/Structured- terminology has never had greater Pathology Laboratories, which is Pathology-Reporting-of-Cancer/Cancer- demand. Protocols a standard on the supervision of The RCPA has a policy statement on molecular testing in laboratories. With substantial evidence that implementation of SPRC and the The RCPA has begun the formal standardised structured reporting requirements of level 3 – this can be application process for formal improves the quality of pathology viewed at: certification of several disciplines such reporting, the federally funded http://www.rcpa.edu.au/Library/ as Haematology, Microbiology and Structured Pathology Reporting of College-Policies/Position-Statements/ Immunopathology, with Chemical Cancer (SPRC) Project continues to Structured-Pathology-Reporting-of- Pathology and Anatomical Pathology expand, having now completed 38 Cancer to follow. Non-genetic pathologists protocols. This included 7 new, and with designated clinical governance 5 updated genitourinary protocols. International terminology responsibility for supervising molecular A Liver cancer protocol and Thyroid standardisation testing in their own discipline will now cytology protocol are being finalised In 2018 an international project to have access to certification through ahead of publication. A further 9 develop SNOMED CT terminology a standard training and assessment
49 - ANNUAL REPORT 2017
for data elements in cancer datasets TROG CANCER were then randomly allocated to was initiated. This project is led by have either an additional 12 months Scott Campbell from University of RESEARCH of testosterone suppression therapy Nebraska Medical Center (UNMC) (18 months in total) or no further under the auspice of the International hormone treatment. Pathology and Laboratory Medicine The study found that 18 months Special Interest Group (IPaLM SIG) of testosterone suppression therapy the International Health Terminology option plus radiotherapy emerged as Standards Development Organisation the most effective, compared to the (IHTSDO), an international non-profit six-month time period. organization that owns SNOMED CT. Professor Jim Denham, who headed The ICCR, of which RCPA is a sustaining the landmark trial, said these findings member, has agreed to collaborate Over the past year TROG Cancer showed a 30% reduction in deaths to ensure terminology is developed Research has continued to conduct due to prostate cancer as well as a for cancer reporting such that it world-class research involving 40% reduction in cancer spreading meets the needs of the clinical care radiotherapy to improve the (metastases) to other areas of the teams, national registrars and cancer outcomes and quality of life for body. researchers around the world. The people affected by cancer. In 2018 international group includes the TROG commenced recruitment for “We also found that that men who colleges of the United States of three new trials: received the 18 months of treatment America, United Kingdom and Canada did not experience more side effects SC.24: This is a phase II/III study as well as many other interested parties or impaired quality of life factors than comparing stereotactic body around the world such as Sweden, those who received the six months of radiotherapy versus conventional New Zealand, Malaysia, Spain, and hormone treatment.” palliative radiotherapy for patients The Netherlands. The project aims to with spinal metastases. “The confirmation that quality of life in align terminology development and men treated on the RADAR trial was cancer dataset development efforts to HART: This trial is investigating the not inferior to quality of life outcomes create truly computable, interoperable use of the ‘Deep Inhalation Breath in Australian men of the same age, cancer reporting tools for use by all Hold’ technique to see if it reduces 10 years after treatment, came from participating nations. cardiac toxicity in patients with the 421 men who participated in our left sided breast cancer who are Pathology Update ‘Life ten years after prostate cancer undergoing radiotherapy. Each year, the RCPA holds the treatment’ sub-study,” said Professor Pathology Update Conference and ROAM: The study will investigate Denham. Exhibition. whether radiation therapy is a “Around 17,000 Australian men each better approach to treating atypical http://www.rcpa.edu.au/Events/ year are diagnosed with prostate meningioma (a tumour that arises Pathology-Update cancer and we are constantly looking from the lining of the brain) than at ways to beat this disease which sees This conference is a significant event surgical removal. so many men go undiagnosed for a on the pathology calendar. The next Ten Year Prostate Cancer Trial proves long period of time.” conference will be at the Melbourne optimal treatment duration Convention and Exhibition Centre from “Thanks to this trial men with newly- The 10-year results of TROG 03.04 22-24 February 2019. diagnosed aggressive but localised RADAR trial were published in The prostate cancer can be spared Lancet Oncology in late 2018. the many long-term side effects This study identified the best associated with longer durations of treatment regime for men suffering testosterone suppression (28 to 36 from newly-diagnosed aggressive months), which have commonly been but localised prostate cancer. The used in conjunction with radiotherapy study compared the use of hormone around the world.” treatment (longer versus short term The RADAR trial is one of many use) coupled with radiation therapy. significant cancer studies conducted This trial enrolled 1,071 men with through TROG Cancer Research. locally advanced prostate cancer at 23 treatment centres across Australia and TROG 2018 ASM highlights More than 270 people attended the New Zealand, who were monitored TROG 2018 Annual Scientific Meeting Kenneth Lee over a 10-year period. Council representative, RCPA (ASM) in Hobart, Tasmania in March During the trial all men received six 2018. Delegates heard from a host months of testosterone suppression of engaging and knowledgeable therapy, using the drug leuprorelin, speakers including Dr Walter Curran, followed by radiotherapy. Participants Radiation Oncologist at Winship
49 - 50 COSA BOARD + COSA REPORTS
COSA GROUP REPORTS
ANNUAL REPORT 2017
AFFILIATED ORGANISATION REPORTS
OTHER REPORTS
FINANCIAL STATEMENTS
Professor Jim Denham, who headed the RADAR trial with trial volunteer Colin Sandeman and his wife Marcel.
Cancer Institute of Emory University in In this role, she was a key player in a TROG Cancer Research CEO Susan the US and Professor Andreas Adam strategic expansion of the Newcastle- Goode said the grant received enables from the Interventional Radiology based cancer research infrastructure. TROG Cancer Research to continue Department of Radiology from King's The TROG Board was pleased to to develop industry-independent College in the UK. appoint Susan to this key strategic clinical trials, increase the number of position to move TROG into the next trials open for patients and to increase For the first time a poster session was phase of its development as a leading clinical trial participation. held as part of the meeting, which research group. allowed delegates to share and The research that TROG Cancer promote their research achievements. Former CEO, Joan Torony, resigned in Research undertakes occurs through Another highlight was the Clinical April 2018. enormous commitment and Research Education Workshop (CREW) teamwork from TROG members and Successful Cancer Australia Grant and the Technical Research Workshop the community and with that support TROG Cancer Research was awarded (TRW), which were both well attended. we will continue our endeavours in in 2018 a $1.5-million grant (2018- The CREW workshop provided a cancer research. We look forward 2020) from Cancer Australia under the forum for professional development to further exciting opportunities for Cancer Australia Support for Cancer for clinical trial coordinators, collaboration in 2018. Clinical Trials Program. The funding data managers and other related provides essential infrastructure for disciplines, while the TRW focused TROG to build capacity to undertake on radiation oncology technologies, cancer clinical trials. TROG’s primary advancements and clinical trials. business is the conduct of clinical trials The 2019 TROG ASM will be held from involving radiation therapy to establish 12-15 March in Melbourne, Victoria. whether new cancer therapies or new ways of using existing treatments are New CEO appointment effective and safe for patients. The board of TROG Cancer Research announced the appointment of Susan The Support for Cancer Clinical Trials Goode to the position of TROG Chief Program will allow TROG to increase Executive Officer in 2018. Susan has the number of cancer clinical trials more than 12 years’ experience in conducted in Australia and increase clinical research and was formerly the the participation in clinical trials Farshad Foroudi Centre Manager for the Hunter Cancer by people affected by cancer. The President, TROG Research Alliance at the University of program also provides opportunities Newcastle. for more clinicians, researchers and Puma Sundaresan patient advocates to participate in the Council representative, TROG development of cancer clinical trials. 51 - ANNUAL REPORT 2017
OTHER REPORTS
COSA TELE-TRIAL Queensland Health in collaboration This project also receives funding with COSA have finalised and released through the MTPConnect Project PROJECT key documents for implementation Fund Program – a dollar-for-dollar of the tele-trial model. These include matched program investing in big, the Australian ICH GCP (including bold ideas to improve the productivity, Teletrials) SOPs and supervision plan competitiveness and innovative template; a Tele-Trials Subcontract capacity of Australia’s medical for use between primary and technology, biotechnology and satellites sites and a revised SSA form pharmaceutical sector. MTPConnect incorporating tele-trial sub forms. is supported by the Australian Government Industry Growth Centres The project continues to engage key Initiative. The project to pilot the stakeholders through four advisory implementation of the Australasian groups; the Department of Health If you would like further information Tele-Trial model which commenced in Project Advisory Group, the Medicines or have any questions please contact August of 2017 has made significant Australia (MA) Industry Advisory Group, the COSA Tele-Trials Project Manager progress. There are now two new the Cancer Cooperative Trials Groups Chantal Gebbie at tele-trials open and recruiting in Advisory Group and the Tele-Trials [email protected] Queensland and Victoria. Project Steering Committee.
In Queensland the Eli Lilly Monarch E The MA Industry Advisory Group have study is open in the ‘Northern Tele- developed Clauses to be added to Trials Cluster’ which has Townsville as Schedule 7 of the standard MA CTRA the primary and Cairns, Mackay and for tele-trials. This was approved by Mt Isa as the satellites. One patient has the MA Research and Development been recruited at Mackay and two at Taskforce and has been submitted Cairns. The patient enrolled at Mackay to National Mutual Acceptance Hospital has avoided a monthly 7 for approval together with the hour round trip to Townsville Hospital subcontract for use between primary by participating in the Monarch E and satellite sites based on the study as a tele-trial. This is a perfect Queensland Health subcontract. It example of how the tele-trial model is hoped that once these templates can transform cancer care for patients are approved a standardised national Sabe Sabesan in regional and rural Australia. approach to contracting within the Co-Chair Tele-Trial model can be achieved. Implementation of the The Monarch E study will also be Australasian Tele-Trial Model opening in the Gold Coast cluster Stakeholder engagement through which has Gold Coast Hospital as presentations at conferences and the primary working with Wide bay meetings continues. Most notably the Hospital as the satellite and several Australasian Tele-Trial Model and the other commercially and cooperative Tele-Trials project have been presented group sponsored trials are planned for at several major conferences including 2019. ARCS, the Australasian Ethics Network Conference and the Cancer Institute The Victorian Comprehensive Innovations Conference. We will Cancer Centre (VCCC) have opened continue to actively engage key an investigator-initiated tele-trial stakeholders and promote the Tele- between Peter Mac as the primary and Trial Model in 2019. Albury Wodonga and Bendigo as the satellites. Currently two patients have We would like to take this opportunity been recruited. It is expected that at to thank our funding consortium least one more regional site will be partners for this project; Rare Cancers John Zalcberg OAM included in the next two VCCC Tele- Australia, Cancer Voices NSW, Co-Chair Trials. Australian Institute of Tropical Health Implementation of the and Medicine, The Garvan Institute of The AGITG ASCOLT study which has Australasian Tele-Trial Model Medical Research, The Walter and Eliza been open as a tele-trial between Hall Institute of Medical Research, Orange and Dubbo hospital in NSW Icon Group, St John of God Hospital, since December 2017 also continues to Medicines Australia, AbbVie, Jansen, recruit patients. Novartis and Pfizer.
51 - 52 COSA BOARD + COSA REPORTS
COSA GROUP REPORTS
AFFILIATED ORGANISATION REPORTS
ANNUAL REPORT 2017
OTHER REPORTS
FINANCIAL STATEMENTS
CANCER COUNCIL directly from our current prevention our research investment along with policy but will extend over time to some key data about our support incorporate treatment and health service reach. We will continue to service delivery. augment the impact site with more stories of our work to better inform The Blueprint work directly links to Australian’s about how we are working the third focus area of supporting together towards a cancer free future. a learning cancer system. Cancer Cancer Council is proud that last Council Australia’s support for the year we invested almost $60 million development of clinical practice in research each year along with guidelines will continue but be our research partners, our support The 2018-19 reporting year sees augmented by the development of services were used 250,000 times and Cancer Council Australia setting forth a vision and plan for improving the we helped protect 2 million young new strategic directions that focus use of cancer data in Australia and Australians from UV radiation through on improving cancer outcomes for through scoping best mechanisms to our SunSmart Schools program. Find all Australians in the context of a foster the spread and uptake of clinical out more on impact.cancer.org.au refreshed Cancer Council Vision: A innovation and improvement. Cancer Free Future and an aligned or visit our annual report on national purpose as Australia’s In all this work COSA is a partner. www.cancer.org.au leading cancer charity, uniting the Under the work on inequalities we community, providing support, launched a draft standard of informed investing in research and saving lives. financial consent at the ASM in Perth, 2018. COSA is represented on the To improve cancer outcomes for all Health Services Advisory Committee Australian’s Cancer Council Australia overseeing our work on cancer data will continue to reduce risk factors, and clinical improvement. COSA improve early detection, reduce cancer members continue to be used as deaths, extend survival and improve expert spokespeople on clinical quality of life through our important matters and in the development policy and advocacy work. In addition, of core public messaging and in we have framed three areas of focus development of clinical practice for the next three years: reduce guidelines. inequalities in cancer outcomes; Sanchia Aranda AM develop a cancer blueprint; and, We were excited in 2018 to publish CEO, Cancer Council Australia support a learning cancer system. several new guidelines. Updated CPGs for the Diagnosis and Management of In developing a focus on reducing Melanoma were published in May 2018 inequalities in cancer outcome we in collaboration with the Melanoma recognise that despite Australia having Institute of Australia and supported by some of the best cancer outcomes the Skin Cancer College of Australasia in the world, this is not uniformly and the Australasian College of experienced across the population. If Dermatologists. This followed closely you are poor, of Aboriginal or Torres on the release of updated guidelines Strait Islander heritage, rural dwelling for the prevention, early detection and or are diagnosed with a poor survival management of colorectal cancer in cancer your chance of great outcomes October 2017. These guidelines were is much lower. Over the next year augmented in December 2018 by our priority is to better understand CPGs for surveillance colonoscopy, the factors leading to outcome to be released to the public in early inequalities, to increase awareness of 2019. We continue to work with COSA the issues and to engage with partners members in guideline development. in developing an action plan to improve outcomes for disadvantaged In 2018 we also launched a Cancer populations. Council campaign focused on informing Australians about the ways Deciding where to invest in cancer we help across their cancer journey. to have the biggest impact is a Research had shown us that people complex issue. The development know us for our fundraising campaigns of an Australian Cancer Blueprint and research investment but know aims to address this complexity by less about how we help people at risk determining for each cancer, where of or affected by cancer. In late 2018 investment would make the biggest we also launched a national research difference in either preventing cancer impact site aiming to tell the story of or improving survival. This work builds
53 - COSA BOARD + COSA REPORTS
COSA GROUP REPORTS
AFFILIATED ORGANISATION REPORTS
OTHER REPORTS
ANNUAL REPORT 2017 CLINICAL ONCOLOGY SOCIETY OF AUSTRALIA LIMITED FINANCIAL STATEMENTS (ABN 97 631 209 452)
FINANCIAL STATEMENTS AT 30 JUNE 2018 AND INDEPENDENT AUDIT REPORT
About Clinical Oncology Society of Australia Limited...... 55
Directors’ Report...... 57
Declaration of Independence from the Auditors...... 62
Statement of Profit or Loss and Other Comprehensive Income...... 63
Statement of Financial Position...... 64
Statement of Changes of Equity...... 65
Statement of Cash Flow ...... 66
Notes to the Financial Statements...... 67
Directors’ Declaration...... 76
Independent Auditor’s Report...... 77
53 - 54 COSA BOARD + COSA REPORTS
COSA GROUP REPORTS
AFFILIATED ORGANISATION REPORTS
OTHER REPORTS
ANNUAL REPORT 2017 CLINICAL ONCOLOGY SOCIETY OF AUSTRALIA LIMITED FINANCIAL STATEMENTS (ABN 97 631 209 452)
ABOUTAbout Clinical CLINICAL Oncology Society ONCOLOGY of Australia Limite d Clinical Oncology Society of Australia The Clinical Oncology Society of Australia (COSA) is the peak national body representing health Limited SOCIETYprofessionals from all OFdisciplines AUSTRALIA whose work involves the careLIMITED of cancer patients. (A company limited by guarantee)
Our vision Corporate Information Quality multidisciplinary cancer care for all. ABN 97 631 209 452
Our mission The following persons were Directors of COSA during or since the end of the To improve cancer care and control through collaboration. financial year: Professor Sanchia Aranda COSA achieves this by: Professor Phyllis Butow AM • supporting the professional and educational needs of cancer health professionals Dr Christine Carrington • enhancing cancer care and control through network development Ms Sandie Angus • advocating for improvements in cancer care and control Dr Haryana Dhillon • facilitating research across the spectrum of cancer Mr Peter Dowding Professor Meinir Krishnasamy Ms Sandra McKiernan Guiding Principles Dr Wayne Nicholls As a membership organisation, COSAʼs activities are driven by the needs of our members. The following A/Professor Nick Pavlakis guiding principles are intended to provide an overarching direction for all COSA activities. Ms Felicity Shaw Professor Nik Zeps • COSA activities should have a multidisciplinary focus • COSA activities should have a clinical focus • COSA activities should have outcomes relevant to its members, patients and carers • COSA will act as a hub and facilitator for idea generation Company Secretary & Chief Executive Officer Ms Marie Malica
Registered Office and Principal place of business Level 14 Strategic Directions 2016-2019 477 Pitt Street 1. Advocate for matters affecting cancer service delivery, policy and care Sydney NSW 2000 2. Meet the educational needs of COSAʼs multidisciplinary membership 3. Promote and facilitate cancer research P: +61 (0)2 8063 4100 4. Ensure the sustainability of COSA F: +61 (0)2 8063 4101
Our history Company contact details GPO Box 4708 In July 2013, The Clinical Oncological Society of Australia Incorporated (The Society) decided to migrate from an Incorporated Association to a Company limited by Guarantee. This new company was Sydney NSW 2001 incorporated with an ABN 97 631 209 452 and started trading from 1 July 2013. COSA was registered E: [email protected] with the Australian Charities and Not-for profits Commission (ACNC) on 3 December 2012. W: www.cosa.org.au
Auditors BDO East Coast Partnership Level 11 1 Margaret Street Sydney NSW 2000
2 55 - 3 ANNUAL REPORT 2017
CLINICALClinical Oncology ONCOLOGY Society of Australia SOCIETY OFLimited AUSTRALIA LIMITED (A company limited by guarantee)
Corporate Information
ABN 97 631 209 452
The following persons were Directors of COSA during or since the end of the financial year: Professor Sanchia Aranda Professor Phyllis Butow AM Dr Christine Carrington Ms Sandie Angus Dr Haryana Dhillon Mr Peter Dowding Professor Meinir Krishnasamy Ms Sandra McKiernan Dr Wayne Nicholls A/Professor Nick Pavlakis Ms Felicity Shaw Professor Nik Zeps
Company Secretary & Chief Executive Officer Ms Marie Malica
Registered Office and Principal place of business Level 14 477 Pitt Street Sydney NSW 2000
P: +61 (0)2 8063 4100 F: +61 (0)2 8063 4101
Company contact details GPO Box 4708 Sydney NSW 2001 E: [email protected] W: www.cosa.org.au
Auditors BDO East Coast Partnership Level 11 1 Margaret Street Sydney NSW 2000
55 - 56 3 COSA BOARD + COSA REPORTS
COSA GROUP REPORTS
AFFILIATED ORGANISATION REPORTS
OTHER REPORTS
ANNUAL REPORT 2017 CLINICAL ONCOLOGY SOCIETY OF AUSTRALIA LIMITED FINANCIAL STATEMENTS (ABN 97 631 209 452) DIRECTORS’Clinical Oncology Society REPORT of Australia Limited (ABN 97 631 209 452) Clinical Oncology Society of Australia Limited (ABN 97 631 209 452) Directors' Report Directors' Report (contʼd) 3030 June JUNE 2018 2018 30 June 2018
The Directors present their report on Clinical Oncology Society of Australia Limited ("the Company") for Principal activities the year ended 30 June 2018. The principal activities of the Clinical Oncology Society of Australia during the year were focused on furthering both our short and long term objectives, referenced above. More detail on the achievements Objectives against these activities are detailed in the 2018 Annual Report. The Company's primary short-term objectives over the reporting period were: Review of financial operations and results of Clinical Oncology Society of • Continue working to the agreed strategic plan for the period July 2014 to June 2019 • Develop and implement policies to ensure operational efficiencies Australia Limited The total income for the financial year ended 30 June 2018 was $1,052,270 (2017: $893,283). In the • Review the Board, Council and COSA Groups to ensure their memberships are appropriate and same period, expenditure was $888,355 (2017: $757,047) leaving a surplus of $163,915 (2017: $136,236 engaged surplus). The level of spending for the organisation varies from year to year as the range of activities to • Build and maintain collaborative relationships with relevant government agencies, NGOs and industry support our members, and the costs associated with them, also vary. groups involved in cancer care to ensure strategic alignment and collaboration and to avoid duplication of effort • Respond to government and other relevant stakeholder requests for submissions Matters Subsequent to the end of Financial Year As at the date of this directors' report, the directors are not aware of any matter or circumstance that has • Host a successful Annual Scientific Meeting arisen that has significantly affected, or may significantly affect, the operations of the Company, the results of those operations or the state of affairs of the Company in the financial years subsequent to 30 The Company's long term objectives are to: June 2018. • Advocate for matters affecting cancer service delivery, policy and care • Meet the educational needs of COSA's multidisciplinary membership Indemnity and insurance of officers The Company has indemnified the directors and executives of the Company for costs incurred, in their • Promote and facilitate cancer research capacity as a director or executive, for which they may be held personally liable, except where there is a • Ensure the sustainability of COSA lack of good faith.
During the financial year, the Company paid a premium of $1,600 in respect of a contract to insure the Strategy for achieving the objectives directors and executives of the company against a liability to the extent permitted by the Corporations Act • Ensure COSA's advocacy work is in accordance with best practice 2001. • Hold strong and mutually beneficial relationships with national and international oncology Indemnity and insurance of auditor organisations The Company has not, during or since the end of the financial year, indemnified or agreed to indemnify • Reinforce COSA's position as the peak national body representing multidisciplinary health the auditor of the Company or any related entity against a liability incurred by the auditor. professionals whose work encompasses cancer care and control • Ensure COSA's educational opportunities remain relevant to the membership During the financial year, the Company has not paid a premium in respect of a contract to insure the • Build on the strength and success of the COSA Annual Scientific Meeting auditor of the Company or any related entity. • Build on the strength and success of the COSA Trainees Weekend Proceedings on behalf of the Company • Build on the strength and success of the COSA Clinical Professional Days No person has applied to the Court under section 237 of the Corporations Act 2001 for leave to bring • Build on current, and investigate new opportunities for, industry sponsored events outside the COSA proceedings on behalf of the Company, or to intervene in any proceedings to which the Company is a ASM party for the purpose of taking responsibility on behalf of the Company for all or part of those • Extend the reach of COSA's current educational activities proceedings. • Provide a forum for the discussion of common issues in cancer research Environmental Regulation • Facilitate a collective voice for the cancer cooperative trials groups COSA is not subject to any significant environment regulations. • Align COSA's governance and operational structure in accordance with best practice • Ensure COSA remains relevant to its membership Dividends COSA does not permit any dividends and therefore no dividends have been paid or declared. • Ensure COSA remains financially viable as a not-for-profit organisation Contributions on winding up In the event of the company being wound up, all members are required to contribute a maximum of $10 each.
4 5 57 - ANNUAL REPORT 2017
Clinical Oncology Society of Australia Limited (ABN 97 631 209 452) Directors' Report (contʼd) 30 June 2018
Principal activities The principal activities of the Clinical Oncology Society of Australia during the year were focused on furthering both our short and long term objectives, referenced above. More detail on the achievements against these activities are detailed in the 2018 Annual Report.
Review of financial operations and results of Clinical Oncology Society of Australia Limited The total income for the financial year ended 30 June 2018 was $1,052,270 (2017: $893,283). In the same period, expenditure was $888,355 (2017: $757,047) leaving a surplus of $163,915 (2017: $136,236 surplus). The level of spending for the organisation varies from year to year as the range of activities to support our members, and the costs associated with them, also vary.
Matters Subsequent to the end of Financial Year As at the date of this directors' report, the directors are not aware of any matter or circumstance that has arisen that has significantly affected, or may significantly affect, the operations of the Company, the results of those operations or the state of affairs of the Company in the financial years subsequent to 30 June 2018. Indemnity and insurance of officers The Company has indemnified the directors and executives of the Company for costs incurred, in their capacity as a director or executive, for which they may be held personally liable, except where there is a lack of good faith.
During the financial year, the Company paid a premium of $1,600 in respect of a contract to insure the directors and executives of the company against a liability to the extent permitted by the Corporations Act 2001. Indemnity and insurance of auditor The Company has not, during or since the end of the financial year, indemnified or agreed to indemnify the auditor of the Company or any related entity against a liability incurred by the auditor.
During the financial year, the Company has not paid a premium in respect of a contract to insure the auditor of the Company or any related entity. Proceedings on behalf of the Company No person has applied to the Court under section 237 of the Corporations Act 2001 for leave to bring proceedings on behalf of the Company, or to intervene in any proceedings to which the Company is a party for the purpose of taking responsibility on behalf of the Company for all or part of those proceedings. Environmental Regulation COSA is not subject to any significant environment regulations. Dividends COSA does not permit any dividends and therefore no dividends have been paid or declared. Contributions on winding up In the event of the company being wound up, all members are required to contribute a maximum of $10 each.
5 57 - 58 COSA BOARD + COSA REPORTS
COSA GROUP REPORTS
AFFILIATED ORGANISATION REPORTS
OTHER REPORTS
ANNUAL REPORT 2017 CLINICAL ONCOLOGY SOCIETY OF AUSTRALIA LIMITED FINANCIAL STATEMENTS (ABN 97 631 209 452) ClinicalDIRECTORS’ Oncology Society REPORT of Australia Limited (ABN 97 631 209 452) Clinical Oncology Society of Australia Limited (ABN 97 631 209 452) Directors' Report (contʼd) Directors' Report (contʼd) 3030 June JUNE 2018 2018 (Cont’d) 30 June 2018
Directors Audit, Risk & The names of the Directors of the Company in office during or since the end of the year are: Board Finance Date Committee Name, Qualifications and Experience Role Date Joined Audit, Risk & Ceased Board Finance Attended / Attended / Eligible to Eligible to Date Committee Name, Qualifications and Experience Role Date Joined Ceased attend attend Attended / Attended / Eligible to Eligible to Dr Haryana Dhillon BSc MA PhD attend attend Dr Dhillon is a Senior Research Fellow in the Survivorship Director, Research Group and a Director of the Centre for Medical Member Audit, Professor Phyllis Butow AM, BA (Hons) Dip Ed MClinPsych 1 July 2013 - 4 / 5 4 / 5 MPH PhD Psychology & Evidence-based Decision-making, School of Risk & Finance Professor Phyllis Butow is an NHMRC Senior Principal Psychology, Faculty of Science at the University of Sydney. Committee Research Fellow and Founding Director of the Centre for President and She is the former Chair of the COSA Survivorship Group. Medical Psychology and Evidence-based Decision-making Board Chair 06-Mar-15 - 5 / 5 - (CeMPED) at the University of Sydney. She has worked for over (2017-2018), Mr Peter Dowding BSC (Hons) MBA 20 years in the areas of Psycho-Oncology and doctor-patient Director Mr Dowding is co-founder and Chairman of Propel Investments, Director, communication and plays an active role in promoting these a mid-market private equity firm based in Sydney and Chair Audit, issues within the cancer community. She is the inaugural Chair established in 2007. He has over 30 years' experience in the 12-May-14 - 3 / 5 5 / 5 of the Psycho-oncology Co-operative Research Group (PoCoG). Risk & Finance private equity sector, having been a Director on several Committee Associate Professor Nick Pavlakis BSc MBBS Mmed investments and was appointed as a Director to the COSA (ClinEpi) PhD FRACP Board for his experience in corporate governance. Professor Pavlakis is a medical oncologist at Royal North Shore Ms Sandra McKiernan BAppSc (Nsg) MPH Hospital and Northern Cancer Institute in St Leonards Sydney Ms McKiernan is the Executive Manager Specialist Community whose clinical interest is in lung cancers, mesothelioma, and Director, gastrointestinal cancers including NETs. His clinical research Services St Vincent de Paul Society WA, and previous Director President Elect Member Audit, of Cancer Information and Support Services at Cancer Council 18-May-15 - 5 / 5 4 / 5 focuses on trials in these tumour types and includes new (2017-2018), 24-Nov-16 - 2 / 5 - Risk & Finance cancer drug development, including translational research Director WA (2009-2018). Sandy is a Past President (2013-14) of the Committee interest into drug resistance in oncogene driven lung cancer, Cancer Nurses Society of Australia and a graduate of the biomarkers in gastric cancer and NETs. He is study chair or co- Australian Institute of Company Directors. chair on several ALTG and AGITG trials. He is current Chair of the COSA Lung Cancer Group, President of the ALTG and Profe ssor Me i ni r Kri shna sa m y BA, RN, DipN, MSc, Ph.D Regent for Australasia for the International Association for the Professor Krishnasamy is Immediate Past President of the Study of Lung Cancer (IASLC). Clinical Oncology Society of Australia. She is Chair in Cancer Ms Sandie Angus LLB, GAICD Nursing at the University of Melbourne and Victorian Director 13-Jul-17 - 5 / 5 - Ms Angus is an experienced strategic leader and non-executive Comprehensive Cancer Centre Research and Education Lead director with significant legal, governance, and risk management for Cancer Nursing . She is a past President of the Cancer expertise. She is admitted as a solicitor and has over thirty Nurses Society of Australia. years experience working in law firms and in the government Director 20-Mar-18 - 1 / 1 - finance and electricity sectors. She sits on the boards of Dr Wayne Nicholls MBChB FRACP various not-for-profit companies in the health, sports and Dr Nicholls is the Director of the Oncology Services Group at disability sectors. She was appointed as a Director to the the Lady Cilento Childrenʼs Hospital in Brisbane (formerly the COSA Board for her legal expertise. Royal Children's Hospital) with over 20 yearsʼ experience. He Director 19-May-15 - 4 / 5 - Professor Sanchia Aranda RN, PhD, GAICD has a particular interest in brain tumours and sarcomas. He is Professor Sanchia Aranda was appointed as CEO of Cancer also a senior lecturer in the Department of Paediatrics at the Council Australia in August 2015. She holds academic University of Queensland. appointments with the School of Health Sciences, University of Melbourne, University of Technology and the Faculty of Nursing, Ms Felicity Shaw LLB (Hons I) BSc MEL University of Sydney. She has almost 40 yearsʼ experience in Ms Shaw is a senior commercial lawyer with over 15 years Director, cancer control, having held prior leadership roles in healthcare, Director 27-Aug-15 - 4 / 5 - experience in the public and private sectors. She is currently Member Audit, government and tertiary education. For the last 25 years 19-May-14 08-Mar-18 2 / 4 3 / 4 Risk & Finance Sanchia has worked in international cancer control, with 16 Director of the Commercial Law Practice Group at the Crown Committee years on the board of the International Society of Nurses in Solicitor's Office. She was appointed as a Director to the COSA Cancer Care, including 4 as President (2006-2010). She is the Board for her legal expertise. President of the Union for International Cancer Control and has been on the board of UICC for 8 years. Dr Nik Zeps BSc (Hons) PhD Dr Christine Carrington BPHarm(Hons), MMedSci Doctor Clin Dr Nik Zeps is Group Director of Research and Development at Pharm Epworth HealthCare in Victoria. He is the chair of the COSA Director, Member Audit, Dr Carrington is a Senior Consultant Pharmacist for Cancer Cancer Biology Group, a member of the Scientific Advi s ory 13-Jul-17 - 5 / 5 1 / 1 Services and a Deputy Director of Pharmacy at the Princess Committee of the AGITG, chair of the PC4 Advisory Committee Risk & Finance Alexandra Hospital in Brisbane. She is a past Chair of the and a member of the PC4 Scientific Committee. He is a Committee COSA Cancer Pharmacist Group and has a keen interest in Director 01-Jul-13 - 4 / 5 - founding director and board member of the Australian Clinical safe medication practices in cancer therapy and in developing Trials Alliance (ACTA). educational programs for pharmacists. She has recently led the multidisciplinary working group for the review and development of the COSA national guidelines for the ʻSafe Prescribing, Directors are appointed on an honorary basis and as a result do not receive any remuneration either Dispensing and Administration of Cancer therapyʼ which have directly or indirectly from the Company. been published on the Cancer Council Wiki platform. 7 6 59 - ANNUAL REPORT 2017
Clinical Oncology Society of Australia Limited (ABN 97 631 209 452) Directors' Report (contʼd) 30 June 2018
Audit, Risk & Board Finance Date Committee Name, Qualifications and Experience Role Date Joined Ceased Attended / Attended / Eligible to Eligible to attend attend Dr Haryana Dhillon BSc MA PhD Dr Dhillon is a Senior Research Fellow in the Survivorship Director, Research Group and a Director of the Centre for Medical Member Audit, 1 July 2013 - 4 / 5 4 / 5 Psychology & Evidence-based Decision-making, School of Risk & Finance Psychology, Faculty of Science at the University of Sydney. Committee She is the former Chair of the COSA Survivorship Group.
Mr Peter Dowding BSC (Hons) MBA Mr Dowding is co-founder and Chairman of Propel Investments, Director, a mid-market private equity firm based in Sydney and Chair Audit, 12-May-14 - 3 / 5 5 / 5 established in 2007. He has over 30 years' experience in the Risk & Finance private equity sector, having been a Director on several Committee investments and was appointed as a Director to the COSA Board for his experience in corporate governance.
Ms Sandra McKiernan BAppSc (Nsg) MPH Ms McKiernan is the Executive Manager Specialist Community Director, Services St Vincent de Paul Society WA, and previous Director Member Audit, 18-May-15 - 5 / 5 4 / 5 of Cancer Information and Support Services at Cancer Council Risk & Finance WA (2009-2018). Sandy is a Past President (2013-14) of the Committee Cancer Nurses Society of Australia and a graduate of the Australian Institute of Company Directors.
Profe ssor Me i ni r Kri shna sa m y BA, RN, DipN, MSc, Ph.D Professor Krishnasamy is Immediate Past President of the Clinical Oncology Society of Australia. She is Chair in Cancer Nursing at the University of Melbourne and Victorian Director 13-Jul-17 - 5 / 5 - Comprehensive Cancer Centre Research and Education Lead for Cancer Nursing . She is a past President of the Cancer Nurses Society of Australia.
Dr Wayne Nicholls MBChB FRACP Dr Nicholls is the Director of the Oncology Services Group at the Lady Cilento Childrenʼs Hospital in Brisbane (formerly the Royal Children's Hospital) with over 20 yearsʼ experience. He Director 19-May-15 - 4 / 5 - has a particular interest in brain tumours and sarcomas. He is also a senior lecturer in the Department of Paediatrics at the University of Queensland.
Ms Felicity Shaw LLB (Hons I) BSc MEL Ms Shaw is a senior commercial lawyer with over 15 years Director, experience in the public and private sectors. She is currently Member Audit, 19-May-14 08-Mar-18 2 / 4 3 / 4 Director of the Commercial Law Practice Group at the Crown Risk & Finance Solicitor's Office. She was appointed as a Director to the COSA Committee Board for her legal expertise.
Dr Nik Zeps BSc (Hons) PhD Dr Nik Zeps is Group Director of Research and Development at Epworth HealthCare in Victoria. He is the chair of the COSA Director, Member Audit, Cancer Biology Group, a member of the Scientific Advi s ory 13-Jul-17 - 5 / 5 1 / 1 Committee of the AGITG, chair of the PC4 Advisory Committee Risk & Finance and a member of the PC4 Scientific Committee. He is a Committee founding director and board member of the Australian Clinical Trials Alliance (ACTA).
Directors are appointed on an honorary basis and as a result do not receive any remuneration either directly or indirectly from the Company. 7
59 - 60 COSA BOARD + COSA REPORTS
COSA GROUP REPORTS
AFFILIATED ORGANISATION REPORTS
OTHER REPORTS Tel: +61 2 9251 4100 Level 11, 1 Margaret St Fax: +61 2 9240 9821 Sydney NSW 2000 ANNUAL REPORT 2017 Australia CLINICAL ONCOLOGY SOCIETY www.bdo.com.au
OF AUSTRALIA LIMITED FINANCIAL STATEMENTS (ABN 97 631 209 452) Clinical Oncology Society of Australia Limited (ABN 97 631 209 452) DIRECTORS’Directors' Report (contʼd) REPORT 30 June 2018 30 JUNE 2018 (Cont’d)
Tel: +61 2 9251 4100 Level 11, 1 Margaret St Company Secretary and Chief Executive Officer Fax: +61 2 9240 9821 Sydney NSW 2000 Ms Marie Malica is the Company Secretary and Chief Executive Officer of the Company. Ms Malica www.bdo.com.au Australia DECLARATION OF INDEPENDENCE BY PAUL CHEESEMAN TO THE DIRECTORS OF CLINICAL ONCOLOGY joined the Company in March 2011 and has 15 yearsʼ experience working in the cancer not-for-profit sector and state government having previously held the position of Manager, Research Strategy Unit at SOCIETY OF AUSTRALIA Cancer Council NSW and Manager, Research Support Office with South Eastern Sydney Area Health Service, Northern Hospital Network. As lead auditor of Clinical Oncology Society of Australia for the year ended 30 June 2018, I declare that, to the best of my knowledge and belief, there have been: Auditor's Independence Declaration 1. No contraventions of the auditor independence requirements of the Corporations Act 2001 in A copy of the auditor's independence declaration as required under section 307C of the Corporations Act relation to the audit; and
2001 is set out on the following page. 2. No contraventions of any applicable code of professional conduct in relation to the audit.
This report is made in accordance with a resolution of directors, pursuant to section 298(2)(a) of the DECLARATION OF INDEPENDENCE BY PAUL CHEESEMAN TO THE DIRECTORS OF CLINICAL ONCOLOGY Corporations Act 2001. SOCIETY OF AUSTRALIA
As lead auditor of Clinical Oncology Society of Australia for the year ended 30 June 2018, I declare that, to the best of my knowledge and belief, there have been: Paul1. NoCheeseman contraventions of the auditor independence requirements of the Corporations Act 2001 in Partnerrelation to the audit; and On behalf of the directors 2. No contraventions of any applicable code of professional conduct in relation to the audit.
BDO East Coast Partnership
Sydney, 17 October 2018 ______
Prof Phyllis Butow AM A/Prof Nick Pavlakis President President-Elect Paul Cheeseman Sydney Partner 17 October 2018
BDO East Coast Partnership
Sydney, 17 October 2018
BDO East Coast Partnership ABN 83 236 985 726 is a member of a national association of independent entities which are all members of BDO Australia Ltd ABN 77 050 110 275, an Australian company limited by guarantee. BDO East Coast Partnership and BDO Australia Ltd are members of BDO International Ltd, a UK company limited by guarantee, and form part of the international BDO network of independent member firms. Liability limited by a scheme approved under Professional Standards Legislation, other than for the acts or omissions of financial services licensees.
8
61 -
BDO East Coast Partnership ABN 83 236 985 726 is a member of a national association of independent entities which are all members of BDO Australia Ltd ABN 77 050 110 275, an Australian company limited by guarantee. BDO East Coast Partnership and BDO Australia Ltd are members of BDO International Ltd, a UK company limited by guarantee, and form part of the international BDO network of independent member firms. Liability limited by a scheme approved under Professional Standards Legislation, other than for the acts or omissions of financial services licensees.
Tel: +61 2 9251 4100 Level 11, 1 Margaret St Fax: +61 2 9240 9821 Sydney NSW 2000 ANNUAL REPORT 2017 www.bdo.com.au Australia
Tel: +61 2 9251 4100 Level 11, 1 Margaret St Fax: +61 2 9240 9821 Sydney NSW 2000 www.bdo.com.au Australia DECLARATION OF INDEPENDENCE BY PAUL CHEESEMAN TO THE DIRECTORS OF CLINICAL ONCOLOGY SOCIETY OF AUSTRALIA
As lead auditor of Clinical Oncology Society of Australia for the year ended 30 June 2018, I declare that, to the best of my knowledge and belief, there have been:
1. No contraventions of the auditor independence requirements of the Corporations Act 2001 in relation to the audit; and
2. No contraventions of any applicable code of professional conduct in relation to the audit.
DECLARATION OF INDEPENDENCE BY PAUL CHEESEMAN TO THE DIRECTORS OF CLINICAL ONCOLOGY SOCIETY OF AUSTRALIA
As lead auditor of Clinical Oncology Society of Australia for the year ended 30 June 2018, I declare that, to the best of my knowledge and belief, there have been: Paul1. NoCheeseman contraventions of the auditor independence requirements of the Corporations Act 2001 in Partnerrelation to the audit; and 2. No contraventions of any applicable code of professional conduct in relation to the audit.
BDO East Coast Partnership
Sydney, 17 October 2018
Paul Cheeseman Partner
BDO East Coast Partnership
Sydney, 17 October 2018
BDO East Coast Partnership ABN 83 236 985 726 is a member of a national association of independent entities which are all members of BDO Australia Ltd ABN 77 050 110 275, an Australian company limited by guarantee. BDO East Coast Partnership and BDO Australia Ltd are members of BDO International Ltd, a UK company limited by guarantee, and form part of the international BDO network of independent member firms. Liability limited by a scheme approved under Professional Standards Legislation, other than for the acts or omissions of financial services licensees.
61 - 62
BDO East Coast Partnership ABN 83 236 985 726 is a member of a national association of independent entities which are all members of BDO Australia Ltd ABN 77 050 110 275, an Australian company limited by guarantee. BDO East Coast Partnership and BDO Australia Ltd are members of BDO International Ltd, a UK company limited by guarantee, and form part of the international BDO network of independent member firms. Liability limited by a scheme approved under Professional Standards Legislation, other than for the acts or omissions of financial services licensees.
COSA BOARD + COSA REPORTS
COSA GROUP REPORTS
AFFILIATED ORGANISATION REPORTS
OTHER REPORTS
ANNUAL REPORT 2017 CLINICAL ONCOLOGY SOCIETY OF AUSTRALIA LIMITED FINANCIAL STATEMENTS (ABN 97 631 209 452)
Clinical Oncology Society of Australia Limited (ABN 97 631 209 452) STATEMENT OF PROFIT OR LOSS AND Clinical Oncology Society of Australia Limited (ABN 97 631 209 452) Statement of Financial Position Clinical Oncology Society of Australia Limited (ABN 97 631 209 452) Statement of Financial Position OTHERClinicalStatement Oncology of COMPREHENSIVE Profit Society or Loss of and Australia Other ComprehensiveLimited INCOME (ABN 97 Income 631 209 452) As at 30 June 2018 As at 30 June 2018 Note 2018 2017 StatementFor the year of ended Profit or30 LossJune and2018 Other Comprehensive Income Note 2018 2017 FOR THE YEAR ENDED 30 JUNE 2018 $ $ For the year ended 30 June 2018 Note 2018 2017 $ $ ASSETS Note 201$ 8 201$ 7 ASSETS Current Assets Income $ $ Current Assets Cash & cash equivalents 5 600,236 405,192 IncomeMember body subscriptions 1(a)(ii), 4 132,218 130,842 Cash & cash equivalents 5 600,236 405,192 Trade & other receivables 6 97,045 18,548 MemberAnnual Scientific body subscriptions Meeting revenue 1(a)(iii),1(a)(ii), 44 455,984132,218 451,822130,842 Trade & other receivables 6 97,045 18,548 Other current assets 7 1,780,127 1,774,837 NHMRCAnnual Scientific Enabling Meeting Grant revenue revenue 1(a)(iv),1(a)(iii), 4 455,9844,755 451,822 1,145 Other current assets 7 1,780,127 1,774,837 Total Current Assets NHMRC Enabling Grant revenue 1(a)(iv),1 (a)(i), 4 4,755 1,145 Total Current Assets 2,477,408 2,198,577 Other grant & project revenue 408,642 257,447 2,477,408 2,198,577 InterestOther grant income & project revenue 11 (a)(v),(a)(i), 44 408,64250,183 257,447 49,392 Non-Current Assets Non-Current Assets OtherInterest revenue income 1 (a)(vi),(a)(v), 44 50,183488 49,392 2,635 Plant & equipment 8 5,827 1,349 Plant & equipment 8 5,827 1,349 Other revenue 1 (a)(vi), 4 488 2,635 Total Non-Current Assets 5,827 1,349 1,052,270 893,283 Total Non-Current Assets 5,827 1,349 1,052,270 893,283 Total Assets 2,483,235 2,199,926 Expenditure Total Assets 2,483,235 2,199,926 ExpenditureAdministration Expenses (64,667) (66,681) Administration Expenses (64,667) (66,681) LIABILITIES Employment costs (492,402) (436,002) LIABILITIES Employment costs (492,402) (436,002) Current Liabilities Depreciation (1,934) (1,183) Current Liabilities 9 Depreciation (1,934) (1,183) Trade & other payables 272,427 142,796 NHMRC Enabling grant expenses (4,755) (1,145) Trade & other payables 9 272,427 142,796 10 NHMRC Enabling grant expenses (4,755) (1,145) Provision for employee benefits 29,818 28,517 Annual Scientific Meeting (25,932) (48,488) Provision for employee benefits 10 29,818 28,517 OtherAnnual grant Scientific & project Meeting expenses (243,368)(25,932) (152,621)(48,488) Total Current Liabilities 302,245 171,313 Total Current Liabilities 302,245 171,313 Other grantexpenses & project from expensesordinary activities (243,368)(55,297) (152,621)(50,927) Non-Current Liabilities Non-Current Liabilities Other expenses from ordinary activities (55,297) (50,927) Provision for employee benefits 10 4,277 1,060 (888,355) (757,047) Provision for employee benefits 10 4,277 1,060 (888,355) (757,047) Total Non-Current Liabilities 4,277 1,060 Surplus before income tax expense 163,915 136,236 Total Non-Current Liabilities 4,277 1,060 Surplus before income tax expense 163,915 136,236 Income tax expense Total Liabilities 306,522 172,373 1(c) - - Total Liabilities 306,522 172,373 Income tax expense Net surplus after income tax expense for the year 1(c) - - Net Assets 2,176,713 2,027,553 attributable to the members of COSA 163,915 136,236 Net Assets 2,176,713 2,027,553 Net surplus after income tax expense for the year attributable to the members of COSA 163,915 136,236 Other comprehensive income for the year, net of tax - - EQUITY EQUITY TotalOther comprehensive income income for for the the year, year net attributable of tax to - - Grants & Special Projects Reserve 141,132 155,887 163,915 136,236 the members of COSA Grants & Special Projects Reserve 141,132 155,887 Total comprehensive income for the year attributable to 163,915 136,236 General Funds 2,035,581 1,871,666 the members of COSA General Funds 2,035,581 1,871,666
Total Equity 2,176,713 2,027,553 Total Equity 2,176,713 2,027,553
The accompanying notes form part of these financial statements The accompanying notes form part of these financial statements The accompanying notes form part of these financial statements The accompanying notes form part of these financial statements 11 63 - 11 10
10 ANNUAL REPORT 2017
Clinical Oncology Society of Australia Limited (ABN 97 631 209 452) STATEMENTClinical Oncology Society OF of Australia Limited (ABN 97 631 209 452) Statement of Financial Position Statement of Financial Position FINANCIALAs at 30 June 2018 POSITION As at 30 June 2018 Note 2018 2017 Note 2018 2017 30 JUNE 2018 $ $ $ $ ASSETS ASSETS Current Assets Current Assets Cash & cash equivalents 5 600,236 405,192 Cash & cash equivalents 5 600,236 405,192 Trade & other receivables 6 97,045 18,548 Trade & other receivables 6 97,045 18,548 Other current assets 7 1,780,127 1,774,837 Other current assets 7 1,780,127 1,774,837 Total Current Assets Total Current Assets 2,477,408 2,198,577 2,477,408 2,198,577 Non-Current Assets Non-Current Assets Plant & equipment 8 5,827 1,349 Plant & equipment 8 5,827 1,349 Total Non-Current Assets 5,827 1,349 Total Non-Current Assets 5,827 1,349
Total Assets 2,483,235 2,199,926 Total Assets 2,483,235 2,199,926
LIABILITIES LIABILITIES Current Liabilities Current Liabilities Trade & other payables 9 272,427 142,796 Trade & other payables 9 272,427 142,796 Provision for employee benefits 10 29,818 28,517 Provision for employee benefits 10 29,818 28,517 Total Current Liabilities 302,245 171,313 Total Current Liabilities 302,245 171,313 Non-Current Liabilities Non-Current Liabilities Provision for employee benefits 10 4,277 1,060 Provision for employee benefits 10 4,277 1,060 Total Non-Current Liabilities 4,277 1,060 Total Non-Current Liabilities 4,277 1,060 Total Liabilities 306,522 172,373 Total Liabilities 306,522 172,373
Net Assets 2,176,713 2,027,553 Net Assets 2,176,713 2,027,553
EQUITY EQUITY Grants & Special Projects Reserve 141,132 155,887 Grants & Special Projects Reserve 141,132 155,887 General Funds 2,035,581 1,871,666 General Funds 2,035,581 1,871,666
Total Equity 2,176,713 2,027,553 Total Equity 2,176,713 2,027,553
The accompanying notes form part of these financial statements The accompanying notes form part of these financial statements 11 63 - 64 11 COSA BOARD + COSA REPORTS
COSA GROUP REPORTS
AFFILIATED ORGANISATION REPORTS
OTHER REPORTS
ANNUAL REPORT 2017 CLINICAL ONCOLOGY SOCIETY OF AUSTRALIA LIMITED FINANCIAL STATEMENTS (ABN 97 631 209 452)
STATEMENTClinical Oncology Society OF CHANGES of Australia Limited (ABN 97 631 209 452) Clinical Oncology Society of Australia Limited (ABN 97 631 209 452) INStatement EQUITY of Changes FOR in THE Equity YEAR Statement of Cash Flow For the year ended 30 June 2018 For the year ended 30 June 2018 ENDED 30 JUNE 2018 $ $ $ 2018 2017
Grants & Note $ $ Special General Funds Projects Total Funds Reserve Cash flows from operating activities:
Balance at 1 July 2016 1,735,430 157,032 1,892,462 Receipts from member subscriptions and other income 912,728 841,888 (inclusive of GST) Transfer from reserves - (1,145) (1,145)
Transfer to liabilities - - - Payments to suppliers, employees and member bodies (756,165) (751,956) Surplus after income tax for the year 136,236 - 136,236 (inclusive of GST) Other Comprehensive income for the - - - year, net of tax Interest received 50,183 49,392 Total comprehensive income for the year 136,236 - 136,236
Balance at 30 June 2017 1,871,666 155,887 2,027,553 Net cash provided by operating activities 14 206,746 139,324
Cash flows from investing activities:
Balance at 1 July 2017 1,871,666 155,887 2,027,553
Transfer from reserves - (14,755) (14,755) Received from term deposits (5,289) 152,437
Transfer to liabilities - - - Payment for purchase of plant and equipment (6,413) (2,044)
Surplus after income tax for the year 163,915 - 163,915
Other Comprehensive income for the - - - Net cash (used in)/provided by investing activities (11,702) 150,393 year, net of tax
Total comprehensive income for the year 163,915 - 163,915 Net increase in cash & cash equivalents 195,044 289,717
Balance at 30 June 2018 2,035,581 141,132 2,176,713 Cash & cash equivalents at the beginning of the year 405,192 115,475
5 Nature and Purpose of Reserves Cash & cash equivalents at the end of the year 600,236 405,192
Grants & Special Projects Reserve
This reserve relates to funds received by the Company and designated for use for a specific purpose. This may include grant monies received but not yet spent. These funds are held in reserve until spent appropriately, or in line with funding agreements.
The accompanying notes form part of these financial statements The accompanying notes form part of these financial statements
65 - 12 13 ANNUAL REPORT 2017
ClinicalSTATEMENT Oncology Society OF CASHof Australia Limited (ABN 97 631 209 452) StatementFLOW ofFOR Cash THEFlow YEAR For the year ended 30 June 2018 ENDED 30 JUNE 2018 2018 2017
Note $ $
Cash flows from operating activities:
Receipts from member subscriptions and other income 912,728 841,888 (inclusive of GST)
Payments to suppliers, employees and member bodies (756,165) (751,956) (inclusive of GST)
Interest received 50,183 49,392
Net cash provided by operating activities 14 206,746 139,324
Cash flows from investing activities:
Received from term deposits (5,289) 152,437 Payment for purchase of plant and equipment (6,413) (2,044)
Net cash (used in)/provided by investing activities (11,702) 150,393
Net increase in cash & cash equivalents 195,044 289,717
Cash & cash equivalents at the beginning of the year 405,192 115,475
Cash & cash equivalents at the end of the year 5 600,236 405,192
The accompanying notes form part of these financial statements
65 - 66 13 COSA BOARD + COSA REPORTS
COSA GROUP REPORTS
AFFILIATED ORGANISATION REPORTS
OTHER REPORTS
ANNUAL REPORT 2017 CLINICAL ONCOLOGY SOCIETY OF AUSTRALIA LIMITED FINANCIAL STATEMENTS (ABN 97 631 209 452) NOTES TO THE FINANCIAL STATEMENTS Clinical Oncology Society of Australia Limited (ABN 97 631 209 452) Clinical Oncology Society of Australia Limited (ABN 97 631 209 452) Notes to the Financial Statements for the year ended 30 June 2018 FORNotes toTHE the Financial YEAR Statements ENDED for the30 year JUNE ended 2018 30 June 2018 (cont.)
Note 1. Statement of significant accounting policies Note 1. Statement of significant accounting policies (cont.)
Clinical Oncology Society of Australia Limited ("the Company") is not a reporting entity because in the directors' opinion there are unlikely to exist users who are unable to command the preparation of reports ACCOUNTING POLICIES tailored so as to satisfy specifically all of their information needs and these financial reports are therefore a Special Purpose Financial Report that has been prepared solely to meet the financial reporting (a) Revenue Recognition requirements of the ACNC Act 2012. The directors have determined that the policies are appropriate to Revenue is recognised when it is probable that the economic benefit will flow to the Company meet the needs of the members of the Company. and the revenue can be reliably measured. Revenue is measured at the fair value of the consideration received or receivable. The Company is a not for profit entity and an incorporated company limited by guarantee domiciled in Australia. (i) Grants The Company receives grants to fund certain activities. Where the grant is non reciprocal, it is The financial report was authorised for issue by the directors on 17 October 2018. recognised as revenue of the Company upon receipt. Associated expenditure for the completion of the grant is recorded as incurred. Where the grant is subject to a reciprocal transfer, a liability New, revised or amending Accounting Standards and Interpretations adopted associated with the reciprocal transfer is recorded upon receipt of the grant. No income is recorded for reciprocal transfers until conditions associated with the grant are satisfied. The Company has adopted all of the new, revised or amending Accounting Standards and Interpretations issued by the Australian Accounting Standards Board ('AASB') that are mandatory for the current (ii) Member Subscriptions reporting period. Member subscriptions are recorded on an accruals basis and apportioned across the financial year of membership. Any new, revised or amending Accounting Standards or Interpretations that are not yet mandatory have not been early adopted. (iii) Annual Scientific Meeting Income The Company contracts a professional Events Co-ordinator to manage the staging of the Annual BASIS OF PREPARATION Scientific Meeting including the receipt of revenue and payment of expenses in relation to the event. Documents detailing the income and expenses have been received from the Events Co- These financial statements have been prepared in accordance with the recognition and measurement ordinator together with a reconciling statement. A review has been performed on the books and requirements specified by the Australian Accounting Standards and Interpretations issued by the records of the Events Co-ordinator to determine the completeness of the statements received. Australian Accounting Standards Board ('AASB') and the disclosure requirements of AASB 101 Revenue and expenses associated with the Annual Scientific Meeting are recognised through the Presentation of Financial Statements', AASB 107 'Statement of Cash Flows', AASB 108 'Accounting Statement of profit or loss and other comprehensive income for the financial year the Annual Policies, Changes in Accounting Estimates and Errors', AASB 1031 'Materiality' and AASB 1048 Scientific Meeting is conducted. Interpretation and Application of Standards' and AASB1054 'Australian Additional Disclosures', as appropriate for not-for-profit oriented entities. These financial statements do not conform to International Financial Reporting Standards as issued by the International Accounting Standards Board ("IASB"). Net Annual Scientific Meeting income is calculated as the excess of revenue in relation to the Annual Scientific Meeting compared to expenses associated with the meeting. No other Accounting Standards and other professional reporting requirements in Australia have mandatory applicability because the company is not a reporting entity. The net income for the 2017/18 Annual Scientific Meeting was $430,052 (2016/17: 403,334).
REPORTING BASIS AND CONVENTIONS (iv) NHMRC Enabling Grant The financial report has been prepared on an accruals basis (except the statement of cash flows) and is In 2006, the Company began work on activities associated with the NHMRC Enabling Grant, the based on historical costs and does not take into account changing money values or, except where five-year funding provided through The University of Newcastle to facilitate enhancements to the specifically stated, current valuations of non-current assets. operating resources of the ten cancer cooperative clinical trials groups.
The following material accounting policies, which are consistent with the previous period, unless To date, $1,846,000 has been allocated to fund this activity of which $4,755 (excluding otherwise stated, have been adopted in the preparation of this report. employment costs) has been spent in 2017/18 (2016/17: $1,145). The balance of unspent monies is held in the Grants & Special Projects Reserve in the Statement of financial position All amounts are in Australian dollars. awaiting future expenditure.
15 67 - 14 ANNUAL REPORT 2017
Clinical Oncology Society of Australia Limited (ABN 97 631 209 452) Notes to the Financial Statements for the year ended 30 June 2018 (cont.)
Note 1. Statement of significant accounting policies (cont.)
ACCOUNTING POLICIES (a) Revenue Recognition Revenue is recognised when it is probable that the economic benefit will flow to the Company and the revenue can be reliably measured. Revenue is measured at the fair value of the consideration received or receivable.
(i) Grants The Company receives grants to fund certain activities. Where the grant is non reciprocal, it is recognised as revenue of the Company upon receipt. Associated expenditure for the completion of the grant is recorded as incurred. Where the grant is subject to a reciprocal transfer, a liability associated with the reciprocal transfer is recorded upon receipt of the grant. No income is recorded for reciprocal transfers until conditions associated with the grant are satisfied.
(ii) Member Subscriptions Member subscriptions are recorded on an accruals basis and apportioned across the financial year of membership.
(iii) Annual Scientific Meeting Income The Company contracts a professional Events Co-ordinator to manage the staging of the Annual Scientific Meeting including the receipt of revenue and payment of expenses in relation to the event. Documents detailing the income and expenses have been received from the Events Co- ordinator together with a reconciling statement. A review has been performed on the books and records of the Events Co-ordinator to determine the completeness of the statements received. Revenue and expenses associated with the Annual Scientific Meeting are recognised through the Statement of profit or loss and other comprehensive income for the financial year the Annual Scientific Meeting is conducted.
Net Annual Scientific Meeting income is calculated as the excess of revenue in relation to the Annual Scientific Meeting compared to expenses associated with the meeting.
The net income for the 2017/18 Annual Scientific Meeting was $430,052 (2016/17: 403,334).
(iv) NHMRC Enabling Grant In 2006, the Company began work on activities associated with the NHMRC Enabling Grant, the five-year funding provided through The University of Newcastle to facilitate enhancements to the operating resources of the ten cancer cooperative clinical trials groups.
To date, $1,846,000 has been allocated to fund this activity of which $4,755 (excluding employment costs) has been spent in 2017/18 (2016/17: $1,145). The balance of unspent monies is held in the Grants & Special Projects Reserve in the Statement of financial position awaiting future expenditure.
15 67 - 68 COSA BOARD + COSA REPORTS
COSA GROUP REPORTS
AFFILIATED ORGANISATION REPORTS
OTHER REPORTS
ANNUAL REPORT 2017 CLINICAL ONCOLOGY SOCIETY OF AUSTRALIA LIMITED FINANCIAL STATEMENTS (ABN 97 631 209 452) NOTES TO THE FINANCIAL STATEMENTS Clinical Oncology Society of Australia Limited (ABN 97 631 209 452) Clinical Oncology Society of Australia Limited (ABN 97 631 209 452) NotesClinical to Oncologythe Financial Society Statements of Australia for the yearLimited ende (ABNd 30 June97 631 2018 209 (cont.) 452) FORNotes to THE the Financial YEAR Statements ENDED for the 30 year JUNEended 30 June2018 2018 (Cont’d) (cont.) Notes to the Financial Statements for the year ended 30 June 2018 (cont.) Note 1. Statement of significant accounting policies (cont.) Note 1. Statement of significant accounting policies (cont.) Note 1. Statement of significant accounting policies (cont.)
Funding is recognised as income as the funds are spent. measured at amortised cost and are not discounted. The amounts are unsecured and are usually measuredpaid within at30 amortised days of recognition. cost and are not discounted. The amounts are unsecured and are usually (v) Interest paid within 30 days of recognition. Interest revenue is recognised as interest accrues using the effective interest method. This is a (g) Income in Advance method of calculating the amortised cost of a financial asset and allocating the interest income (g) Income inin Advance Advance includes subscription revenue and clinical trials insurance for the 2017/18 over the relevant period using the effective interest rate, which is the rate that exactly discounts Incomeyear. in Advance includes subscription revenue and clinical trials insurance for the 2017/18 estimated future cash receipts through the expected life of the financial asset to the net carrying year. amount of the financial asset. (h) Cash and Cash Equivalents (h) Cash andand cashCash equivalents Equivalents includes cash on hand, deposits held at call with financial institutions (vi) Other Revenue Cashand other and short-term,cash equivalents highly includesliquid investments cash on hand, with originaldeposits maturities held at call of withless financialthan 90 daysinstitutions that Other revenue is recognised when it is received or when the right to receive payment is andare readilyother short-term, convertible highly to known liquid amounts investments of cash with and original which maturities are subject of toless an than insignificant 90 days riskthat of established. arechanges readily in convertiblevalue. to known amounts of cash and which are subject to an insignificant risk of changes in value. (b) Current and non-current classification (i) Goods and Services Tax (GST) Assets and liabilities are presented in the statement of financial position based on current and (i) GoodsRevenue, and expenses Services and Tax assets (GST) are recognised net of the amount of GST, except where the non-current classification. Revenue,amount of expensesGST incurred and isassets not recoverable are recognised from net the of Australian the amount Taxation of GST, Office. except In wherethese the amountcircumstances, of GST theincurred GST is recognisednot recoverable as part from of thethe Australiancost of acquisition Taxation of Office. the asset In these or as part of An asset is current when: it is expected to be realised or intended to be sold or consumed in circumstances,an item of expense. the GST Receivables is recognised and payables as part of in the the cost Statement of acquisition of financial of the position asset or are as shown part of normal operating cycle; it is held primarily for the purpose of trading; it is expected to be realised aninclusive item of of expense. GST. Cash Receivables flows are andpresented payables in the in theStatement Statement of cash of financial flow on position a gross arebasis, shown within twelve months after the reporting period; or the asset is cash or cash equivalent unless inclusiveexcept for of the GST. GST Cash component flows are of presentedinvesting andin the financing Statement activities, of cash which flow onare a disclosed gross basis, as restricted from being exchanged or used to settle a liability for at least twelve months after the exceptoperating for cashthe GST flows. component of investing and financing activities, which are disclosed as reporting period. All other assets are classified as non-current. operating cash flows. Commitments and contingencies are disclosed net of the amount of GST recoverable from, or A liability is current when: it is expected to settled in normal operating cycle; it is held primarily for Commitmentspayable to the andtax authority.contingencies are disclosed net of the amount of GST recoverable from, or the purpose of trading; it is due to be settled within twelve months after the reporting period; or payable to the tax authority. there is no unconditional right to defer the settlement of the liability for at least twelve months (j) Comparative figures after the reporting period. All other liabilities are classified as non-current. (j) Comparative figures figures of the Company for the previous 12 month period are included throughout Comparativethese statements. figures of the Company for the previous 12 month period are included throughout (c) Taxation these statements. The Company is a charitable institution in terms of subsection 50-5 of the Income Tax (k) Plant & equipment Assessment Act 1997, as amended; it is therefore exempt from income tax. This exemption has (k) Plant and& equipment equipment is stated at historical cost less accumulated depreciation and impairment. been confirmed by the Australian Taxation Office. PlantHistorical and costequipment includes is statedexpenditure at historical that is costdirectly less attributable accumulated to thedepreciation acquisition and of theimpairment. items. Historical cost includes expenditure that is directly attributable to the acquisition of the items. (d) Trade and other receivables Depreciation Trade and other receivables are recognised at amortised cost, less any provision for impairment. Depreciation is calculated on a straight-line basis to write off the net cost of each item of Depreciationproperty, plant is andcalculated equipment on a (excluding straight-line land) basis over to writetheir expectedoff the net useful cost of lives each as item follows: of (e) Other Current Assets property, plant and equipment (excluding land) over their expected useful lives as follows: Prepayments included in other assets primarily relate to prepayments for future Annual Scientific Class of plant and equipment Useful Life Meetings and other events. Held to maturity investments are non-derivative financial assets with ComputerClass of plant Equipment and equipment Useful 3 years Life fixed or determinable payments and fixed maturities that the Company's management has the Computer Equipment 3 years intention and ability to hold to maturity. The residual values, useful lives and depreciation methods are reviewed, and adjusted if
Theappropriate, residual atvalues, each reportinguseful lives date. and depreciation methods are reviewed, and adjusted if (f) Trade and other payables appropriate, at each reporting date. These amounts represent liabilities for goods and services provided to the Company prior to the An item of property, plant and equipment is derecognised upon disposal or when there is no end of the financial year and which are unpaid. Due to their short-term nature they are Anfuture item economic of property, benefit plant to and the equipmentCompany. isGains derecog andnised losses upon between disposal the orcarrying when thereamount is noand the futuredisposal economic proceeds benefit are taken to the to Company. profit and loss.Gains and losses between the carrying amount and the disposal proceeds are taken to profit and loss. 17 69 - 16 17 ANNUAL REPORT 2017
Clinical Oncology Society of Australia Limited (ABN 97 631 209 452) NotesClinical to Oncologythe Financial Society Statements of Australia for the yearLimited ende (ABNd 30 June97 631 2018 209 (cont.) 452) Notes to the Financial Statements for the year ended 30 June 2018 (cont.) Note 1. Statement of significant accounting policies (cont.) Note 1. Statement of significant accounting policies (cont.)
measured at amortised cost and are not discounted. The amounts are unsecured and are usually measuredpaid within at30 amortised days of recognition. cost and are not discounted. The amounts are unsecured and are usually paid within 30 days of recognition. (g) Income in Advance (g) Income inin Advance Advance includes subscription revenue and clinical trials insurance for the 2017/18 Incomeyear. in Advance includes subscription revenue and clinical trials insurance for the 2017/18 year. (h) Cash and Cash Equivalents (h) Cash andand cashCash equivalents Equivalents includes cash on hand, deposits held at call with financial institutions Cashand other and short-term,cash equivalents highly includesliquid investments cash on hand, with originaldeposits maturities held at call of withless financialthan 90 daysinstitutions that andare readilyother short-term, convertible highly to known liquid amounts investments of cash with and original which maturities are subject of toless an than insignificant 90 days riskthat of arechanges readily in convertiblevalue. to known amounts of cash and which are subject to an insignificant risk of changes in value. (i) Goods and Services Tax (GST) (i) GoodsRevenue, and expenses Services and Tax assets (GST) are recognised net of the amount of GST, except where the Revenue,amount of expensesGST incurred and isassets not recoverable are recognised from net the of Australian the amount Taxation of GST, Office. except In wherethese the amountcircumstances, of GST theincurred GST is recognisednot recoverable as part from of thethe Australiancost of acquisition Taxation of Office. the asset In these or as part of circumstances,an item of expense. the GST Receivables is recognised and payables as part of in the the cost Statement of acquisition of financial of the position asset or are as shown part of aninclusive item of of expense. GST. Cash Receivables flows are andpresented payables in the in theStatement Statement of cash of financial flow on position a gross arebasis, shown inclusiveexcept for of the GST. GST Cash component flows are of presentedinvesting andin the financing Statement activities, of cash which flow onare a disclosed gross basis, as exceptoperating for cashthe GST flows. component of investing and financing activities, which are disclosed as operating cash flows. Commitments and contingencies are disclosed net of the amount of GST recoverable from, or Commitmentspayable to the andtax authority.contingencies are disclosed net of the amount of GST recoverable from, or payable to the tax authority. (j) Comparative figures (j) Comparative figures figures of the Company for the previous 12 month period are included throughout Comparativethese statements. figures of the Company for the previous 12 month period are included throughout these statements. (k) Plant & equipment (k) Plant and& equipment equipment is stated at historical cost less accumulated depreciation and impairment. PlantHistorical and costequipment includes is statedexpenditure at historical that is costdirectly less attributable accumulated to thedepreciation acquisition and of theimpairment. items. Historical cost includes expenditure that is directly attributable to the acquisition of the items. Depreciation Depreciation is calculated on a straight-line basis to write off the net cost of each item of Depreciationproperty, plant is andcalculated equipment on a (excluding straight-line land) basis over to writetheir expectedoff the net useful cost of lives each as item follows: of property, plant and equipment (excluding land) over their expected useful lives as follows: Class of plant and equipment Useful Life ComputerClass of plant Equipment and equipment Useful 3 years Life Computer Equipment 3 years The residual values, useful lives and depreciation methods are reviewed, and adjusted if Theappropriate, residual atvalues, each reportinguseful lives date. and depreciation methods are reviewed, and adjusted if appropriate, at each reporting date. An item of property, plant and equipment is derecognised upon disposal or when there is no Anfuture item economic of property, benefit plant to and the equipmentCompany. isGains derecog andnised losses upon between disposal the orcarrying when thereamount is noand the futuredisposal economic proceeds benefit are taken to the to Company. profit and loss.Gains and losses between the carrying amount and the disposal proceeds are taken to profit and loss. 17 69 - 70 17 COSA BOARD + COSA REPORTS
COSA GROUP REPORTS
AFFILIATED ORGANISATION REPORTS
OTHER REPORTS
ANNUAL REPORT 2017 CLINICAL ONCOLOGY SOCIETY OF AUSTRALIA LIMITED FINANCIAL STATEMENTS (ABN 97 631 209 452)
NOTESClinical Oncology TO THE Society FINANCIAL of Australia Limited STATEMENTS (ABN 97 631 209 452) NotesClinical to Oncologythe Financial Society Statements of Australia for the yearLimited ende (ABNd 30 June97 631 2018 209 (cont.) 452) Clinical Oncology Society of Australia Limited (ABN 97 631 209 452) FORNotes to THE the Financial YEAR Statements ENDED for the 30 year JUNEended 30 June2018 2018 (Cont’d) (cont.) Notes to the Financial Statements for the year ended 30 June 2018 (cont.) Note 1. Statement of significant accounting policies (cont.) Note 1. Statement of significant accounting policies (cont.) Note 2. Nature and objects of the Company
(l) Provision for employee benefits The Company is an incorporated Company Limited by Guarantee under the Corporations Act 2001. (l) ProvisionShort term foremployee employee benefits benefits
ShortLiabilities term for employee wages and benefits salaries, including non-monetary benefits, annual leave and long service Liabilitiesleave expected for wages to be and settled salaries, within including 12 months non-monetary of the reporting benefits, date annualare recognised leave and in longcurrent service Its objects are: leaveliabilities expected in respect to be of settled employees' within services 12 months up toof thethe reportingreporting datedate andare recognisedare measured in current at the a. to promote excellence in the multidisciplinary care and research relating to cancer – from liabilitiesamounts inexpected respect toof beemployees' paid when services the liabilities up to arethe reportingsettled. date and are measured at the prevention, diagnosis and treatment to follow-up, palliation and survivorship; amounts expected to be paid when the liabilities are settled. b. to encourage multidisciplinary collaboration of all professionals involved in cancer care and Other long-term employee benefits research; and c. to foster and promote cancer research. OtherThe liability long-term for annual employee leave benefits and long service leave not expected to be settled within 12 months Theof the liability reporting for annual date are leave recognised and long in service non-current leave liabilities, not expected provided to be there settled is anwithin unconditional 12 months ofright the to reporting defer settlement date are ofrecognised the liability. in Thenon-current liability isliabilities, measured provided as the therepresent is anvalue unconditional of expected In the event of the Company being wound up, the members undertake to contribute an amount rightfuture to payments defer settlement to be made of the in liability.respect Theof services liability providedis measured by employeesas the present up to value the reportingof expected not exceeding $10.00 to the assets of the Company. futuredate using payments the projected to be made unit incredit respect method. of services Consideration provided is by given employees to the expected up to the future reporting wage dateand salaryusing thelevels, projected experience unit credit of employee method. departures Consideration and isperiods given ofto service.the expected Expected future future wage There were 909 financial members of the Company at 30 June 2018 (2017: 936). andpayments salary arelevels, discounted experience using of marketemployee yields departures at the reporting and periods date ofon service. national Expected government future bonds paymentswith terms areto maturity discounted and usingcurrency market that yields match, at as the closely reporting as possible,date on national the estimated government future bondscash withoutflows. terms to maturity and currency that match, as closely as possible, the estimated future cash outflows. Note 3. Economic dependence Defined contribution superannuation expense DefinedContributions contribution to defined superannuation superannuation expense plans are expensed in the period in which they are The ability of the Company to maintain its operations is dependent inter alia on the continuing Contributionsincurred. to defined superannuation plans are expensed in the period in which they are support of its members by way of voluntary membership subscriptions. incurred. (m) Critical accounting judgements, estimates and assumptions (m) CriticalThe directors accounting evaluate judgements, estimates and estimates judgements and incorporated assumptions into the financial report based on Thehistorical directors knowledge evaluate and estimates best available and judgements current information. incorporated Estimates into the assumefinancial areport reasonable based on historicalexpectation knowledge of future andevents best and available are based current on current information. trends Estimatesand economic assume data, a obtainedreasonable both Note 4. Revenue expectationexternally and of withfuture the events Company. and are based on current trends and economic data, obtained both externally and with the Company. 2018 2017
The judgements, estimates and assumptions that have a significant risk of causing a material $ $ The judgements, estimates and assumptions that have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities within the next financial year are Membership subscriptions (also refer to note 1(a) (ii)) 132,218 130,842 adjustment to the carrying amounts of assets and liabilities within the next financial year are discussed below. Interest Revenue 50,183 49,392 discussed below. ASM Income 455,984 451,822 Estimation of useful lives of assets Estimation of useful lives of assets NHMRC Enabling Grant 4,755 1,145 The Company determines the estimated useful lives and related depreciation and amortisation Other Grant income 331,642 176,946 Thecharges Company for its determinesproperty, plant the andestimated equipment. useful The lives depreciation and related and depreciation amortisation and charge amortisation will Recoveries of clinical trials insurance cover 77,000 80,501 chargesincrease forwhere its property, the useful plant lives and are equipment. less than previously The depreciation estimated and lives, amortisation or technically charge obsolete. will Other revenue 488 2,635 increase where the useful lives are less than previously estimated lives, or technically obsolete. Long service leave provision 1,052,270 893,283 LongThe liability service for leave long provision service leave is recognised and measured at the present value of the Theestimated liability future for long cash service flows leaveto be madeis recognised in respect and of measured all employees at the at present the reporting value date.of the In estimateddetermining future the presentcash flows value to ofbe the made liability, in respect estimates of all of employees attrition rates at the and reporting pay increases date. In determiningthrough promotion the present and inflation value of have the liability,been taken estimates into account. of attrition rates and pay increases through promotion and inflation have been taken into account. (n) Use of the term "surplus" (n) UseThe Companyof the term is "surplus"a not-for-profit organisation. As such, the term "profit" is not applicable and the Theterm Company "surplus" is useda not-for-profit where required. organisation. As such, the term "profit" is not applicable and the term "surplus" is used where required. 71 - 18 18 19 ANNUAL REPORT 2017
Clinical Oncology Society of Australia Limited (ABN 97 631 209 452) Notes to the Financial Statements for the year ended 30 June 2018 (cont.)
Note 2. Nature and objects of the Company
The Company is an incorporated Company Limited by Guarantee under the Corporations Act 2001.
Its objects are: a. to promote excellence in the multidisciplinary care and research relating to cancer – from prevention, diagnosis and treatment to follow-up, palliation and survivorship; b. to encourage multidisciplinary collaboration of all professionals involved in cancer care and research; and c. to foster and promote cancer research.
In the event of the Company being wound up, the members undertake to contribute an amount not exceeding $10.00 to the assets of the Company.
There were 909 financial members of the Company at 30 June 2018 (2017: 936).
Note 3. Economic dependence
The ability of the Company to maintain its operations is dependent inter alia on the continuing support of its members by way of voluntary membership subscriptions.
Note 4. Revenue
2018 2017 $ $ Membership subscriptions (also refer to note 1(a) (ii)) 132,218 130,842 Interest Revenue 50,183 49,392 ASM Income 455,984 451,822 NHMRC Enabling Grant 4,755 1,145 Other Grant income 331,642 176,946 Recoveries of clinical trials insurance cover 77,000 80,501 Other revenue 488 2,635 1,052,270 893,283
71 - 72 19 COSA BOARD + COSA REPORTS
COSA GROUP REPORTS
AFFILIATED ORGANISATION REPORTS
OTHER REPORTS
ANNUAL REPORT 2017 CLINICAL ONCOLOGY SOCIETY OF AUSTRALIA LIMITED FINANCIAL STATEMENTS (ABN 97 631 209 452) Clinical Oncology Society of Australia Limited (ABN 97 631 209 452) NOTESClinical Oncology TO THE Society FINANCIAL of Australia Limited STATEMENTS (ABN 97 631 209 452) Notes to the Financial Statements for the year ended 30 June 2018 (cont.) FORNotes to THE the Financial YEAR Statements ENDED for the 30 year JUNEended 30 June2018 2018 (Cont’d) (cont.)
Note 5. Cash & cash equivalents Note 9. Trade and other payables 2018 2017 2018 2017 $ $ $ $ Current Trade creditors & accruals 34,071 38,524 Cash at bank 600,236 405,192 Income in advance 238,356 104,272 600,236 405,192 272,427 142,796
Note 6. Trade and other receivables Note 10. Provisions Current Trade receivables 93,534 10,671 Current: Other receivables 3,511 7,877 Employee benefits 29,818 28,517 97,045 18,548 29,818 28,517
Note 7. Other current assets Non-Current: Employee benefits 4,277 1,060 4,277 1,060 Prepayments 69,395 69,395 Held to maturity investments - term deposits 1,710,732 1,705,443 1,780,127 1,774,837 Note 11. Contingent Liabilities
Note 8. Plant & equipment There are no contingent liabilities as at the end of the year other than those identified elsewhere in this report. Computer equipment - Computer equipment, at cost 18,796 12,385 - Accumulated Note 12. Events subsequent to reporting date depreciation (12,969) (11,036) Total computer equipment 5,827 1,349 No matters or circumstances have arisen since the end of the year which significantly affected or may significantly affect the operations of the Company or the results of those operations for the period under report. Computer Equipment $ Balance at 1 July 2016 489 Note 13. Auditors Remuneration Additions 2,044 Depreciation expense (1,183) During the year, the following fees were paid or payable for services provided by the auditor, BDO East Coast Partnership to the Company: Balance at 30 June 2017 1,349 Additions 6,412 Depreciation expense (1,934) External audit of the financial statement 5,450 5,200
Balance at 30 June 2018 5,827
21 73 - 20 ANNUAL REPORT 2017
Clinical Oncology Society of Australia Limited (ABN 97 631 209 452) Notes to the Financial Statements for the year ended 30 June 2018 (cont.)
Note 9. Trade and other payables 2018 2017 $ $ Current Trade creditors & accruals 34,071 38,524 Income in advance 238,356 104,272
272,427 142,796
Note 10. Provisions
Current: Employee benefits 29,818 28,517 29,818 28,517
Non-Current: Employee benefits 4,277 1,060 4,277 1,060
Note 11. Contingent Liabilities
There are no contingent liabilities as at the end of the year other than those identified elsewhere in this report.
Note 12. Events subsequent to reporting date
No matters or circumstances have arisen since the end of the year which significantly affected or may significantly affect the operations of the Company or the results of those operations for the period under report.
Note 13. Auditors Remuneration
During the year, the following fees were paid or payable for services provided by the auditor, BDO East Coast Partnership to the Company:
External audit of the financial statement 5,450 5,200
21 73 - 74 COSA BOARD + COSA REPORTS
COSA GROUP REPORTS
AFFILIATED ORGANISATION REPORTS
OTHER REPORTS
ANNUAL REPORT 2017 CLINICAL ONCOLOGY SOCIETY OF AUSTRALIA LIMITED FINANCIAL STATEMENTS (ABN 97 631 209 452) NOTESClinical Oncology TO THE Society FINANCIAL of Australia Limited STATEMENTS (ABN 97 631 209 452) Notes to the Financial Statements for the year ended 30 June 2018 (cont.) Clinical Oncology Society of Australia Limited (ABN 97 631 209 452) FOR THE YEAR ENDED 30 JUNE 2018 (Cont’d) Financial report for the year ended 30 June 2018
Note 14. Reconciliation of the surplus/(deficit) for the year to net cash flows Directors' Declaration from operating activities In the directors' opinion: 2018 2017
$ $ Net surplus for the year 163,915 136,236 1. The Company is not a reporting entity because there are no users dependent on general purpose financial statements. Accordingly, as described in note 1 to the financial statements, the attached special purpose financial statements have been prepared for the purpose of complying with the Non-cash flows in surplus from ordinary activities: requirements of the ACNC Act 2012 to prepare and distribute financial statements to the members of Depreciation 1,934 1,183 Clinical Oncology Society of Australia Limited; Transfer from reserves (14,755) (1,145) 2. The attached financial statements and notes thereto comply with the ACNC Act 2012, the Accounting Standards as described in note 1 to the financial statements, the ACNC Regulations 2013 and other Changes in assets and liabilities: mandatory professional reporting requirements; 3. The attached financial statements and notes thereto give a true and fair view of the Company's Decrease/(increase) in trade & other receivables (78,497) 6,083 financial position as at 30 June 2018 and of its performance for the financial year ended on that date; Increase in other current assets - 11,158 and Increase/(decrease) in trade & other payables 129,631 (7,000) 4. There are reasonable grounds to believe that the Company will be able to pay its debts as and when Increase/(decrease) in provisions 4,518 (7,191) they become due and payable.
Net cash provided by operating activities 206,746 139,324 This declaration is made in accordance with a resolution of the Board of Directors and is signed for and on behalf of the directors by:
Note 15. Company details
______The registered office and principal place of business of the Company is: Prof Phyllis Butow AM A/Prof Nick Pavlakis Level 14, 477 Pitt Street President President-Elect Sydney NSW 2000 Australia
Sydney The Company operates entirely in Australia as a Charitable Institution. 17 October 2018
22 23 75 - ANNUAL REPORT 2017
FINANCIAL REPORT FOR THE Clinical Oncology Society of Australia Limited (ABN 97 631 209 452) YEARFinancial ENDEDreport for the 30 year JUNE ended 30 2018 June 2018
Directors' Declaration
In the directors' opinion:
1. The Company is not a reporting entity because there are no users dependent on general purpose financial statements. Accordingly, as described in note 1 to the financial statements, the attached special purpose financial statements have been prepared for the purpose of complying with the requirements of the ACNC Act 2012 to prepare and distribute financial statements to the members of Clinical Oncology Society of Australia Limited; 2. The attached financial statements and notes thereto comply with the ACNC Act 2012, the Accounting Standards as described in note 1 to the financial statements, the ACNC Regulations 2013 and other mandatory professional reporting requirements; 3. The attached financial statements and notes thereto give a true and fair view of the Company's financial position as at 30 June 2018 and of its performance for the financial year ended on that date; and 4. There are reasonable grounds to believe that the Company will be able to pay its debts as and when they become due and payable.
This declaration is made in accordance with a resolution of the Board of Directors and is signed for and on behalf of the directors by:
______
Prof Phyllis Butow AM A/Prof Nick Pavlakis President President-Elect
Sydney 17 October 2018
23 75 - 76 COSA BOARD + COSA REPORTS
COSA GROUP REPORTS
AFFILIATED ORGANISATION REPORTS
OTHER REPORTS
ANNUAL REPORT 2017 Level 11, 1 Margaret St CLINICAL ONCOLOGY SOCIETY Tel: +61 2 9251 4100 Fax: +61 2 9240 9821 Sydney NSW 2000 OF AUSTRALIA LIMITED FINANCIALwww.bdo.com.au STATEMENTS Australia Level 11, 1 Margaret St (ABN 97 631 209 452) Tel: +61 2 9251 4100 Fax: +61 2 9240 9821 Sydney NSW 2000 www.bdo.com.au Australia
Tel: +61 2 9251 4100 Level 11, 1 Margaret St Fax: +61 2 9240 9821 Sydney NSW 2000 www.bdo.com.au Australia
INDEPENDENT AUDITOR'S REPORT
INDEPENDENT AUDITOR'S REPORT Responsibilities of Directors for the Financial Report To the members of Clinical Oncology Society of Australia Limited Responsibilities of Directors for the Financial Report The Directors of the registered entity are responsible for the preparation of the financial report that Thegives Directors a true and of fairthe registeredview and have entity determined are responsible that the for basis the preparation of preparation of the described financial in reportNote 1 thato tth e To the members of Clinical Oncology Society of Australia Limited INDEPENDENT AUDITOR'S REPORT financialgives a true report and isfair appropriate view and haveto meet determined the require thatments the basisof the of ACNC preparation Act and described the needs in of Note the 1 to the financial report is appropriate to meet the requirements of the ACNC Act and the needs of the members. The Directors’ responsibility also includes such internal control as the Directors determine is members. The Directors’ responsibility also includes such internal control as the Directors determine is Report on the Audit of the Financial Report necessary to enable the preparation of a financial report that gives a true and fair view and is free To the members of Clinical Oncology Society of Australia Limited necessary to enable the preparation of a financial report that gives a true and fair view and is free Opinion from material misstatement, whether due to fraud or error. Report on the Audit of the Financial Report from material misstatement, whether due to fraud or error.
We have audited the financial report of Clinical Oncology Society of Australia Limited, which comprises In preparing the financial report, the Directors are responsible for assessing the registered entity’s Opinion In preparing the financial report, the Directors are responsible for assessing the registered entity’s the statement of financial position as at 30 June 2018, the statement of profit or loss and other ability to continue as a going concern, disclosing, as applicable, matters relating to going concern and ability to continue as a going concern, disclosing, as applicable, matters relating to going concern and Wecomprehensive have audited income, the financial the statement report of ofClinical changes On cologyin equity Society and the of Australiastatement Limited, of cash whichflows forcomprise the s using the going concern basis of accounting unless the Directors either intend to liquidate the Report on the Audit of the Financial Report using the going concern basis of accounting unless the Directors either intend to liquidate the theyear statement then ended, of financial and notes position to the asfinancial at 30 June report, 2018, including the statement a summary of profit of significant or loss and accounting other registered entity or to cease operations, or have no realistic alternative but to do so. comprehensiveOpinion income, the statement of changes in equity and the statement of cash flows for the registered entity or to cease operations, or have no realistic alternative but to do so. policies, and the Directors’ declaration. Auditor’s responsibilities for the audit of the Financial Report yearWe have then audited ended, theand financial notes to reportthe financial of Clinical report, Oncology including Society a summary of Australia of significant Limited, accountingwhich comprise s Auditor’s responsibilities for the audit of the Financial Report In our opinion the accompanying financial report of Clinical Oncology Society of Australia Limited, is in Our objectives are to obtain reasonable assurance about whether the financial report as a whole is free thepolicies, statement and the of Directors’financial position declaration. as at 30 June 2018, the statement of profit or loss and other accordance with Division 60 of the Australian Charities and Not-for-profits Commission Act 2012, fromOur objectives material misstatement, are to obtain reasonable whether due assurance to fraud a orbout error, whether and to the issue financial an auditor’s report reportas a whole that is free comprehensive income, the statement of changes in equity and the statement of cash flows for the Inincluding: our opinion the accompanying financial report of Clinical Oncology Society of Australia Limited, is in includesfrom material our opinion. misstatement, Reasonable whether assurance due to is fraud a high or level error, of and assurance, to issue butan auditor’sis not a guarantee report that that an yearaccordance then ended, with Division and notes 60 toof the financialAustralian report, Charities including and Not-for-profits a summary of Commissionsignificant accounting Act 2012, includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an (i) Giving a true and fair view of the registered entity’s financial position as at 30 June 2018 and of audit conducted in accordance with the Australian Auditing Standards will always detect a material policies,including: and the Directors’ declaration. audit conducted in accordance with the Australian Auditing Standards will always detect a material its financial performance for the year then ended; and misstatement when it exists. Misstatements can arise from fraud or error and are considered material misstatement when it exists. Misstatements can arise from fraud or error and are considered material In(i) our Givingopinion a thetrue accompanying and fair view financialof the registered report of entit Clinicaly’s financial Oncology position Society asof atAustralia 30 June Limited, 2018 and is ofin if, individually or in the aggregate, they could reasonably be expected to influence the economic if, individually or in the aggregate, they could reasonably be expected to influence the economic accordance(ii) itsComplying financial with Division with performance Australian 60 of the for Accounting Australianthe year then Standards Charities ended; toand and t heNot-for-profits extent described Commission in Note 1Act and 2012 Division, decisions of users taken on the basis of this financial report. including:60 of the Australian Charities and Not-for-profits Commission Regulation 2013. decisions of users taken on the basis of this financial report. (ii) Complying with Australian Accounting Standards to the extent described in Note 1 and Division A further description of our responsibilities for the audit of the financial report is located at the A further description of our responsibilities for the audit of the financial report is located at the (i)Basis 60Givingfor of opinion the a true Australian and fair Charities view of theand registered Not-for-profits entity’s Commission financial positionRegulation as at2013 30 .June 2018 and of Auditing and Assurance Standards Board website (http://www.auasb.gov.au/Home.aspx) at: its financial performance for the year then ended; and Auditing and Assurance Standards Board website (http://www.auasb.gov.au/Home.aspx) at: BasisWe conducted for opinion our audit in accordance with Australian Auditing Standards. Our responsibilities under http://www.auasb.gov.au/auditors_responsibilities/ar4.pdf (ii)those Complyingstandards arewith further Australian described Accounting in the Standards Auditor’s toresponsibilities the extent described for the auditin Note of 1the and Financial Division http://www.auasb.gov.au/auditors_responsibilities/ar4.pdf We conducted our audit in accordance with Australian Auditing Standards. Our responsibilities under This description forms part of our auditor’s report. Report60 section of the ofAustralian our report. Charities We are and independent Not-for-profits of the Commission registered Regulationentity in accordance 2013. with the those standards are further described in the Auditor’s responsibilities for the audit of the Financial This description forms part of our auditor’s report. auditor independence requirements of the Australian Charities and Not-for-profits Commission Act BasisReport2012 for(ACNC section opinion Act) of and our report.the ethical We requirementsare independent of the of theAcc ountingregistered Professional entity in accordanceand Ethical withStandards the auditor independence requirements of the Australian Charities and Not-for-profits Commission Act BDO East Coast Partnership WeBoard’s conducted APES 110our Codeaudit ofin Ethicsaccordance for Professional with Australian Accountants Auditing (the Standards. Code) that Our are responsibilities relevant to our under audit BDO East Coast Partnership 2012 thoseof the (ACNC standards financial Act) arereportand further the in ethical Australia. described requirements We in have the Auditor’s also of thefulfilled Acc responsibilitiesounting our other Professional ethical for the responsibilities andaudit Ethical of the Standards Financial in Code of Ethics for Professional Accountants Board’sReportaccordance sectionAPES with 110 of theour Code.report. We are independent of the registered (the Code) entity that in accordanceare relevant with to our the audit of the financial report in Australia. We have also fulfilled our other ethical responsibilities in auditorWe believe independence that the audit requirements evidence ofwe the have Australian obtained Charities is sufficient and and Not-for-profits appropriate Commissionto provide a Actbasis 2012accordance (ACNC withAct) andthe Code.the ethical requirements of the Accounting Professional and Ethical Standards for our opinion. Board’sWe believe APES that 110 the Code audit of Ethicsevidence for weProfessional have obtained Accountants is sufficient (the andCode) appropriate that are relevant to provide to oura basis audit forofEmphasis the our financial opinion. of matter report – inBasis Australia. of accounting We have also fulfilled our other ethical responsibilities in Paul Cheeseman Paul Cheeseman accordance with the Code. Partner EmphasisWe draw attentionof matter to – BasisNote of1 to accounting the financial report, which describes the basis of accounting. The Partner Wefinancial believe report that thehas auditbeen evidenceprepared wefor havethe purpose obtained of isfulfilling sufficient the and registered appropriate entity’s to provide financial a basis We draw attention to Note 1 to the financial report, which describes the basis of accounting. The forreporting our opinion. responsibilities under the ACNC Act. As a result, the financial report may not be suitable for financial report has been prepared for the purpose of fulfilling the registered entity’s financial Sydney, 17 October 2018 another purpose. Our opinion is not modified in respect of this matter. Sydney, 17 October 2018 Emphasisreporting responsibilitiesof matter – Basis under of accounting the ACNC Act. As a result, the financial report may not be suitable for another purpose. Our opinion is not modified in respect of this matter. We draw attention to Note 1 to the financial report, which describes the basis of accounting. The financial report has been prepared for the purpose of fulfilling the registered entity’s financial
reportingBDO East Coast responsibilities Partnership ABN 83 236 985under 726 is athe member ACNC of a national Act. association As a result, of independent the entitiesfinancial which are report all members may of BDO not Australia be suitable Ltd for ABN 77 050 110 275, an Australian company limited by guarantee. BDO East Coast Partnership and BDO Australia Ltd are members of BDO International Ltd, anothera UK company purpose. limited by guarantee, Our opinion and form part is ofnot the internationalmodified BDO in network respect of independent of this member matter. firms. Liability limited by a scheme approved under Professional Standards Legislation, other than for the acts or omissions of financial services licensees. BDO East Coast Partnership ABN 83 236 985 726 is a member of a national association of independent entities which are all members of BDO Australia Ltd
ABN 77 050 110 275, an Australian company limited b y guarantee. BDO East Coast Partnership and BDO Australia Ltd are members of BDO International Ltd, a UK company limited by guarantee, and form part of the international BDO network of independent member firms. Liability limited by a scheme approved under Professional Standards Legislation, other than for the acts or omissions of financial services licensees. 77 -
BDO East Coast Partnership ABN 83 236 985 726 is a member of a national association of independent entities which are all members of BDO Australia Ltd ABN 77 050 110 275, an Australian company limited by guarantee. BDO East Coast Partnership and BDO Australia Ltd are members of BDO International Ltd, a UK company limited by guarantee, and form part of the international BDO network of independent member firms. Liability limited by a scheme approved under Professional Standards Legislation, other than for the acts or omissions of financial services licensees.
ANNUAL REPORT 2017
Responsibilities of Directors for the Financial Report Responsibilities of Directors for the Financial Report The Directors of the registered entity are responsible for the preparation of the financial report that Thegives Directors a true and of fairthe registeredview and have entity determined are responsible that the for basis the preparation of preparation of the described financial in reportNote 1 thato tth e financialgives a true report and isfair appropriate view and haveto meet determined the require thatments the basisof the of ACNC preparation Act and described the needs in of Note the 1 to the members.financial report The Directors’ is appropriate responsibility to meet thealso require includesments such of internal the ACNC control Act andas the the Directors needs of determinethe is necessarymembers. toThe enable Directors’ the preparation responsibility of alsoa financial includes report such thatinternal gives control a true asand the fair Directors view and determine is free is fromnecessary material to enable misstatement, the preparation whether of due a financial to fraud report or error. that gives a true and fair view and is free from material misstatement, whether due to fraud or error. In preparing the financial report, the Directors are responsible for assessing the registered entity’s abilityIn preparing to continue the financial as a going report, concern, the Directors disclosing, are as responsible applicable, for matters assessing relating the registered to going concern entity’s and abilityusing the to goingcontinue concern as a goingbasis concern,of accounting disclosing, unless as the applicable, Directors eithermatters intend relating to liquidateto going concernthe and registeredusing the going entity concern or to cease basis operations,of accounting or haveunless n othe realistic Directors alternative either intend but to to do liquidate so. the registered entity or to cease operations, or have no realistic alternative but to do so. Auditor’s responsibilities for the audit of the Financial Report Auditor’s responsibilities for the audit of the Financial Report Our objectives are to obtain reasonable assurance about whether the financial report as a whole is free fromOur objectives material misstatement, are to obtain reasonable whether due assurance to fraud a orbout error, whether and to the issue financial an auditor’s report reportas a whole that is free includesfrom material our opinion. misstatement, Reasonable whether assurance due to is fraud a high or level error, of and assurance, to issue butan auditor’sis not a guarantee report that that an auditincludes conducted our opinion. in accordance Reasonable with assurance the Australian is a hi ghAuditing level of Standards assurance, will but always is not detect a guarantee a material that an misstatementaudit conducted when in accordance it exists. Misstatements with the Australian can ari Auditingse from Standardsfraud or error will andalways are detectconsidered a material material misstatementif, individually when or in itthe exists. aggregate, Misstatements they could can reasonably arise from be fraud expected or error to influenceand are considered the economic material decisionsif, individually of users or intaken the aggregate,on the basis they of this could finan reasonablycial report. be expected to influence the economic decisions of users taken on the basis of this financial report. A further description of our responsibilities for the audit of the financial report is located at the AuditingA further and description Assurance of Standardsour responsibilities Board website for the (http://www.auasb.gov.au/Home.aspx audit of the financial report is located) at:at the Auditing and Assurance Standards Board website (http://www.auasb.gov.au/Home.aspx) at: http://www.auasb.gov.au/auditors_responsibilities/ar4.pdf http://www.auasb.gov.au/auditors_responsibilities/ar4.pdf This description forms part of our auditor’s report. This description forms part of our auditor’s report.
BDO East Coast Partnership BDO East Coast Partnership
Paul Cheeseman PartnerPaul Cheeseman Partner
Sydney, 17 October 2018 Sydney, 17 October 2018
77 - 78
2018
EDUCATION 2018
COLLABORATION
Level 14, 477 Pitt Street ADVOCACY Sydney NSW 2000 GPO Box 4708 Sydney NSW 2001 EDUCATION RESEARCH COLLABORATIONADVOCACY Telephone: (02) 8063 4100 RESEARCH Facsimile: (02) 8063 4101 www.cosa.org.au